Mississippi State University

Scholars Junction
Theses and Dissertations

Theses and Dissertations

8-14-2015

Effects of the In Ovo Injection of Inovocox Em1 Vaccine on the
Embryogenesis, Posthatch Performance, and Gut Pathology of
Ross Ross 708 Broilers
Adebayo Oluwaseun Sokale

Follow this and additional works at: https://scholarsjunction.msstate.edu/td

Recommended Citation
Sokale, Adebayo Oluwaseun, "Effects of the In Ovo Injection of Inovocox Em1 Vaccine on the
Embryogenesis, Posthatch Performance, and Gut Pathology of Ross Ross 708 Broilers" (2015). Theses
and Dissertations. 1807.
https://scholarsjunction.msstate.edu/td/1807

This Dissertation - Open Access is brought to you for free and open access by the Theses and Dissertations at
Scholars Junction. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of
Scholars Junction. For more information, please contact scholcomm@msstate.libanswers.com.

Automated Template B: Created by James Nail 2011V2.1

Effects of the in ovo injection of Inovocox EM1 vaccine on the embryogenesis, posthatch
performance, and gut pathology of Ross × Ross 708 broilers

By
Adebayo Sokale

A Dissertation
Submitted to the Faculty of
Mississippi State University
in Partial Fulfillment of the Requirements
for the Degree of Doctor of Philosophy
in Agricultural Science
in the Department of Poultry Science
Mississippi State, Mississippi
August 2015

Copyright by
Adebayo Sokale
2015

Effects of the in ovo injection of Inovocox EM1 vaccine on the embryogenesis, posthatch
performance, and gut pathology of Ross × Ross 708 broilers
By
Adebayo Sokale
Approved:
__________________________________
E. David Peebles
(Major Professor)

__________________________________
Linda M. Pote
(Minor Professor)

____________________________________
G. Todd Pharr
(Committee Member)
____________________________________
Wei Zhai
(Committee Member)
____________________________________
Christopher J. Williams
(Committee Member)
____________________________________
Timothy S. Cummings
(Committee Member)
____________________________________
Christopher D. McDaniel
(Graduate Coordinator)
____________________________________
George M. Hopper
Dean
College of Agriculture and Life Sciences

Name: Adebayo Sokale
Date of Degree: August 14, 2015

ABSTRACT
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Title of Study: Effects of the in ovo injection of Inovocox EM1 vaccine on the
embryogenesis, posthatch performance, and gut pathology of Ross ×
Ross 708 broilers
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Candidate for Degree of Doctor of Philosophy
Effects of the in ovo injection of Inovocox EM1 vaccine (EM1 vaccine)
suspended in commercial diluent on developing broiler embryos were investigated in 3
trials. Effects of the EM1vaccine administered by in ovo injection on broiler
embryogenesis and posthatch performance was determined by evaluating site of injection
(SOI), embryo staging (ES), hatchability, and chick quality parameters. Oocyst output,
microscopic lesion scores, and grow-out performance were further examined through day
35 posthatch. In these studies, it was shown that oocyst output began at day 3 posthatch
(6 days post-injection), and peaked at day 7 posthatch (10 days post-injection). The EM1
vaccine had no effects on hatchability, various and chick quality parameters that were
examined in the study. Similarly, grow-out performance through day 35 posthatch was
not affected by the EM1 vaccine. SOI and ES provided information on the accuracy of in
ovo vaccine delivery to the embryos, and were found to be significantly influenced by
embryo age.

In conclusion, in ovo injection of the EM1 vaccine has no detrimental effect on
broiler embryogenesis, hatching chick quality, or the performance characteristics of Ross
× Ross 708 broilers.
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CHAPTER I
INTRODUCTION
The broiler chicken industry has grown exponentially over the past two decades.
This growth can be attributed to the ability of the commercial poultry industry to
incorporate advanced scientific methods into their production of fast-growing broiler
chickens that are raised under intensive management systems. In spite of the numerous
advantages associated with increased poultry production, which essentially provides food
security in the world, the intensive system of poultry production provides opportunities
for the development and transmission of numerous poultry diseases that limit the ability
of the industry to meet the increasing demands for poultry products. Enteric diseases are
of greatest global concern to broiler chicken producers because they cause production
losses associated with increased morbidity, mortality, and risks associated with the
contamination of poultry products that make them unsafe for human consumption.
The infectious disease, coccidiosis, which is caused by a protozoan parasite of the
genus Eimeria, is still considered the greatest disease challenge to the worldwide poultry
industry (Tyzzer, 1932; Chapman et al., 2002). Coccidia parasites multiply in the
intestinal tract, and cause damage to intestinal tissues, resulting in reductions in feed
intake, and body weight gain that are accompanied by diarrhea, morbidity, mortality, and
an increased susceptibility to other diseases (Williams 1999a; Mc Dougald, 2003). The
control of coccidiosis by the use of anticoccidial drugs dates back to the early twentieth
1

century. However, coccidia have developed various degrees of resistance to all
anticoccidial drugs that have been introduced to date (Chapman, 1997a; Chapman, 2014).
Although several poultry integrators have adopted rotational or combinational usages of
various anticoccidials in order to overcome the problem of drug resistance. The
deposition of drug residues in poultry products has become a bigger concern among
consumers. This has led to the withdrawal of several in-feed coccidial drugs from broiler
feed (McEoy, 2001; Young and Craig, 2001, Farrant, 2001). Therefore, poultry producers
are shifting from the chemotherapeutic control of coccidiosis to the use of vaccines.
Coccidiosis vaccines consist of a low dose mixture of live Eimeria oocysts that can be
administered to embryos or day-old chicks. This has been shown to produce adequate
immune responses against coccidial challenges that may occur later in the chicken’s life
(Chapman, 2014). Since the inception of the Coccivac vaccine in 1952, several
commercial coccidiosis vaccines have been made available. Inovocox EM1 vaccine is a
non-attenuated vaccine that is administered to 18 to 19 day-old embryos using a
commercial in ovo injection machine. This method of coccidiosis control ensures the
delivery of a precise vaccinal dose of Eimeria oocysts to each embryo in order to achieve
an early onset of immunity in the hatchling. Several studies have been conducted to
evaluate the effects of coccidiosis vaccines on various performance variables in broiler
chickens. For example, an improvement in posthatch performance of broilers and a
reduction in the number of shed oocysts have been reported following day-of-age spray
application of Coccivac B, in the presence of mixed coccidia infection (Schering-Plough
Animal Health, 2007; Mathis, 1999). However, there is very limited information
regarding the effects of the EM1 vaccine on the physiological characteristics of broiler
2

embryos and hatched chicks, as well as the posthatch performance characteristics of
broiler chickens during grow-out. Therefore, the objective of this current study was to
investigate effects of the Inovocox EM1 vaccine suspended in commercial diluent, when
injected in ovo at various embryonic age and dosages on embryogenesis, posthatch
performance, and gut pathology of broilers.
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CHAPTER II
REVIEW OF LITERATURE
Embryogenesis and incubation
The development of the chicken (Gallus gallus domesticus) embryo from
fertilization to hatching is a rapidly changing process that lasts approximately 21 days.
This process of development is influenced by a combination of several endogenous and
exogenous factors. More specifically, the process is optimized by environmental factors
that are provided during incubation, namely temperature, turning, humidity, and
ventilation (Romanoff, 1929; Molenaar et al., 2008; Willemsen et al., 2008). These
environmental factors influence the developmental and metabolic requirements of the
chicken embryo, and in addition can affect posthatch chick development (Molenaar et al.,
2010). Optimum incubational dry and wet bulb temperatures are approximately 37.5 ±
0.5 oC and 28.9 ± 0.5oC, respectively. During embryonic development, the embryo
produces internal heat as a result of its metabolic processes. The external temperature
need of the embryo therefore decreases as the embryo matures towards hatch. A lower set
temperature is necessary on the machine beginning from at d 15 of incubation in order to
coincide with the heat production of the embryo, especially in large size embryos
(Lourens et al., 2006). The impact on temperature on embryos and chick performance has
been studied extensively. Sozcu and Ipek (2014) showed that chronic high eggshell
temperature in late-stage embryos can affect their hatchability, performance, and the
4

incidence of ascites. In addition to temperature, relative humidity is an important
component of incubation. A relative humidity of 50 to 65% is further required for optimal
incubation (Peebles and Brake, 1987; Pulikanti et al., 2012). Humidity occurs in
consonance with temperature, in that as temperature increases, relative humidity
decreases during incubation (Townsley, 1931). During the process of incubation, the
embryonated egg loses some amount of moisture (Rahn, 1977). The amount of water loss
can affect hatchability (Ar and Rahn, 1980). Hatchability is not affected when moisture
loss is between 12 to 14 % of the fresh egg weight at d 18 of incubation. However
increased embryonic mortality can occur with moisture loss that is lower than 9 % or
greater that 18.5 % (Buhr, 1995; Davis and Ackerman, 1987). Humidity is essential for
control of the loss of moisture from the incubated egg (Landauer, 1948; Buhr, 1995).
During incubation when temperature is high, a decrease in relative humidity will allow
for an increase in moisture loss. However, during late-stage incubation as temperature is
decreased as embryo approach hatch, the relative humidity is increased (Hamdy et al.,
1991). Oxygen is a key nutrient required by the growing embryo, and is influenced by
the incubator ventilation. Adequate ventilation not only ensures that a uniform
temperature is maintained, but also that an adequate supply of oxygen and the removal of
carbon dioxide is maintained within the incubator as the embryo develops (Atwood and
Weakley, 1915; French, 1997). Further, efficient air circulation within the incubation
system ensures that incubation temperature, oxygen, and carbon dioxide are maintained
at levels which are acceptable to the growing embryo. In addition to incubation
ventilation, egg pore quality impact gaseous exchange between the embryo and its
external environment. A decrease in the number of pores on the egg surface can lead to
5

reduced oxygen availability to the growing embryo (Wineland, 2014). Oxygen demand
by the embryo increases as the embryo increases in size. This need for oxygen increases
for embryo growth and development especially in the first 14 days of incubation. A
plateau phase of oxygen utilization occurs at d 14 of incubation due to maximum
saturation of the chorio-allontoic membrane, and egg pores with oxygen. Oxygen demand
increases again when the embryo begins pipping at d 19 of incubation. During the plateau
phase, the embryo reverts back to alternative energy sources that are anaerobic such as
glycogen or protein (Wineland, 2014). A gentle turning frequency of at least 3 times and
no more than 96 times every 24 h at an angle of 45o is essential for the incubation
process, especially during the first 14 days of incubation (Olsen and Byerly, 1936; Funk
and Forward, 1960; Elibol and Brake, 2006). Embryonic development begins with
fertilization of the ovum by spermatozoa, which occurs in the infundibulum and, results
in fusion of the two gametes to produce the zygote (Romanoff, 1960). Following
formation of the zygote prior to oviposition, cell division (cleavage) begins in the
germinal disc. The process of cleavage begins with a cluster of cells in a single layer
called the blastoderm. Continuation of the process of cleavage produces the blastodermal
stages (Patten, 1920; Fig. 2.1). Following oviposition, when eggs are collected and stored
under cold conditions (at physiological zero), embryonic development is arrested.
Appropriate incubation conditions are necessary to reinitiate cell divisions in the
blastoderm (Edwards, 1902). As cell differentiation continues, the primitive streak arises
from the blastoderm (epiblastic portion of the blastoderm) resulting in formation of the
germinal epithelia, which consists of the ectoderm, endoderm and mesoderm (Patten,
1920). The ectoderm differentiates into the integuments, nervous system, and sense
6

organs. The endoderm develops into the epithelial lining of the respiratory, digestive and
secretory organs, while the mesoderm differentiates into the circulatory, lymphatic, and
reproductive systems (Patten, 1920). The development of embryos during incubation can
generally be categorized into three phases: early, mid, and late. The early phase of
development occurs during embryonic days (ED) 1 to 7, the mid phase extends from ED
8 to 14, and the late-phase extends from ED 15 to 21 (Hamburger and Hamilton,1992).
The early- and mid- phases are characterized by formation of the organ and systems,
while growth and maturation of those systems occurs during the late-phase. The daily
developmental stages of the chicken embryo as they relate to the days of incubation, are
presented in Table 2.1. In addition, Hamburger and Hamilton (1992) described and
classified the stages of chicken embryonic development into 45 stages based on
morphogenetic changes from cell division to hatching (Fig. 2.2). The early stages (1 to 6)
correspond to d 1 of incubation and are characterized by the development of the primitive
streak. The middle stages (7 to 14) are characterized by organ systems, and correspond to
d 2 to 3 of incubation. The last stages (15 to 45) which corresponds to d 4 to 21 of
incubation, are characterized by morphological changes leading up to the maturation of
features that become more evident as hatch approaches. For example, stage 28 of the
Hamburger and Hamilton classification scheme corresponds to d 6 of incubation and is
characterized by rapid differentiation, with the formation of appendages and the egg
tooth. In general, the initial stages of chick embryonic development are very rapid. For
example, as early as 44 h into incubation, the vascular system is beginning to function,
with full formation of the heart occurring by d 7 of incubation. By d 3 to 6 of incubation,
the limb buds are visible, the auditory pits are established, the reproductive organs are
7

formed, and sex differentiation begins. By the mid-phase of incubation, the appendages
(beak and toes) are fully formed, and can be used as points of reference for distinguishing
the various phases of incubation. By end of the mid-phase (d 14 to 15 of incubation), the
embryo begins to move into hatching position, with its head turned toward the large end
of egg. During the late-phase, the developing embryo undergoes several maturation
changes in preparation for hatching. By d 17 of incubation, the chick's beak is turned
toward the air cell. By d 19 of incubation, the yolk sac begins to enter the body cavity,
and internal pipping begins. By d 20 to 21 of incubation, the yolk sac is completely
drawn into the body cavity and the hatching process begins.

8

Figure 2.1

The process of cleavage leading to the formation of blastodermal stages.

Drawing taken from Patten (1920)

9

Table 2.1

Stages of embryonic development during of incubation

D
Embryonic Developmental Event
ay
s
1 Formation of the blastoderm. Area pellucida and opeca on blastoderm. Primitive
streak and somite appears
2 Heart is beat, vascular systems are linked.
3 Circulatory system continues to develop, limb buds for wings and legs are visible,
auditory pit is established
4 Eye pigment present, leg and wing buds present, vasculature is present
5 Formation of reproductive organs, sex differentiation
6 Complete embryo differentiation, embryo has bird-like appearance, beak and egg
tooth formed, embryo voluntary movement evident
7 Feather tracts becoming prominent. heart is completely enclosed in the thoracic cavity
8 Eyes becoming prominent
9 Allantois completely covers the embryo, amnion, and yolk
10 Beak and toes hardens and are fully formed
11Comb serration, and down feathers begin to appear
12Eye lids closed
13Overlapping scales on legs, down feathers covers the body of embryo
14 Head turns toward the large end of egg, embryo begins turning to hatching position.
15 Rapid-eye-movement, intestines enters the abdomen, embryo reaches a growth phase
prior to hatching
16 Feather cover are present, yolk is the primary source of nutrient, albumen regressed
17 Amniotic fluid begins to regress and embryo begins to prepare for hatch with head
between legs.
18 Regression of amniotic fluid, beginning of yolk sac absorption into the embryo’s
body cavity. Head under right wing
19 Complete regression of the amniotic fluid , yolk sac half drawn into body cavity, beak
pips through air-sac (internal pipping), and embryo starts to breath with the lungs
20 Yolk sac completely drawn into the body, external pipping and vocalization, allantoic
respiration and circulation changes to pulmonary respiration
21 Pipping completed, normal hatching.
(Mauldin and Buhr, 1990; Parkhurst and Mountney, 1988)
Functional structure of the embryonated chicken egg
The functional compartments of the chicken embryo during incubation are shown
in Fig. 2.3. As the embryo differentiates from the blastoderm stage to a fully developed
embryo, there are at least 5 important compartments that must encompass and support the
10

embryo in its development. These include: the eggshell, yolk, chorioallantois, allantois,
and amnion. In addition, during embryonic development, the embryo utilizes the nutrients
that are contained within the maternal egg. These nutrients are found specifically in the
yolk, albumen, and shell.

Figure 2.2

Comparisons of major embryonic developmental milestones between
Hamburger and Hamilton stage classification and the entire embryonic
incubational period.

Drawing taken from Hamburger and Hamilton (1992).
Yolk
The yolk is an important extra-embryonic structure, providing essential nutrients
for the embryo throughout incubation (Romanoff, 1960) and during the first 3 to 4 days
of the chick’s posthatch life (Parkhurst and Mountney, 1988). The chicken embryo
eventually develops from secondary oocyte containing a large amount of yolk that is
ovulated by the hen. The yolk proteins are primarily formed in the liver and are
transported to the ovary via the blood. The yolk is formed from one of many small
cellular structures called oocytes located on the surface of the ovary. Once formed, a
secondary oocyte is released (ovulated) from the ovary and is captured by the
infundibulum of the oviduct, and after further maturation to an ovum is fertilized by a
11

sperm. The yolk makes up approximately 30 % of the total weight of an egg, and is
composed of water (48 %), digestible proteins (17 %), lipids (31 %), vitamins, and
minerals. The yolk lipids provide the energy needed for rapid embryonic development
and growth of the embryonic tissues (Moran, 2007). The fat soluble vitamins A, D, E,
and K, and the water soluble vitamins B2 (riboflavin) and B9 (folate), are distributed in
the yolk. In addition, the egg yolk contains a sufficient amount of iron and phosphorus
that support embryo growth and development. Other important function of the yolk
include: (1) embryonic formation - the yolk houses the germ cell (where fertilization
occurs) which is present at the upper pole of the yolk; (2) embryonic development - the
yolk provides a readily available source of nutrients to the developing embryo; (3)
immunological competence - the egg yolk contains yolk Immunoglobulins (IgY), which
are synthesized in the hen’s serum and are transported into the yolk to provide specific
antibody in the embryonic chicken (Leslie and Clem, 1969).
Albumen
Albumen makes up approximately 60 % of the total egg. Of this, 87 % of the
albumen is water, 11 % is protein, and 1 % is carbohydrate (Romanoff and Romanoff,
1949). The protein of the albumen maintains the viscosity and thickness of the albumen.
Albumen proteins include ovalbumin, ovotransferrin, ovomucoid, ovoglobulin, lysozyme
and ovomucin (Alleoni, 2006). Albumen also contains elements including potassium,
sodium, phosphorus, calcium, and iron. The primary function of the albumen is to protect
the embryo from adverse effects of microorganisms, as well as provide water, protein and
minerals for the developing embryo. The albumen surrounds the yolk and is attached to
the yolk by the chalaziferous layer. During embryonic development the albumen is
12

rapidly consumed by the embryo to supply amino-acids for protein synthesis within the
body to enhance development. Albumen is essential for embryonic development
compared to yolk and manipulating albumen can alter embryonic development during
incubation (Romanoff, 1960). Al-Murrani (1982) showed that injection of albumen into
late-stage embryo increased embryonic growth just prior to hatching. Similarly, when
albumen was removed from the egg prior to incubation, whole-body protein synthesis
was decreased (Muramatsu et al., 1990). These suggests that the albumen is plays a
significant role in regulating protein synthesis of the whole body of the developing
embryo during incubation.
Eggshell
As the egg travels down the oviduct, the eggshell is deposited around the egg in
the shell gland (uterus) prior to being laid. It takes approximately 20 to 22 hours for
complete egg shell calcification to occur in the uterus. The egg shell is made of calcite,
which is a crystalline form of calcium carbonate. The egg shell is made up of
approximately 98 % calcium carbonate, and 2 % organic shell matrix. The organic shell
matrix is made up of layers of proteins and mucopolysaccharides on which calcification
occur. Microscopically, the shell consists of inner and outer shell membranes that are
made up of a mesh work of protein fibers that are semipermeable, thus permitting the
passage of gases and water through them. These shell membranes stick together across
the entire surface area of the egg, except at the large end of the egg where they separate
to form the air cell. The egg shell consists of the mammillary layer, palisade layer,
surface crystal layer, and the cuticle. The mammillary layer forms the bases of the
palisade layer and is the site of initial calcium deposition on the shell membrane. The
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palisade layer, which is composed of calcium carbonate in columns, forms over the
mammillary layer. Outside of this, there is a vertical surface crystal layer that marks the
actual beginning of the egg shell and is characterized by a dense crystalline structure. The
cuticle is a thin, waxy coating made up of protein, polysaccharides, and lipid, which seals
the pores that open on the surface of the egg shell, and protects the egg from moisture
loss and microbial invasion. The major function of the eggshell is to protect and maintain
the embryo within a controlled internal environment. The pigment of the eggshell lies
beneath the cuticle (Parsons, 1982).
Amnion
The development of the amniotic membrane is evident by day 5 of incubation,
and completely envelopes the embryo by day 9 of incubation. The amniotic membrane is
formed by the differentiation of the ectoderm and mesoderm (Parkhurst and Mountney,
1988). The amniotic cavity becomes maximally filled with amniotic fluid at day 12 of
incubation (Patten, 1920). The amniotic fluid hydrates the embryo (Romanoff, 1960),
protects the embryo from physical and environmental changes during development, and
provides the necessary environment needed by the developing embryo as it changes
position during incubation (Patten, 1920). The embryo begins to ingest the amniotic fluid
during late stage of incubation (approximately day 17 of incubation), with complete
regression by day 19 to 20 of incubation. Jochemsen and Jeurissen (2002) showed that
substances injected into the amnion of an embryo at day 18 of incubation are taken up
through the mouth into the digestive and respiratory tract beginning 24 hours post
injection. Similarly, Weber et al. (2001) found Eimeria oocysts within the intestine of the
embryo within a few hours following the in ovo injection of Eimeria tenella life cycle
14

stages. Furthermore, Jochemsen and Jeurissen (2002) showed that when embryos were
injected at day 16 of incubation, only 50 % of the injected substances were recovered
from their organs. However by day 18 of incubation, all injected substances reached the
embryonic organs. This showed that injection of substances into the amnion at day 18 of
incubation is effective, due to the large size of the amnion at this time. In addition, late
stage embryos, at day 18 of incubation, display strong rhythmic movement as they
approach hatching, and are able to actively imbibe the amniotic fluid and its constituent
substances, allowing these substances to be actively distributed throughout their organs
and tissues as early as 24 hours post injection. Several authors have demonstrated great
success in injecting in the amnion on day 18 of incubation (Sharma et al., 1984; Sharma,
1986; Jochemsen and Jeurissen, 2002; Weber et al., 2004; Williams and Hopkins, 2011;
Zhai et. al., 2011a, b; Bello et al., 2013; Bello et al., 2014).
Chorio-allantois
The chorioallantoic membrane (CAM) of the chick embryo is formed by the
partial fusion of the chorionic and allantoic membranes. The CAM completely surrounds
the chicken embryo by day 10 of incubation, and along with other contents of the egg,
becomes attached to the shell membrane, thus allowing the vascular system to be in direct
contact with the eggshell membranes (Parkhurst and Mountney, 1988). Based on this
arrangement, the CAM performs at least 2 important functions in the developing chick
embryo. Firstly, the CAM is responsible for mobilizing shell calcium into the circulation
of the embryo for bone ossification during embryonic development (Terepka et al.,
1976). Secondly, the CAM functions as an embryonic lung by serving as the medium for
gas exchange, as carbon dioxide is released and oxygen is taken in through the pores in
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the eggshell. In addition, the CAM is responsible for the reabsorption of water and
electrolytes from the allantois where urinary waste products are discharged, and it
provides acid-base balance within the egg of the developing embryo (Gabrielli and
Accili, 2010).

Amnion

Embryo body
Figure 2.3

Compartments of the chicken embryonic egg on day 18 of incubation,
accessible by in ovo injection

Image taken from Embryo Development 101; Zoetis Animal Health, Poultry Health
Division.
Allantois
The allantoic membrane is a thin cell layer between the amnion and the chorion,
and encloses the allantoic fluid (Gabrielli and Accili, 2010). The allantoic membrane is
formed by the differentiation of the mesoderm layer at approximately day 5 of incubation
(Parkhurst and Mountney, 1988). As the embryo continues to develop, the allantois
stores metabolic wastes (uric acid) produced by the embryo. It also plays a role in the
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excretion, respiration and metabolic processes of the developing embryo (Parkhurst and
Mountney, 1988). During incubation, the volume of the allantoic fluid initially increases,
reaching a maximum by day 13, which allows it to meet the functional needs of the
embryo. It then declines rapidly until hatching. In addition, the allantoic membrane
facilitates the reabsorption of water from the allantoic fluid, as well as facilitating the
absorption of the remaining albumen (Parkhurst and Mountney, 1988).
Coccidiosis
Coccidiosis is an infectious disease caused by protozoa in the phylum
Apicomplexa, and family Eimeriidae. Poultry coccidiosis is caused by species of the
genus Eimeria, and there are at least 9 distinctly recognized species of Eimeria that infect
chickens (Chapman, 2000; Dalloul and Lillehoj, 2005; Lillehoj and Lillehoj, 2000).
Eimeria species are distinguishable by individual biological characteristics associated
with each species. These biological characteristics include: oocyst size and shape, size of
tissue stages produced during their life cycle, site of intestinal infection, pathogenicity,
gross appearances of lesions, and immunogenicity (McDougald and Fitz-Coy, 2008).
Eimeria species parasitizes and replicates in specific portions of the intestinal tract,
resulting in various levels of pathogenicity (McDougald, 2003).
Coccidia life cycle
Development of Eimeria parasites within the host involves both endogenous and
exogenous stages (Fig. 2.4). Within 48 h at optimal temperature (30 oC), oxygen
concentration, and relative humidity levels, unsporulated oocysts present within the
poultry environment become viable infective sporulated oocysts (Reid, 1978). Infection
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occurs when a susceptible chicken host ingests sporulated oocysts from its environment.
After the sporulated oocysts are ingested, they are subjected to enzymatic and grinding
actions in the gastrointestinal tract (GIT) and gizzard, respectively. This processes leads
to the excystation and release of sporozoites (Reid, 1978). Sporulated oocysts contain 4
sporocysts, with each sporocyst containing two sporozoites (infective stage). The
grinding action of the gizzard causes a release of the sporocysts from the oocysts,
whereas actions of digestive enzymes results in the release of sporozoites from the
sporocysts. The released sporozoites initially penetrate the host’s intestinal wall,
extending from the surface epithelium to the deep epithelium of the intestinal glands.
Invasion of the intestinal wall occurs in various regions of the intestine where specific
Eimeria species have a predilection (Reid and Long, 1979).
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Figure 2.4

Stages of Eimeria life cycle occur in exogenous (external environment) and
endogenous (within the host) phases

Drawing taken from Price (2012).
The sporozoites further develop into trophozoites (feeding stage), which absorb
nutrients from the intestinal tissues. Trophozoites increase in size and undergo multiple
asexual divisions in a process referred to as schizogony or merogony, which leads to the
formation of schizonts. At maturity, schizonts rupture and release merozoites (small
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parasitic stages within the schizont). The merozoites, which are released from the initial
infected cells, infect new epithelial cells, and the process of development through the
trophozoite and schizogony stages are repeated. At least 2 to 4 generations of merogony
asexual development occurs depending on the species of Eimeria (Reid and Long, 1979).
After completion of the last merogony cycle, the resulting merozoites penetrate new
epithelial cells and initiate the sexual phase of the cycle. The sexual phase involves
formation of male (microgametocyte) and female (macrogametocyte) gametocytes in a
process referred to as gametogony (Fayer, 1980). During gametogony, the male
gametocyte undergoes multiple divisions releasing numerous biflagellate male gametes
(microgametes). The female gametocyte (macrogametocyte) matures to a single large
macrogamete. A process of fertilization occurs between the microgamete and
macrogamete within the host intestinal epithelium, leading to the formation of a zygote.
The zygote forms a thickened wall and matures into an oocyst (Fig. 2.5). The mature
oocyst, consisting of 4 sporocysts, each containing 2 sporozoites, is released from the
host gut and passed out in the feces of the bird (Reid, 1978). The entire life cycle process
may take up to 14 days, depending on the specie of Eimeria (Reid and Long 1979). The
timelines encompassing the complete life cycle of the various species of Eimeria have
been previously described (Reid and Long, 1979). These include the length of time for
sporozoite excystation, which usually occurs within 2 h post ingestion of intact oocysts;
the prepatent period (period required for complete endogenous development into a zygote
i.e. from sporozoites excystation to gametogony stage), which can range from 4 to 7 days
depending on the species of Eimeria (Reid and Long, 1979); and environmentally-
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influenced exogenous phase, which can occur over a period of 2 to 3 days (Chapman et
al., 2002).

Figure 2.5

Overview of the 7-day life cycle of Eimeria tenella

Stages include 2 or more asexual and 1 sexual cycle during the 6 days following oocyst
ingestion. Taken from McDougald and Fitz-Coy (2008).
Etiology, diagnosis and pathogenicity of coccidiosis in chickens
Coccidia oocysts can be shed in the feces of infected and recovered birds,
contaminating feed, water, and litter. The coccidia oocyst is ubiquitous to the chicken
house, especially under an intensive rearing system, providing an opportunity for
increased fecal-oral transmission of viable oocysts among susceptible birds. Intact
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unsporulated oocysts can remain in the chicken environment and remain non-infective for
a long period of time. However, under appropriate optimal temperature, humidity, and
oxygen concentration conditions, the oocysts sporulate and can become infective within 1
to 2 days (McDougald, 2003). The sporulated oocysts can survive in the environment for
a long period of time, depending on environmental conditions. Although a total of 9
species of Eimeria affecting chickens have been described (E. acervulina, E. brunetti, E.
hagani, E. maxima, E. mitis, E. mivati, E. necatrix, E. praecox, and E. tenella), only 7
species commonly parasitize commercial chicken operations (E. acervulina, E. brunetti,
E. maxima, E. mitis, E. necatrix, E. praecox, and E. tenella). Of those, 3 are commonly
reported in broiler chicken operations (E. acervulina, E. maxima, and E. tenella)
(Chapman, 2000; Lillehoj and Lillehoj, 2000; McDougald, 2003). The development of
Eimeria in specific locations of the chicken digestive tract (Fig. 2.6) has been used to
differentiate the different types of Eimeria species (McDougald and Fitz-Coy, 2008).
Eimeria acervulina and E. praecox parasitize the duodenum but can extend to the midintestine in heavy infections. E. mitis, E. maxima, and E. necatrix typically parasitize the
mid-intestine, but can extend to the lower portion of the intestine in heavy infections.
Eimeria. tenella parasitize the ceca, and E. brunetti parasitize the lower intestine and
rectum (Levine, 1942; Joyner, 1978). The pathogenicity of coccidia infections range from
moderate to severe, and may be influenced by the age, immune status and genetic
background of the affected bird, its possession of concurrent diseases, the species of
coccidia that infect it, and the number of coccidia oocysts that it ingests (Vermeulen et
al., 2001). Infections by E. acervulina and E. mitis result in mild enteritis, which results
in nutrient malabsorption, reduced growth rate, and poor feed efficiency. Infections by E.
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brunetti and E. maxima result in inflammation and thickening of the small intestinal wall,
with tiny petechial hemorrhages on the serosa and mucosa surfaces of the epithelium, and
subsequent epithelial sloughing. Mild infections may go unnoticed, but may produce
moderate mortality, reduced weight gain, and a poor feed conversion ratio. Infections by
E. necatrix and E. tenella, which are the most pathogenic of chicken coccidia, result in
weight loss, high morbidity and mortality, extensive hemorrhage, and bloody feces.
Mortalities as a result of natural infections may be as high as 25 % in commercial flocks,
and birds that survive the infection appear unhealthy, and suffer from cachexia and
secondary infections. Eimeria praecox is generally considered to have little
pathogenicity. However, heavy infections may cause intestinal contents to be watery, and
may result in reduced weight gain, poor feed conversion, morbidity, and dehydration in
birds.
Johnson and Reid (1970) developed a scoring system based on the visual
examination of the different lesions produced by Eimeria species in different locations of
the host’s intestine. Lesion scoring was mainly initially used for experimental infections
with known outcomes based on the species of Eimeria. However, the scoring system has
become part of commercial operations, especially in the commercial broiler industry to
continuously monitor the development of coccidiosis infections and the development of
immunity within the broiler flock during grow-out. Lesion scoring is a technique which
provides a numerical ranking based on the severity of gross lesions caused by different
species of Eimeria. Scoring is based on the examination of 4 separate sections of the
intestine. The upper intestine (duodenum) is examined and scored for lesions caused by
E. acervulina and E. mitis. The mid-intestine (from the duodenum past the meckle’s
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diverticulum) is examined for lesions caused by E. maxima, E. praecox, E. necatrix, and
E. mitis. The lower small intestine (from the yolk sac diverticulum to the cecal junctures)
is examined for lesions caused by E. maxima, E. brunetti, E. necatrix, and E. mitis. The
cecum is examined for lesions caused by E. tenella, only (Fig. 2.6). In the scoring
technique developed by Johnson and Reid (1970), a score of 0 to 4 is assigned (0 = no
gross lesions, and 4 = most severe gross lesion). In addition to gross lesion scoring, other
diagnostic tools used to detect the severity of coccidiosis infections include microscopic
lesion scoring, which is especially useful in detecting Eimeria species, such as E. mitis
and E. praecox, that do not produce evident gross lesions (Idris et al., 1997), oocysts
output (Idris et al., 1997), or histopathology (Idris et al., 1997; McDougald and Fitz-Coy,
2008). Several molecular methods that can differentiate between Eimeria species have
been successfully developed. These methods include starch block electrophoresis, which
differentiates between species based on isoenzyme patterns of the oocysts (Shirley 1975),
and rRNA and rDNA probes which identify species by their characteristic restriction
fragment patterns (Ellis and Bumstead, 1990). PCR techniques such as: conventional
PCR and real-time PCR (Shirley, 1994); amplification of the internal transcribed spacer
region 1 from genomic DNA (Shirley and Harvey, 1996); PCR RFLP techniques; and
TaqMan probe-based qPCR (Woods et al., 2000), have all been used to detect and
differentiate between Eimeria species.
Interaction between coccidiosis and gut health
Coccidia oocysts are ubiquitous in the environment because they are easily
transmitted from one chicken house to another through the host (chickens), vermin,
contaminated equipment, feed, litter, and humans (Williams, 2005). Once the coccidia
24

oocysts finds its way into the chicken house, it spreads via fecal-oral route, and birds may
be exposed to coccidia throughout their lives. In practise, under the intensive
management conditions, coccidiosis does not occur alone but rather occurs in consonance
with other diseases that affect poultry, and management practices. In addition, the
microflora of the gastrointestinal tract (GIT) consists predominantly of bacteria, and
fungi and protozoa to a lesser degree. The interplay between these various organisms
determines the microbial environment in the GI tract (Gabriel et al., 2006), and can
influence the outcome of the coccidiosis infection. Because the GIT is a microbial
community, several endogenous and exogenous factors can alter the microbiota balance
within the GIT community thereby leading to presence of a disease state in the form of
coccidiosis. These factors include infectious disease agents, nutrition, and management
practices (Hughes, 2005). The interaction of coccidiosis with disease agents is reviewed
in this section:
Coccidiosis and necrotic enteritis
Clostridium perfringens is part of the normal microflora of the chicken gut.
However certain predisposing factors creates an imbalance of this bacteria within the gut,
leading to clinical necrotic enteritis (NE). Damage to the GIT by bacteria such as
Clostridium perfringens results in loss of performance e.g. reduction in BWG associated
with coccidiosis. On the other hand it is thought that damage to the GIT by coccidiosis is
a predisposing factor to NE, because coccidiosis often occur prior to or concurrently with
NE outbreaks in the field (Williams, 2005; McDevitt et al., 2006). Therefore, evidence
indicates that there is a relationship between NE and coccidiosis, so that the effects on
performance in broiler may be synergistic in nature rather than coccidiosis alone. The
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relationship between NE and coccidiosis has also been proven based on the methods of
control (Williams, 2005).
a) Ionophores that are used in the control of coccidiosis also exert effect on NE.
b) The administration of coccidiosis vaccine in the absence of in-feed ionophores
in leads to an increased risk of NE.
c) It is thought that mild coccidial infection produced by live-coccidial oocyst
vaccine can predispose to NE. this potential risk associated with coccidial
vaccine prevents its use by certain commercial producers.
Several studies have shown that vaccination with non-attenuated or attenuated
anticoccidial vaccine, or medication with ionophores and antimicrobial growth promoter
(AGP) can occasionally lead to the development of NE and coccidiosis in broilers
(Williams, 2002a). Disturbances in balance of microbiota within the chicken gut is the
single most important factor that may affect health status and production performance of
birds in commercial poultry operations.
Coccidiosis and Immunosuppressive diseases
Immunosuppresive disease such as infectious bursal disease, chick infectious
anemia virus and Marek’s disease, and stressors may exacerbate or complicate Eimeria
infection, producing severe coccidiosis (Rice and Reid, 1973; McDougald et al., 1979).
In addition, gangrenous dermatitis (GD), caused mainly by Clostridium perfringens and
Clostridium septicum in immunosuppressed birds, may predispose birds to coccidiosis
(Li et al., 2010). The enteric and non-enteric viruses such as adenoviruses, reoviruses,
enteroviruses, and rotaviruses, can complicate coccidiosis, leading to depression in
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weight gain, impaired feed utilization, high morbidity, and poor flock uniformity
(Reynolds, 2003; McNulty and Guy, 2003).
Coccidiosis and nutritional factors
Diets make up over 70 % of poultry production and producers continue to look for
ways to produce least cost diets, leading to the use of feed ingredients that compromise
the chicken’s gut health. Non-starch polysaccharides (NSP) commonly found in cereals
such as barley, wheat, rye, and oats are resistant to the host’s digestive enzyme, and leads
to high viscosity within the intestinal lumen and the digesta. Increased viscosity of the
digesta can promote resident bacteria colonization, increased passage time, depressed
digestive enzyme action, decrease nutrient digestion, and overall poor performance such
as depressed growth rate (Waldenstedt et al., 2000). In addition, feed form have also been
shown to affect gut health leading to mortalities associated with a combination of NE and
coccidiosis. Finely ground feed form may cause higher mortality attributed to NE
compared to coarsely ground feed form (Branton et al., 1987). Feeding whole wheat to
broiler chickens increased gut health and nutrient absorption, reduced bacterial counts
(Salmonella Typhimurium and Clostridium perfringens) in the intestinal tract of the birds
and increased feed efficiency (Plavnik et al., 2002; Engberg et al., 2004). In addition,
high concentrations of animal proteins (fish-meal) and animal fat in broiler diets may
lead to high counts of ileal and cecal C. perfringens (Drew et al., 2004)
Immunogenicity of coccidiosis
Extensive research has been conducted at the cellular and molecular levels to
understand mechanisms of the protective immune responses against coccidiosis infection
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in chickens. Following an initial exposure to Eimeria oocysts by ingestion, a non-specific
immune response is activated by low pH and inflammatory reactions, specifically to limit
the number of active sporozoites that reach the specific site of infection.
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Diagnostic features of different Eimeria species found in chicken

Taken from McDougald and Fitz-Coy (2008).

Figure 2.6
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Once sporozoites reach the site of infection and infection is established, the first
defensive response elicited by the bird is the formation of specific immunity which
include cell-mediated and humoral immune responses (Lillehoj et al., 1999). Although
under commercial conditions chickens are often simultaneously infected by multiple
species of Eimeria, it has been established that a specific immune response to one
Eimeria species induces little or no protection against challenges from other species
(Lillehoj and Lillehoj, 2000). In early studies, it was suggested that cell-mediated
immune responses (cellular immunity) play a major role in the development of active
protection against Eimeria, with humoral immunity playing only a minor role (Rose and
Hesketh, 1979; Lillehoj and Choi, 1998; Dalloul and Lillehoj, 2005). Lillehoj (1987)
reported that protective immunity against coccidiosis challenge was not significantly
affected in bursectomized chickens despite an inability to produce specific antibodies. It
was then concluded that T-cell immunity plays a major role during infection with
Eimeria, whereas antibodies have little or no effect against Eimeria. The direct role of Tcell subsets, referred to as cytotoxic CD8+ and CD4+ helper T-cells, has been
demonstrated in the development of active immunity in chickens (Lillehoj et al., 2004;
Lillehoj et al., 2007; Trout and Lillehoj, 1995). There is evidence that CD4+ cells are
involved in primary coccidiosis infections, while CD8+ cells are important in later
infections (Lillehoj and Choi, 1998). Eimeria species generate specific immune responses
in different ways depending on their location within the gut. It was found that both CD4+
and CD8+ T-cells were stimulated at specific sites of infection after a primary infection
(Bessay et al., 1996). Cornelissen et al. (2009) showed that infection with E. acervulina
induced the production of CD8+ T-cells, which is similar to findings showing an increase
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in CD4+ and CD8+ T-cells with E. maxima and E. acervulina infections, respectively
(Trout and Lillehoj, 1995). Following infections by E. acervulina and E. maxima,
sporozoites have been reported within CD8+ cells, and occasionally in CD4+ cells. Also,
CD4+ cell counts remain elevated during later infections, indicating that IEL cytotoxic
CD8+ and CD4+ T-cells provide both active and protective immunity (Trout and Lillehoj,
1995). Furthermore, the roles of cytokines, NK cells, macrophages, and helperT-cells
(Th1 and Th2) in cell-mediated protection against Eimeria have also been reported. It
was shown that increases in interferon-γ (IFN- γ) production by effector T-cells, inhibits
parasite invasion, and, therefore, elicits protection (Lillehoj et al., 2004). Cornelissen et
al. (2009) noted an increase in macrophages, Th1 (IL-2, IL-18 and IFN- γ), Th 2 (IL-4
and IL-10), and helper T-cells following infections with E. acervulina, E. maxima, E.
maxima. The Th1 and Th2 immune pathways, which are important in resolving
intracellular and extracellular parasites, respectively, play key roles in enhancing parasite
killing by NK cells, T-cells, and macrophages.
In addition to the role of cell-mediated immunity, several studies have also shown
that humoral immunity plays a role in protection against coccidiosis infections. Although
the role of Eimeria specific antibodies in immune responses is limited and has not been
well defined, IgM, IgG, and IgA antibodies have been recovered in chickens following
their recovery from a coccidiosis infection. Circulating levels of coccidial specific IgY
and IgA were detected in birds 7 days after a coccidiosis infection, with peak levels
reached by day 14 (Lillehoj, 1987). The type of antibody and the time they are produced
(during a primary infection or in a convalescence stage) is dependent on the Eimeria
species involved in the infection. Trout and Lillehoj (1995) suggested that after a
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coccidiosis infection, parasites enter the intestinal epithelium, but parasite development is
prevented by humoral immune responses. This suggests that both cell-mediated and
humoral immunity is activated following a coccidial infection, although innate immunity
plays a major role in the development of immune responses against coccidiosis (Lillehoj
et al., 2007).
Impact of coccidiosis on broiler industry
Of all the intestinal pathogens that affect the broiler chicken, coccidiosis is
regarded as a parasitic disease with a substantial economic impact on the poultry industry
(Williams, 2002). The significant economic impact of coccidiosis is attributed to losses
due to poor performance (poor feed efficiency and body weight gain) associated with
subclinical infections. Furthermore, high morbidity and mortality are associated with
clinical coccidiosis infections, and the cost involved in prophylaxis and curative
treatments (Vermeulen et al., 2001; Peek and Landman, 2011). In the United States of
America (US), it is estimated that over $700 million per year is lost for the control and
treatment of coccidiosis (Chapman, 1998). The estimated loss to the worldwide
commercial poultry industry due to coccidiosis is approximately $3 billion (Williams,
1999a; Peek and Landman, 2011), while in the United Kingdom, the loss has been
estimated to be GB£38.6 million (Williams, 1999a; Shirley et al. 2007). Commercial
broiler chicken production in the US involves the raising of large numbers of birds (up to
50,000 chickens) on built-up litter within a single house, with litter changes occurring
only between a minimum of 6 flock grow-outs each year (Bell and Weaver, 2002). This
intensive method of production provides a good opportunity for the transmission of
Eimeria parasites between flocks, and between individual birds. Coccidial oocysts can
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survive in chicken houses for a very long time, and the presence of the oocyst cell wall
makes them resistant to the environment and to disinfectants commonly used in
commercial chicken house cleaning. Similarly, sporulated oocysts can survive in the
environment for up to 2 years (Reid, 1990). Hence, it is almost impossible to find a
commercialized broiler chicken flock that is completely free of coccidia (Williams,
1999a). Although clinical coccidiosis is not commonly found in commercial operations,
subclinical coccidiosis continues to be a persistent problem (Williams, 1999b; Lee et. al.,
2009). In general, there are 3 classifications for coccidiosis infections, all of which cause
some type of adverse effects on economic performance. These 3 classifications are:
1.

Clinical coccidiosis: This is characterized by visible pathological changes
in the intestinal epithelium leading to diarrhea, bloody feces, blood loss,
hypovolemic shock, mortality, and morbidity.

2.

Subclinical coccidiosis: This is perhaps the most common form. This type
of coccidiosis unlike clinical coccidiosis is not very visible, because there
are no obvious signs of disease. However, it causes some pathological
changes to the intestinal lining, leading to growth depression, a high feed
conversion ratio, and sometimes mortality (due to debilitation of the host).

3.

Coccidiasis: This is regarded as a mild infection with no adverse effects on
the host (Levine, 1961).

Three species of Eimeria are most commonly reported in commercial chicken
operations in the US, with each species causing distinctly recognizable diseases. The
EM1 vaccine is formulated with these 3 species of Eimeria, and can therefore provide
immune protection against the 3 species of Eimeria. These species are: E. acervulina, E.
maxima, and E. tenella. E. acervulina is the most frequently encountered worldwide in
commercial poultry (Chapman, 2005). The oocysts are ovoid in shape, with an average
size of 18.3 × 14.6 µm. Mild infection may not be prominent, but can result in reduced
weight gain, reduced feed efficiency, and loss of skin pigmentation. Heavy infections can
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result in diarrhea, a pronounced reduction in weight gain, and even mortality. Lesions
may coalesce, resulting in a thickening of the intestinal mucosa and reduced nutrient
absorption within the small intestine. Gross pathological signs may be limited to the
duodenal loop in light infections, but may extend to the proximal small intestine in heavy
infections. Microscopic smears during field posting sessions may indicate coccidia
infections at varying developmental stages. Histopathological tests of the duodenal loop
and proximal small intestine may reveal coccidial infections at various stages in the villi
lining, with subsequent damage to the tips of the villi and thickening of the mucosa.
E. maxima predominantly parasitize the mid-small intestine from the end of the
duodenal loop to areas past the yolk sac diverticulum. In heavy infection, lesions may
extend throughout the small intestine. The characteristically large oocysts of E. maxima
are easily recognizable, measuring an average of 30.5 × 20.7 µm. Large infections with
up to 200,000 oocysts can result in weight loss, rough feathers, poor weight gain,
diarrhea, morbidity, and occasional mortalities. Gross lesions develop approximately 5 to
8 days post-infection when coccidial sexual life cycle stages develop in deeper tissues.
Lesions include congestion, edema, thickening of the intestinal mucosa, and yelloworange fluid accumulations in the mid-gut (ballooning). Microscopic lesions include
cellular infiltration, edema, the presence of various life cycle stages of Eimeria, and the
destruction of intestinal villi structure.
E. tenella infection is the most recognizable type of poultry coccidiosis, because
of the lesions it produces in the ceca. Gross lesions include bleeding, and loss of skin
pigmentation, and subsequently cause weight loss, anemia, high levels morbidity, and
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eventual mortality in birds. The average oocyst size is 22.0 × 19.0 µm, and infections by
1,000 to 10,000 sporulated oocysts can produce clinical disease in birds.
Control of coccidiosis
Since 1948, broad spectrum anticoccidial drugs have been used for the control of
coccidiosis in poultry. These anticoccidial drugs can be classified into 2 main categories
based on their specific modes of action (Chapman, 1999). These 2 categories are:
1.

Synthetic anticoccidials: These compounds are produced by chemical
synthesis and are often referred to as ‘chemicals’. Their mode of action is
generally by affecting parasite metabolism. However, their specific mode
of action depends on the actual compound itself. For example, decoquinate
and clopidol inhibit the mitochondrial respiration of the parasite, and
sulphonamides inhibit the folic acid metabolic pathway and uptake of
vitamin B1 by the parasite. Other synthetic anticoccidials with unknown
modes of action include halofuginone, nicarbazin, robenidine, and
diclazuril.

2.

Polyether ionophores (ionophore antibiotics): These anticoccidials are
produced by fermentation using Streptomyces or Actinomadura species.
Their mode of action is primarily by altering the transport of monovalent
and divalent cations (such as Na+, K+, Ca++) across cell membranes and
the subsequent disruption of osmotic balance (Kant et al., 2013). They can
be classified as monovalent ionophores (e.g. Monensin, Narasin and
Salinomycin), and divalent ionophores (e.g. Lasalocid). Ionophores allow
for the development of immunity against coccidia (Chapman, 1999), and
can have antimicrobial and growth promoting activities, such as the
inhibition of gram-positive organisms (Vissiennon et al., 2000).

3.

Some anticoccidial products consist of both chemical and ionophore
compounds (e.g. Maxiban®, which contains a mixture of Nicarbazin and
Narasin), or a combination of two chemical compounds (e.g Lerbek ®,
which contains methylclorpindol and methylbenzoquate). These types of
anticoccidials are widely used in poultry production for the control of
coccidiosis. The various in-feed anticoccidials that are commonly used in
broilers are described in Table 2.2.

Anticoccidial drugs remain the main stay for poultry producers in the control of
coccidiosis, because they are a good preventative method when added to chicken feed,
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and because they are well adaptable for large-scale use (Chapman, 2010). However, the
intense and widespread use of anticoccidial drugs has led to the worldwide development
of an acquired resistance to the drugs by coccidia (Chapman, 1997). Resistance
occurrences have been reported wherever poultry are intensively reared, in the US, South
America, Europe, and China (Jeffers, 1975; Chapman 1997; Peek and Landman 2003).
Resistance to some chemical anticoccidials can develop quickly, or resistance to
ionophores may take several years (Chapman, 1997; McDougald, 2003). Acquired drug
resistance to coccidia may be complete (in which increasing doses up to maximum levels
that are tolerated by the host are ineffective, e.g. nicarbazin). However, it is possible that
drug resistance may allow trickle-like infections to occur, which can lead to the eventual
development of immunocompetence (Chapman, 1998; Peek and Landman, 2003). In
order to ameliorate the problem of drug resistance, poultry producers have adopted
rearing programs that make use of compounds with different modes of action. This
rationale is based on the fact that reducing the length of anticoccidial drug exposure tends
to increase the sensitivity of coccidia to the various drugs. Shuttle and rotation programs
are most commonly employed (McDougald, 2003; De Gussem, 2007). In a shuttle
program, different drugs are used in the different feed-type phases during the grow-out
period. For example, a chemical (i.e. Nicarbazin) may be added to the starter feed,
whereas an ionophore may be added to the grower feed. In a rotation program, different
drugs are used in successive flocks. Although there has been a reduction in coccidiosis
outbreaks, due in part to an increase in the effectiveness of anticoccidial drugs
administered through the shuttle and rotation programs, the use of these programs does
not fully prevent drug resistance, because most Eimeria isolates found in commercial
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poultry practices exhibit varying levels of resistance to more than one drug (Chapman,
1997). Another important factor affecting the use of in-feed anticoccidials are concerns
about drug residues in poultry products and the desire of consumers to ban the use of
drugs in animal feeds (Young and Craig, 2001; McEvoy, 2001). The use of
antimicrobials and antibiotic growth promoters in feed has received enormous criticism,
particularly in the European Union, where new legislation is being proposed that would
phase-out the use of these drugs (Farrant, 2001). There is, therefore, a pressing need to
shift from the use of chemotherapeutics for the control of coccidiosis to other alternative
control options.
Alternatives for anticoccidial drugs
The occurrence of anticoccidial drug resistance together with increasing consumer
and regulation concerns on the use of anticoccidial drugs in chicken feed has resulted in
the search for alternative control strategies. The effects of these alternative compounds
for the control of coccidiosis have been extensively reviewed. These include (1) natural
products that are rich in fatty acids (Allen and Danforth, 1998), (2) plant extracts (Naidoo
et al., 2008), (3) antioxidants (Augustine et al., 1999; Youn and Noh, 2001), (4) pre- and
probiotics (Peek and Landman, 2011) and (5) vaccines (Vermeulen, 2001; Williams,
2002; Chapman, 2002, 2014; Tewari, 2011).
Sources rich in fatty acids
Fat sources containing high amounts of n-3 fatty acids (docosahexaenoic acid,
eicosapentaenoic acid, and linolenic acid), such as fish oils, flaxseed oil, and whole
flaxseed, added to chick starter rations at 1 day of age, have been shown to effectively
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reduce the amount of lesions resulting from challenge infections with E. tenella.
Conversely, these fat sources have not proven effective for challenge infections by E.
maxima (Allen et. al., 1997a). There is evidence that fish oil and flaxseed oil diets reduce
lesions associated with the development of E. tenella in the gut. These oils have also been
shown to cause the ultrastructural degradation of both the asexual and sexual stages of the
organism, which are characterized by cytoplasmic vacuolization and chromatin
condensation within the nucleus (Allen et.al., 1997a; Allen and Danforth, 1998). It was
concluded that the presence of a high percentage of easily oxidized double bonds in diets
rich in n-3 fatty acids would induce a state of oxidative stress that is detrimental to
Eimeria parasite development.
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Ionophore

Ionophore
Ionophore

Coban,
Elancoban
Avatec
Bio-cox,
Salinomax,
Sacox
Cygro

Monensin

Lasalocid

Salinomycin

Maduramicin

Chemical

Robenz,
Cycostat

Amprol

Clinacox

Robenidine

Amprolium

Diclazuril

Schering-plough

MSD-AGVET

American
Cyanamid

Elanco

American
Cyanamid

Agri-Bio

Thiamine antagonist, blocks the thiamine receptors and makes thiamine
unavailable to the parasite. It is effective against 1st generation of
trophozoites and schizonts and shows peak activity early in day 3 of
cycle. It is active against E. tenella, E. necatrix and E. acervulina and to
lesser extent E. maxima. Effective at 0.0125 to 0.025% mixture in the
feed
Effective at 1 ppm mixture in the feed

Inhibits oxidative phosphorylation in late first generation and second
stage schizonts, but mostly effective against the maturing first generation
schizonts.It is effective at 0.0066% mixture in the feed. It is used to a less
extent in Europe and South America, but not in USA

Most potent among the polyether Ionophores. Aministered at 5 to 6 ppm
in feed. Has ionic affinity. May cause severe cardiovascular defects in
host cells
Has anticoccidial activity at 54 to72g/T in feed, and affinity for sodium
and potassium ions

Closely related to monensin. It has anticoccidial activity at 0.01% in the
feed. Has affinity for sodium and potassium ions

Biological activity and mode of action
Broad spectrum activity. Acts on trophozoites and 1st generation
schizonts, within first 2 days of life cycle. Form complexes with sodium
Elanco
and potassium ions in the host and developing parasite. The monensincation complex renders membrane permeable to sodium and potassium
ions. Effective at 0.01 to 0.121% concentration in the feed
Effective at 0.005 to 0.0075% concentration. Has affinity for divalent
Hoffmann-La Roche
cations as well as monovalent ions

Company

Chart information taken from Mathis et al. (1984), McDougald and Fitz-Coy, (2008), Chapman, (2010), and Kant et al. (2013).

Chemical

Chemical

Ionophore

Monteban

Narasin

Ionophore

Class

Trade name

Various anticoccidial drugs used in poultry feeds.

Chemical name

Table 2.2
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Deccox

Stenorol

Decoquinate

Halofuginone

Sulphaquinoxaline

SQ

Maxiban

Amprol Plus

Nicarb

Nicarbazin

Amprolium +
Ethopabate
Narasin +
Nicarbazin

Trade name

Chemical name

Table 2.2 (continued)
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Chemical

Chemical +
Chemical
Ionophore +
Chemical

Chemical

Chemical

Chemical

Class

Merck

Elanco

Merck

Agri-vet

Rhone-Poulenc

Merck

Company

Has broad spectrum activity and effective against all Eimeria spp. This
compound has coccidiocidal activity, mainly against the 2nd generation
schizonts. It alters the intracellular energy-supplying ATP of the
coccidial parasite, and effective at 0.0125% concentration in feed. It
should not be used in egg laying birds because it reduces egg production
and number of fertile eggs. It also causes depigmentation of eggs,
malformed egg yolk, and poor hatchability.
Has broad spectrum coccidiostat activity and inhibits sporozoite
development. It is used at a concentration of 0.003% in the feed. Has no
withdrawal requirements
Has potent broad spectrum coccidiocidal and coccidiostatic activity
against 1st and 2nd generation schizonts. Effective at a feed
concentration of 3 ppm. Use in young birds upto 12 weeks of age but
not be used in egg laying birds
Effective at a feed concentration of 0.0125% amprolium and 0.004%
Ethopabate
Synagestic effect of an ionophore and chemical anticoccidial. Effective
at a feed concentration of 54-90 g/T
Has an inhibitory effect on schizogony at feed concentration of 0.025 to
0.033% against E. acervulina, E. necatrix, and E. tenella. Feed
concentration of 0.1% inhibited invasion by the sporozoites.
Synergestic effect with pyrimethamine gave better control of E.
acervulina, and E. maxima

Biological activity and mode of action

Plant extracts
Different herbal substances have been studied for their potential use as dietary
supplements to control coccidiosis. Artemisinin, a Chinese herbal extract obtained from
Artemisia annua and Artemisia sieberi, is a naturally occurring endoperoxide with
antimalarial properties, and has been shown to be effective in reducing oocyst output of
E. acervulina and E. tenella infections, but not E. maxima, when incorporated in starter
diets (Allen et al. 1997a, b). Its mode of action is thought to be by the induction of
oxidative stress in the parasites. It is most effective against E. acervulina and E. tenella
infections when fed at levels of 8.5 ppm and 17 ppm, respectively (Allen and Danforth,
1998). In a study by Youn and Noh (2001), the anticoccidial activity of 15 Asian herb
extracts was evaluated following challenge infections with E. tenella. Although all 15
herbal extracts showed varying degrees of effect, extracts from Sophora flavescens Aiton
was the most effective in maintaining body weight gain, improving survival rates, and
reducing bloody diarrhea, lesion scores, and oocyst production. Extracts from Sophora
japonica, Torreya nucifera affected weight gain, clinical signs of disease, survival rates
and lesion scores less, when compared to an infected control group. It can therefore be
concluded that plant extracts can vary in their mode of action, and effects on coccidiosis
control.
Antioxidants
Use of plant extracts with antioxidant activities for the control of coccidiosis has
also been studied. Allen et al. (1997a) showed that chick feed supplemented with the
potent antioxidant Gamma-tocopherol, found abundantly in seed oils such as flax, wheat,
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corn and soybean, at a level of 8 ppm improved chick weight gain, and reduced lesion
scores and oocyst output in the upper and mid area of the small intestine that were
infected by E. acervulina and E. maxima. However, this potent antioxidant had little
effect in chickens infected with E. tenella. The osmoprotective effect of Betaine (a sweet
crystalline alkaloid found in sugar beets) was examined against a coccidiosis infection
(Augustine and Danforth, 1999). Betaine fed at 0.15 % in combination with 66 ppm
Salinomycin significantly improved the weight gain and feed efficiency of birds infected
with E. acervulina, E. maxima, and E. tenella. Betaine and Salinomycin either alone or
together inhibited the gut invasion of E. acervulina. It was concluded that their
combination may improve the performance of chickens infected with coccidiosis, either
directly by inhibiting the development of second generation E. acervulina schizonts or by
providing an osmoprotective effect on intestinal structure. Using toltrazuril as a positive
control, plant extracts demonstrating antioxidant activity, such as Tulbaghia violacea
(35 mg/kg), Vitis vinifera (75 mg/kg) and Artemisia afra (150 mg/kg) were examined for
their anticoccidial activities. The effects of these plant extracts on feed conversion ratio
were similar to toltrazuril. In addition, T. violacea significantly decreased oocyst
shedding in the birds. From this study, it was concluded that plant extracts rich in
antioxidants have potential positive benefits in birds infected by coccidia infections
(Naidoo et al., 2008). Several other natural products that have been tested in birds with
coccidiosis infections include mushrooms and their extracts (Guo et al., 2004; Guo et. al.,
2005; Dalloul and Lillehoj, 2006). It was found in all these studies that when birds were
challenged with E. acervulina, and E. tenella, lectin (mushroom extract) induced cellular
and humoral-based immunities, thereby improving performance and reducing oocyst
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output. Essential oil blends have also been shown to reduce lesions and oocyst shedding,
while maintaining growth performance during mixed coccidial infections (OviedoRondón et al., 2006). Allen and Fetterer (2002) suggested that natural products that elicit
oxidative stress responses (e.g. n-3 FA and artemisinin), can be particularly effective
against E. tenella; whereas products that have antioxidant properties (e.g. γ-tocopherol),
can be more effective against E. maxima and E. acervulina. Although the use of natural
products alone or in combination with current coccidiosis control programs have
tremendous potential, several studies needs to be conducted to determine the safe dosages
and efficient ways of application of these natural products.
Pre- and probiotics
Gibson and Roberfroid (1995) defined a prebiotic as “a non-digestible food
ingredient that beneficially affects the host by selectively stimulating the growth and/or
activity of one or a limited number of bacteria in the colon that can improve host health”.
Mannanoligosaccharides (MOS), derived from the cell wall of the yeast Saccharomyces
cerevisiae, have been described as a prebiotic that is used in animal feed to promote
gastrointestinal health and improve performance. MOS competes with the mannosespecific binding of pathogens, resulting in a reduction of their colonization (Ofek et al.,
1977). MOS are also thought to block the binding of pathogens to mannan receptors on
the intestinal mucosa surface (Spring et al., 2000). Dietary MOS administered at rates of
1g/Kg and 10g/Kg in feed have reduced the severity of E. tenella and E. acervulina
infections, respectively (Elmusharaf et al., 2007). Prebiotics function in targeting the
bacteria already present within and adapted to the gut environment. Studies have shown
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that the effect of MOS on the control of coccidiosis may be dependent of the amount of
dietary MOS incorporated into the feed (McCann et al., 2006).
A probiotic is defined as “a live microbial feed supplement which beneficially
affects the host animal by improving its intestinal microbial balance”. Probiotics consist
of beneficial live bacteria or yeast that are added to diets. The most commonly used
probiotics in livestock are Bacillus, Enterococcus, and the yeast Saccharomyces.
Probiotics ensures gut health and a balanced intestinal microflora by modulating the
immune system and enhancing host resistance to enteric infections. The benefit of
probiotics in developing immunity against a coccidiosis challenge has been demonstrated
in several studies (Jin et al., 1996; 1998; 2000; Zulkifli et al., 2000, Mathis et al., 2014).
Anticoccidial vaccines
Coccidia live vaccines comprised of oocysts of various Eimeria species, are the
preferred alternative to anticoccidial drugs for the control of coccidiosis in poultry. The
commercialization of anticoccidial vaccines began with the production of the Coccivac®
in the 1950s (Williams, 2002). It is thought that the administration of low doses of
coccidia oocysts early in the life of the bird can induce protective immunity (after 2 to 3
cyclic infections) before the occurrence of a field challenge (Long et al., 1986). For a
long time, the use of coccidia vaccines were limited to broiler breeders and replacement
layer stocks (William, 2002; Shapiro, 2001), but 2 major factors have enhanced the use of
live oocyst vaccines for the control of coccidiosis in broilers. These include: (1)
understanding that protective immunity can be produced following immunization with
low doses of oocysts in day old chicks, (2) the development of new methods that
facilitate vaccine application in the hatchery (Chapman, 2002).
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Development of protective immunity from a coccidiosis vaccine
The process of developing an immune response following the administration of a
coccidial vaccine is similar to that previously described for a challenge infection.
Coccidiosis vaccines provide low controlled numbers of Eimeria parasites that ensures
the development of substantial immunocompetence after two to three consecutive cycles
of infections. The asexual developmental stage (multiplication of trophozoites) plays a
key role in generating a protective immune response, and immunity develops primarily
through a cellular response (Jenkins et al. 1991; Dalloul and Lillehoj, 2005). T cells and
cytokines play important roles in protective immunity against Eimeria. Th1-type
cytokines function to limit the multiplication of Eimeria parasites within the gut, during
the early stages of infection (vaccine application). Regulatory cytokines and cellular
responses are important in limiting proinflammatory cytokine-associated pathologies
(Roberts et al. 1996). Immunity is specie specific (i.e. immunity against one species of
Eimeria will not provide protection against a different species). Protective immunity is
generally regarded as the absence of oocyst production, and the absence of clinical signs
in birds infected with coccidiosis (Price, 2012). All commercial anticoccidial vaccines
used in the field today can generally be classified into 2 categories. These 2 categories
are: (1) nonattenuated live oocyst vaccines, and (2) attenuated live oocyst vaccines.
Live nonattenuated vaccines consist of a controlled but variable number of wildtype Eimeria species oocysts (Lee, 1987). Examples of this type of vaccine include
Inovocox®, Immucox®, Coccivac®-B and Coccivac®-D (Table 2.3; Chapman, 2014).
Because live nonattenuated vaccines only contain a small but sufficient number of
Eimeria oocyst species, their effectiveness is dependent on the recycling of the initial low
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dose that is administered. This leads to the gradual buildup of solid immunity (Dalloul
and Lillehoj, 2005). The first commercial live nonattenuated vaccine (Coccivac® D)
launched in 1952 contained oocysts of the 8 wild-type Eimeria species, and was used to
vaccinate broiler breeders and replacement pullets (Williams, 2002). Currently,
anticoccidial vaccines used in the broiler industry contain oocysts of various types of
Eimeria species. Such vaccines with combinations of various species include: E.
acervulina, E. maxima and E. tenella (Inovocox®), or 4 Eimeria species; E. acervulina,
E. maxima, Eimeria necatrix, and E. tenella (Immucox® C1); E. acervulina, Eimeria
mivati, E. maxima, and E. tenella (Coccivac® B) (Vermeulen et al., 2001). Birds are
vaccinated within the first week of life using vaccination methods that ensures uniformity
of vaccine application and the uptake of an adequate amount of vaccine oocysts for
sufficient cycling (Dalloul and Lillehoj, 2005). Although vaccination with a
nonattenuated live oocyst vaccine has proven to be effective for the development of
protection against subsequent Eimeria challenges (Williams, 2003), there has been a
skepticism regarding the use of vaccination programs for US broiler production,
especially in broilers subjected to short grow-out periods. This is largely due to reports
noting negative effects of nonattenuated live oocyst vaccine on grow-out performance
(Allen and Fetterer, 2002). Nonattenuated vaccines are formulated to introduce a
controlled coccidial infection during early grow-out and have been shown to decrease
BW gain and lead to a poorer feed efficiency in broilers (Danforth, 1998).
Attenuated live oocyst vaccines have the advantage of exhibiting reduced
pathogenicity but being capable of inducing protective immunity with minimal potential
for clinical disease (McDougald, 2003). Attenuated strains are selected via several
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passages through embryonated eggs or by the selection for precocious (early)
development (Williams, 2002). Examples of these types of commercial vaccines include
Paracox® (Williams, 1994) and Livacox® (BedrnI´k, 1993). The second generation
schizonts and sexual development are completely absent in the attenuated vaccines,
which results in a loss of virulence with only moderate tissue damage (McDougald and
Jeffers, 1976).
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Breeders, Layers
Broilers, Roasters
Breeders, Layers
Broilers
Broilers
Broilers
Caged chickens

Coccivac®-D1,2,3

Immucox® C11,2,3

Immucox® C21,2,3

Inovocox®1,2,3

Inovocox®EM11,2,3

Advent®2

Livacox® D3

E. acervulina, E. tenella

Broilers

Broilers/Breeders

E. acervulina, E. maxima, E.
mivati, E. tenella

Yes

Yes

Yes

Yes

Yes

None

None

None

None

Single dose at 1 to 9 d
Single dose at 1 or 3 d

Hatchery spray,
drinking water, feed
spray

Single dose at 1 to 10 d

Single dose at 1 to 10 d

Drinking water, feed
spray

Drinking water,
ocular
Drinking water,
ocular

Single dose at 1 to 10 d

Spray single dose in
hatchery or on first feed

Hatchery spray, feed
spray
Drinking water

Single dose in ovo

In ovo

Single dose in ovo

Single dose 1 to 4 d

Drinking water, oral
gel
In ovo

Single dose 1 to 4 d

Single dose at 1 to 14 d

Single dose at 1 to 14 d

Age of birds

Drinking water, oral
gel

Route of
administration
Hatchery spray,
ocular, drinking
water, feed spray
Hatchery spray,
ocular, drinking
water, feed spray

Taken from Williams (2002), Pfizer Animal Health (2011), and Vermeulen (2001).
1
Currently approved for use in Canada;
2
Currently approved for use in the United States;
3
Currently approved for use in countries outside of Canada and the United States

Paracox®-53

Paracox®3

Livacox® Q3

None

E. acervulina, E. brunetti, E.
hagani, E. maxima, E. mivati, E.
necatrix, E. praecox, E. tenella
None

None

E. acervulina, E. maxima, E.
mivati, E. tenella

E. acervulina, E. maxima, E.
necatrix, E. tenella
E. acervulina, E. brunetti, E.
maxima, E. necatrix, E. tenella,
E. mivati, E. praecox
E. tenella, E. acervulina, 2 strains
of E.maxima
E. tenella, E. acervulina, 1 strain
of E.maxima
E. acervulina, E. maxima, E.
tenella

Attenuation

Eimeria Species

E. acervulina, E. maxima, E.
tenella
E. acervulina, E. brunetti, E.
Broilers
maxima, E. tenella
E. acervulina, E. brunetti, E.
Broilers, breeders,
maxima, E. mivati, E. necatrix, E.
Layers
praecox, E. tenella

Broilers

Coccivac® -B1,2,3

Livacox® T3

Bird type

Schering-Plough
Animal Health (UK)

Schering-Plough
Animal Health (UK)

Biopharm (Czech Republic)

Biopharm (Czech Republic)

Biopharm (Czech Republic)

Novus Int. (USA)

Zoetis Animal Health (USA)

Zoetis Animal Health (USA)

Vetech Laboratories
(Canada)

Vetech Laboratories
(Canada)

Schering-Plough
Animal Health (USA)

Schering-Plough
Animal Health (USA)

Manufacturer/Distributor

Live attenuated and nonattenuated anticoccidial vaccines developed for various classes of chicken

Vaccine Trade name

Table 2.3
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Methods of vaccine administration
Improvements in the methods of vaccine delivery have improved the efficiency
and efficacy of the coccidiosis vaccine as a means for control in coccidiosis (Lee et al.,
2009). Williams (2002) described various methods by which commercial live coccidiosis
vaccines are administered to poultry. Uniform distribution of live vaccine oocysts is
crucial for the induction of protective immunity. The development of hatchery-based
delivery methods, which ensures uniform vaccine delivery, has avoided the need to
vaccinate birds in the poultry house, and has been embraced by commercial broiler
producers (Williams, 2002). Early formulations of live vaccines have been administered
to birds via drinking water and feed, but it soon became evident that the induction of
immunity was not maximized by these routes of administration. Vaccine delivery through
feed and water reduces the chances of individual birds receiving a full dose of vaccine in
equal proportion. It has been a common problem that some birds received higher vaccine
doses than others through their drinking water, thereby creating uneven vaccine
distribution and poor development of immunity in the flock as a whole (Williams, 2002).
A similar scenario has been found when birds were immunized through feed. Colored
edible gels containing oocysts (Immucox®) have been provided to 1 day old birds. The
gels were placed in feed trays at the poultry house or in chick crates at the hatchery.
Although these methods of vaccine administration to poultry, especially in breeder flocks,
are still being used in some countries, these methods have been replaced with hatchery
based vaccinations in the US. The two most widely used methods in hatcheries in the US
are spray vaccination and in ovo administration.
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In spray vaccination, the oocysts are suspended in colored water (mostly bright
colors, such as red) and sprayed over the chicks in open trays using a spray cabinet. This
method is commonly used for Coccivac®, Paracox®-5, ADVENT®, and Viracox®. The
color promotes preening, and provides for a visual evaluation of vaccine distribution and
ingestion. Chicks likely ingest the oocysts by direct oral and ocular routes, but ingestion
mainly occurs by the self-preening and pecking of drops of diluted vaccine oocysts off a
neighboring chick (Chapman et al., 2002; Dalloul and Lillehoj, 2005). Factors which may
influence preening include the application of biologically active materials, increases in
sound and light intensity, and decreases in temperature (Caldwell et al., 2001b). Because
the oocysts are suspended in water, the vaccinated chicks become wet, but the water
eventually dry off from the chicks’ body. It has been shown that over 94% of spray
vaccinated birds ingest the oocysts (Schetters et al., 1999).
In ovo injection is a more recent and well embraced method of vaccination, which
is the inoculation of embryonated eggs with vaccine oocysts. The in ovo injection
concept was first developed by Sharma and Burmester (1982). Although in ovo
vaccination was initially developed for vaccination against Marek’s disease, it has
become widely utilized for vaccination against numerous poultry disease including
coccidiosis. Today, in ovo vaccination is being used in both research and commercial
applications (Williams, 2007). Conventional vaccine application methods have included
posthatch feed and drinking water supplementation, hand vaccination, ocular instillation.
However, these methods are time and labor intensive, and inefficient, and lead to
inconsistent vaccine delivery. In ovo vaccination presents several advantages over these
methods. These include uniform and fast delivery, increased efficiency, and early
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development of immunity (Williams, 2007). Today, the US broiler industry employ in
ovo injection technology for vaccinations against Marek`s disease (Williams and
Hopkins, 2011), coccidiosis (Mathis et al., 2014), and infectious bursal disease (Moura,
2007). Commercial in ovo technology has expanded its capabilities from laboratory
single egg injectors to multi-egg injectors capable of injecting between 50,000 to 70,000
eggs per hour (William, 2007). Because in ovo injection requires the injection of
embryonated eggs, the stage of development of the embryos is critical in determining the
correct time and site of injection. Successful in ovo vaccinations are dependent the timing
of the injection in relation to the stage of the embryo development (William, 2007). It has
been shown through various studies that the optimal time for in-ovo injection is during
late stage incubation. This is typically between 17.0 and 19.0 day of incubation
(Keralapurath et al., 2010; Zhai et al., 2011a, b, and c; Jochemsen and Jeurissen, 2002).
This time corresponds to the period between the beginning of yolk sac absorption into the
body and the positioning of the head of the bird under its right wing, to the beginning of
internal and external pipping, with active imbibition of the amniotic fluid (Williams,
2007; Jochemsen and Jeurissen, 2002).
There are 5 basic compartments in a developing embryo that can be potentially
accessed by in ovo injection. These areas include the air cell, allantoic sac, amniotic sac,
the embryo body, and the yolk sac (Fig. 2.7; William and Hopkins, 2011). Because these
compartments rapidly change during the late stages of incubation, it is critical to identify
the ‘safe’ window for injection between days 17.0 and 19.0 of incubation. Although all
the compartments can be accessed during in ovo injection, it is important to understand
that each area represents a distinct route for specific vaccine administration and for a
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subsequent specific for immune response. It is essential to ensure that specific vaccines
are deposited in appropriate correct locations inside the egg. In addition to the
commercial in ovo application of vaccines, substances that have been injected in ovo
include carbohydrates (Tako et al., 2004; Uni et al., 2005; Zhai et al., 2011a, b, and c),
electrolyte solutions (McGruder et al., 2011), amino acids (Kadam et al., 2008),
stimulants (Keralapurath et al., 2010; Zhai et al., 2008), and soluble and particulate
substances (Jochemsen and Jeurissen, 2002). The Embrex Inovoject® system
manufactured by Zoetis Animal Health (Durham, NC), is one type of in ovo injection
machine used in commercial application. The Inovoject® system has an injection depth
of approximately 2.54 cm, which targets the amnion of the embryo for coccidiosis
vaccine application (Fig. 2.7; William and Hopkins 2011).
In ovo injection of late stage embryo with coccidiosis Inovocox® EM1 vaccine
Using the Embrex Inovoject® system, the Inovocox® EM1 vaccine (EM1) is
recommended for the vaccination of 18- to 19- day-old chicken embryos for the
prevention of coccidiosis cause by Eimeria acervulina, E. maxima, and E. tenella. For
correct delivery, the EM1 vaccine should be deposited within the amniotic sac, or in the
subcutaneous and intramuscular regions of the embryo. The preferable site of
intramuscular delivery is in the right breast muscle of the embryo’s body (Williams and
Hopkins, 2011). Injection of the EM1 vaccine into the air cell, allantoic sac, abdomen,
cranium, eye, and thorax of the embryo are regarded as inferior delivery sites and will
have subsequent negative effects on vaccination efficacy and embryo survival (Williams
and Hopkins, 2011). Research has shown that the in ovo administration of live coccidia
oocyst vaccines to late-stage chicken embryos is safe (Weber, et al., 2004). Today, in ovo
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vaccination occurs routinely in approximately 98 % of commercial broiler hatcheries in
the US. As with most in ovo vaccinations, in order to ensure that the EM1vaccine is
delivered into the amnion, an understanding of the developmental events in late stage
embryos is critical (these stages have been previously described in the avian
embryogenesis section of this chapter). Although most literature categorically describes
the physiological state of embryos on day 18 and 19 of incubation, common commercial
practice is to inject embryonated eggs at the time of transfer from the setter to the
hatcher, which is commonly at day 18.5 or 19.0 of incubation. The development of
embryo at d 18.5 of incubation is, therefore, described in this section.
During the late stages of incubation, the embryo prepares itself for hatching. This
preparation involves the folding and tucking of the embryo’s head under the air cell
membrane and vigorously moving the head and beak into positon for the hatching
process (Tong et al., 2013). On embryonic day (ED) 18.5, the following changes begins
to occur in the embryo: (1) head is tilted to the right and under the right wing, (2) the
allantois starts to dry up, (3) the amniotic fluid is present but is beginning to regress due
to the embryo’s swallowing reflexes, and (4) absorption of the yolk sac into the embryo
begins (Parkhurst and Mountney, 1988). In ovo vaccination is optimized at this time due
to the presence of the amnion, which is actively imbibed by the embryo. The immune
response to the EM1 vaccine is largely mediated by a T-cell reaction. This same reaction
was previously described for nonattenuated live oocyst vaccines. The nature of this T-cell
response can be influenced by the age of the bird, the type of Eimeria species, and the
number of parasites present.
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Prehatch and posthatch factors that participate in the immune response to an
Eimeria infection
In day 18.5 embryos, the structural integrity, length, and width of the intestine is
developing. At this time, the relative weight of the small intestine is approximately 3.5 %
(Zhai et al., 2011a,b; Uni et al., 2003). Furthermore, associated gut lymphocyte
populations are beginning to differentiate, and a relatively low level of T-cell infiltration
is occurring at the time of in ovo injection (Holling et al., 2004). This low T-cell
infiltration may be associated with the immaturity of the embryo immune system. It may
also be associated with a lower level of reactive T-cell stimulation by foreign antigens
(Holling et. al., 2004). At hatch, the immature small intestine undergoes significant
changes within the first 24 hours undergoing morphological, biochemical, and molecular
changes. There is signiﬁcant inﬂux of CD4+ and CD8+ cells into the gut of chickens
inoculated with sporulated Eimeria oocysts (Swinkels et al., 2006). CD4+ cells or helper
T cells are produced in response to infections and send signals to other types of immune
cells, including CD8+ killer cells. CD4+ cells send signal and CD8+ cells destroy the
infection. The CD4+ and CD8+ cells are produced at the beginning of the Eimeria life
cycle in order to limit the reaction to vaccinal oocysts or to clear the infection (Swinkels
et al., 2006). By day 7 posthatch, the proportion of CD8+, MHC II (Major
Histocompatibility Complex II) and TCR (T cell Receptors recruited from the spleen)
cells increase in response to the Eimeria antigen (Holling et al., 2004; Swinkels et al.,
2006; Wallach, 2010). The main function of MHC class II molecules is to present
antigens to CD4+ T-lymphocytes. MHC class II molecules are important for the initiation
of the antigen-specific immune response (Holling et al., 2004).
54

Figure 2.7

Individual injection tool of the Inovoject® multi-egg injector system
showing the site (amnion) of injection in day 18 embryo

Images taken from Embryo Development 101; Zoetis Animal Health, Poultry Health
Division.
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Similarly, the uptake of oocysts by macrophages results in the activation and up
regulation of MHC II expression. By day 14 posthatch, Interleukin-8 (IL-8) levels are
significantly increased. IL-8 is a chemotactic factor that attracts neutrophils, basophils,
and T-cells. Chemotactic factor IL-8 is released in response to epithelial necrosis caused
by the reproductive life cycle stages of Eimeria. The neutrophils and macrophages
recruited in response to IL-8 help to reduce the rate of infection (Swinkels et al., 2006).
Technical information on the biology of the EM1 vaccine is limited in the scientific
literature. Therefore, the goal of this study was to evaluate the physiological effects of the
EM1 vaccine in Ross × Ross 708 broiler chickens when used for the control of
coccidiosis.

56

References
Atwood, H., and C.E. Weakley Jr. 1915. The amount of carbon dioxide thrown off by
eggs during the incubating process. Poult. Sci. 1:26-28.
Al-Murrani, W. K. 1982. Effect of injecting amino acids into the egg on embryonic and
subsequent growth in the domestic fowl. Br. Poult. Sci. 23:171-174.
Allen, P. C. 1997. Nitric oxide production during Eimeria tenella infections in chickens.
Poult. Sci. 76:810-813.
Allen, P. C., H. D. Danforth, and O. A. Levander. 1997a. Interaction of dietary flaxseed
with coccidia infections in chickens. Poult. Sci. 76:822-827.
Allen, P. C., J. Lydon, and H. D. Danforth. 1997b. Effects of components of Artemisia
annua on coccidia infections in chickens. Poult. Sci. 76:1156-1163.
Allen, P. C., and H. D. Danforth. 1998. Effects of dietary supplementation with n-3 fatty
acid ethyl esters on coccidiosis in chickens. Poult. Sci. 77:1631-1635.
Allen P. C., and R. H. Fetterer. 2002. Effects of dietary vitamin E on chickens infected
with Eimeria maxima: Observations over time of primary infection. Avian
Dis.46:839-846.
Allen, P. C., and R. H. Fetterer. 2002. Recent advances in biology and immunobiology of
Eimeria species and in diagnosis and control of infection with these coccidian
parasites of poultry. Clin. Microbiol. Rev. 15:58-65.
Ana, C., and C. Alleoni. 2006. Albumen protein and functional properties of gelation and
foaming. Sci. Agric. 63:291-298.
Augustine, P. C., H. D. Danforth.1999. Influence of betaine and salinomycin on intestinal
absorption of methionine and glucose and on the ultrastructure of intestinal cells
and parasite development stages in chicks infected with Eimeria acervulina.
Avian Dis. 43:89-97.
Bedrnı´k, P. 1993. Livacox, a Vaccine against coccidiosis of domestic fowl, Research
Institute of Feed Supplements and Veterinary Drugs, Jilove´1.
Bell, D. D., W. D.Weaver. 2002. 5th ed. Kluwer Academic Publishers; Commercial
Chicken Meat and Egg Production.
Bello, A., W. Zhai, P. D. Gerard, and E. D. Peebles. 2013. Effects of the commercial in
ovo injection of 25-hydroxycholecalciferol on the hatchability and hatching chick
quality of broilers. Poult. Sci. 92:2551-2559.

57

Bello, A., W. Zhai, P. D. Gerard, and E. D. Peebles. 2014. Effects of the commercial in
ovo injection of 25-hydroxycholecalciferol on broiler posthatch performance and
carcass characteristics. Poult. Sci. 93:155-162.
Bessay, M., Y. Le Vern, D. Kerboeuf, P. Yvore, and P. Quere. 1996. Changes in
intestinal intra-epithelial and systemic T-cell subpopulations after an Eimeria
infection in chickens: Comparative study between E acervulina and E tenella.
Vet. Res. 27:503-514.
Branton, S. L., F. N. Reece, and W. M. Hagler. 1987. Influence of a wheat diet on
mortality of broiler chickens associated with necrotic enteritis. Poult. Sci.
66:1326-1330.
Buhr, R. J. 1995. Incubation relative humidity effects on allantoic fluid volume and
hatchability. Poult. Sci. 74:874-884.
Caldwell, D.Y., R. W. Moore, D. J. Caldwell, and B. M. Hargis. 2001b. Effect of
photointensity, sound intensity, and ambient temperature on preening behavior
and ingestion of spray-applied biologics. J. App. Poult. Res. 10:99-106.
Chapman, H. D., and T. E. Cherry. 1997. Comparison of two methods of administering
live coccidiosis vaccines to newly hatched chicks: infectivity and development of
immunity to Eimeria species. In: Shirley, M.W., F. M. Tomley, B. M. Freeman
(Eds.). Control of Coccidiosis into the Next Millennium, VIIth International
Coccidiosis Conference, Institute for Animal Health, Compton, Newbury, p. 133.
Chapman, H. D. 1997a. Biochemical, genetic, and applied aspects of drug resistance in
Eimeria parasites of fowl. Avian Pathol. 26:221-244.
Chapman, H. D. 1998. Evaluation of the efficacy of anticoccidial drugs against Eimeria
species in the fowl. Int. J. Parasitol. 28:1141-1144.
Chapman, H. D. 1999. The development of immunity to Eimeria species in broilers given
anticoccidial drugs. Avian Pathol. 28:155-162.
Chapman, H. D. 2000. Practical use of vaccines for the control of coccidiosis in chicken.
World’s Poult. Sci. J. 56:7-20.
Chapman, H. D., T. E. Cherry, H. D. Danforth, G. Richards, M.W. Shirleye, R. B.
Williams. 2002. Sustainable coccidiosis control in poultry production: the role of
live vaccines. Int. J. for Parasitol. 32:617-629.
Chapman, H. D., P. I. Matsler, V. K. Muthavarapu, and M. E. Chapman. 2005.
Acquisition of immunity to Eimeria maxima in newly hatched chickens given 100
oocysts. Avian Dis. 49:426-429.

58

Chapman H.D., T. K. Jeffers, R. B. Williams. 2010. Forty years of monensin for the
control of coccidiosis in poultry. Poult. Sci. 89:1788-1801.
Chapman, H. D., and T. K. Jeffers. 2014. Vaccination of chickens against coccidiosis
ameliorates drug resistance in commercial poultry production Int. J. Parasitol.
Drugs Drug Resist. 4:214-217.
Chapman, H. D. 2014. Milestones in avian coccidiosis research: A review. Poultry Sci.
93:501-511.
Conway, D. P., and M. E. McKenzie. 1991. Poultry coccidiosis. Diagnostic and testing
procedures. 3:11-20.
Cornelissen, J. B., W. J. Swinkels, W. A. Boersma, and J. M. Rebel. 2009. Host response
to simultaneous infections with Eimeria acervulina, maxima and tenella: a
cumulation of single responses. Vet. Parasitol. 162:58-66.
Dalloul, R.A., and H.S. Lillehoj. 2005. Recent advances in immunomodulation and
vaccination strategies against coccidiosis. Avian Dis. 49:1-8.
Dalloul, R. A., and H. S. Lillehoj. 2006. Poultry coccidiosis: recent advancements in
control measures and vaccine development. Expert Rev. Vaccines 5:143-63.
Danforth, H. D. 1998. Use of live oocyst vaccines for the control of avian coccidiosis;
experimental studies and field trials. Int. J. Parasitol. 28:101-109.
Davis, T. A., and R. A. Ackerman. 1987. Effects of increased water loss on growth and
water content of the chick embryo. J. Exp. Zool. Suppl. 1:357-364.
De Gussem, M. 2007. Coccidiosis in poultry: Review on diagnosis, control, prevention
and interaction with overall gut health. P. 253-261 in Proc. 16th Eur. Symp. Poult.
Nutr. Strasbourg, France.
Drew, M. D., N. A. Syed, B. G. Goldade, B. Laarveld, and A. G. Van Kessel. 2004.
Effects of dietary protein source and level on intestinal populations of Clostridium
perfringens in broiler chickens. Poult. Sci. 83:414420.http://ps.oxfordjournals.org/content/85/4/770.abstract?ijkey=1111b465bc276
cf90c6dcd05124443f463f444b9&keytype2=tf_ipsecsha - aff-2
Edwards, C. L. 1902. The physiological zero and the index of development for the egg of
the domestic fowl, Gallus Domesticus: A contribution to the subject of the
influence of temperature on growth. Am. J. Physiol. 6:351-397.
Elibol, O., and J. Brake. 2006. Effect of egg turning angle and frequency during
incubation on hatchability and incidence of unhatched broiler embryos with head
in the small end of the egg. Poult. Sci. 85:1433-1437.
59

Ellis, J., and J. Bumstead. 1990. Eimeria species: studies using rRNA and rDNA
probes. Parasitol. 101:1-6.
Elmusharaf, M. A., H. W. Peek, L. Nollet, and A. C. Beynen. 2007. The Effect of an infeed mannanoligosaccharide preparation (MOS) on a coccidiosis infection in
broilers. Anim. Feed Sci. Technol. 134:347-354.
Engberg, R. M., M. S. Hedemann, S. Steenfeldt, and B. B. Jensen. 2004. Influence of
whole wheat and xylanase on broiler performance and microbial composition and
activity in the digestive tract. Poult. Sci. 83:925-938.
Farrant, J. 2001. Ministers knock out six anticoccidials. Poult. World, 155:5.
Fayer, R. 1980. Epidemiology of protozoan infections: The coccidia. Vet. Parasitol. 6:75103.
French, N. A. 1997. Modeling incubation temperature: the effects of incubator design,
embryonic development, and egg size. Poult. Sci. 76:124-133.
Funk, E. M., and J. Forward. 1960. The relation of angle of turning and position of the
egg to hatchability of chicken eggs. Poult. Sci. 39:784-785.
Gabriel, I., M. Lessire, S. Mallet, and J. F. Guillot. 2006. Microflora of the digestive
tract: Critical factors and consequences for poultry. World Poult. Sci. J. 62:499511.
Gabrielli, M. G., and D. Accili. 2010. The chick chorioallantoic membrane: A model of
molecular, structural, and functional adaptation to transepithelial ion transport and
barrier function during embryonic development. J. Biomed. & Biotech. p:1-12.
Gibson, G. R., and M. B. Roberfroid. 1995. Dietary manipulation of the human colonic
microbiota: Introducing the concept of prebiotics. J. Nutr. 125:1401-1412.
Guo, F. C., R. P. Kwakkel, B. A. Williams, H. K. Parmentier, W. K. Li, Z. Q. Yang, M.
W. Verstegen. 2004. Effects of mushroom and herb polysaccharides on cellular
and humoral immune responses of Eimeria tenella infected chickens. Poult. Sci.
83:1124-1132.
Guo, F. C., R. P. Kwakkel, B. A. Williams, X. Suo, W. K. Li, and M. W. Verstegen.
2005. Coccidiosis Immunization: Effects of Mushroom and Herb Polysaccharides
on immune responses of chickens infected with Eimeria tenella. Avian Dis. 1:7073.
Hamburger, V., and H. L. Hamilton. 1992. A series of normal stages in the development
of the chick embryo. Dev. Dyn. 195:231-272.

60

Hamdy, A.M.M., W. Van Der Hel, and A. M. Henken. 1991. Effects of air humidity
during incubation and age after hatch on heat tolerance of neonatal male and
female chicks. Poultry Sci. 70:1499–1506.
Holling, T. M., E. Schooten, and P. J. van Den Elsen, 2004. Function and regulation of
MHC class II molecules in T-lymphocytes: of mice and men. Hum. Immunol.
65:282-90.
Hughes, R. J. 2005. An integrated approach to understanding gut function and gut health
of chickens. Asia Pac. J. Clin. Nutr. 14:S27.
Idris, A. B., D. I. Bounous, M. A. Goodwin, J. Brown, and E. A. Krushinskie. 1997.
Quantitative pathology of small intestinal coccidiosis caused by Eimeria maxima
in young broilers. Avian Pathol. 26:731-747.
Jeffers, T. K. 1975. Attenuation of Eimeria tenella through selection for pre-cociousness.
J. Parasitol. 61:1083-1090.
Jenkins, M. C., P. C. Augustine, H. D. Danforth, and J. R. Barta. 1991. X-irradiation of
Eimeria tenella oocysts provides direct evidence that sporozoite invasion and
early schizont development induce protective immune response(s). Infect. Immun.
59:4042-4048.
Jin, L. Z., Y. W. Ho, M. A. Ali, N. Abdullah, K. B. Ong, and S. Jalaludin. 1996.
Adhesion of Lactobacillus isolates to the intestinal cells of chickens. Lette. Appl.
Microbiol. 22:229-232.
Jin, L. Z., Y. W. Ho, M. A. Ali, N. Abdullah, K. B. Ong, and S. Jalaludin. 1998. Effects
of adherent Lactobacillus culture on growth, weight of organs and intestinal
microflora and volatile fatty acids in broilers. Anim. Feed Sci. Technol. 70:197209.
Jin, L. Z., Y. W. Ho, N. Abdullah, and S. Jalaludin. 2000. Digestive and bacterial
enzymes activities in broilers fed diet supplemented with Lactobacillus cultures.
Poult. Sci. 79:886-891.
Jochemsen, P., and S. H. M. Jeurissen, 2002. The localization and uptake of in ovo
injected soluble and particulate substances in the chicken. Poult. Sci. 81:18111817.
Johnson, J., and W. M. Reid. 1970. Anticoccidial drugs: lesion scoring techniques in
battery and floor-pen experiments with chickens. Experimental Parasitol. 28:3036.
Joyner, L. P., and C. C. Norton. 1978. The activity of methyl benzoquate and clopidol
against Eimeria maxima: Synergy and drug resistance. Parasitol. 76:369-377.
61

Kadam, M. M., S. K. Bhanja, A. B. Mandal, R. Thakur, P. Vasan, A. Bhattacharyya, and
J. S. Tyagi. 2008. Effect of in ovo threonine supplementation on early growth,
immunological responses and digestive enzyme activities in broiler chickens. Br.
Poult.Sci. 49:736-741.
Kant, V., S. Pardeep, K. Pawan, I. Bais, S. Mehtab, G. Anu, and V. Gupta. 2013.
Anticoccidial Drugs Used in the Poultry: An Overview Science International 1:
261-265.
Keralapurath, M. M., A. Corzo, R. Pulikanti, W. Zhai, and E. D. Peebles. 2010a. Effects
of in ovo injection of L-carnitine on hatchability and subsequent broiler
performance and slaughter yield. Poult. Sci. 89:1497-1501.
Landauer, W. 1948. The Hatchability of chicken eggs as influenced by environment and
heredity. Storrs Agricultural Experiment Station. Storrs, Connecticut.
Lee, E. H. 1987. Vaccination against coccidiosis in commercial roaster chickens.
Canadian Vet. J. 28:434-436.
Lee, J. T., D. Broussard, S. Fitz-Coy, P. Burke, N. H. Eckert, S. M. Stevens, P. N.
Anderson, S. M. Anderson, and D. J. Caldwell. 2009. Evaluation of live oocyst
vaccination or salinomycin for control of field-strain Eimeria challenge in broilers
on two different feeding programs. J. Appl. Poult. Res. 18:458-464.
Leslie, G. A., and W. L. Clem. 1969. Phylogeny of immunoglobulin structure and
function. Immunoglobulins of the chicken. J. Exp. Med. 130:1337-1352.
Levine, P. P. 1942. Excystation of coccidial oocysts of the chicken. J. of Parasitol. 28:
426-428.
Levine, N.D. 1961. Protozoan Parasites of Domestic Animals and Man. Minneapolis:
Burgess Publishing Company.
Li, G. X., H. S. Lillehoj, K. W. Lee, S. I. Jang, P. Marc, C. G. Gay, D. Ritte, D. A.
Bautista, K. Phillips, A. P. Neumann, T. G. Rehberger, G. R. Siragusa. 2010. An
outbreak of gangrenous dermatitis in commercial broiler chickens. Avian
Pathol. 39:247-253.
Lillehoj, H. S. 1987. Effects of immunosuppression on avian coccidiosis: cyclosporin A
but not hormonal bursectomy abrogates host protective immunity. Infect. Immun.
55:1616-1621.
Lillehoj, H. S., and K. D. Choi. 1998. Recombinant chicken interferon-gamma inhibits in
vitro Eimeria tenella development, and reduces in vivo oocyst production and
body weight loss following challenge infection with Eimeria acervulina. Avian
Dis. 42:307-314.
62

Lillehoj, H. S., C. H. Yun, and E. P. Lillehoj. 1999. Recent progress in poultry vaccine
development against coccidiosis. Korean J. Poult. Sci. 26:149-170.
Lillehoj, H. S., and E. P. Lillehoj. 2000. Avian coccidiosis. A review of acquired
intestinal immunity and vaccination strategies. Avian Dis. 44:408-425.
Lillehoj, H.S., W. Min, and R.A. Dalloul. 2004. Recent progress on the cytokine
regulation of intestinal immune responses to Eimeria. Poult. Sci. 83:611-623.
Lillehoj, H.S., C. H. Kim, C. L. Keeler Jr., S. Zhang. 2007. Immunogenomic approaches
to study host immunity to enteric pathogens. Poult. Sci. 86:1491-1500.
Long, P. L., J. Johnson, M. E. McKenzie, E. Perry, M. S. Crane, P. K. Murray. 1986.
Immunisation of young broiler chickens with low level infections of Eimeria
tenella, E. acervulina or E. maxima. Avian Pathol. 15:271-278.
Lourens, A., R. Molenaar, H. van den Brand, M. J. W. Heetkamp, R. Meijerhof, and B.
Kemp. 2006. Effect of egg size on heat production and the transition of energy
from egg to hatchling. Poult. Sci. 85:770-776.
Mathis, G. F. 1999. The influence of coccidiosis vaccine, Coccivac-B on compensatory
weight gain of broiler chickens in comparison with the anticoccidial, salinomycin.
Poult Sci. 78 (Supplemental):117.
Mathis, G., and L. R. McDougald. 1984. Effectiveness of therapeutic anticoccidial drugs
against recently isolated coccidia. Poult. Sci. 63:1149-1153.
Mathis, G., J. Schaeffer, K. Cookson, J. Dickson, M. LaVorgna, and D. Waldrip. 2014.
Effect of lasalocid or salinomycin administration on performance and immunity
following coccidia vaccination of commercial broilers. J. Appl. Poult. Res.
23:577-585.
Mauldin, J. M., and R. J. Buhr, 1990. Recognize problems in embryonic development
International Hatchery. Practises 4:23-27.
McCann M. E., E. Newell, C. Preston, K. Forbes. 2006. The use of Mannan
oligosaccharides and/or tannin in broiler diets. Int. J. Poult. Sci. 5:873-879.
McDevitt, R. M., J. D. Brooker, T. Acamovic, and N. H. C. Sparks. 2006. Necrotic
enteritis; a continuing challenge for the poultry industry. World Poult. Sci.
J.62:221-247.
McDougald, L. R., T. K. Jeffers. 1976. Eimeria tenella (Sporozoa, Coccidia):
Gametogony following a single asexual generation. Sci.192:258-259.
McDougald, L. R., T. Karlsson, and W. M. Reid. 1979. Interaction of infectious bursal
disease and coccidiosis in layer replacement chickens. Avian Dis. 23:999-1005.
63

McDougald, L. R. 2003. Diseases of poultry, 11th ed., Y. M. Saif, H. J. Barnes, J. R.
Glisson, A. M. Fadley, L. R. McDougald, and D. E. Swayne, ed. Iowa State Press,
Ames, Iowa, p:974-1159.
McDougald, L. R., and S. Fitz-Coy. 2008. Coccidiosis. Diseases of poultry, 12th ed., Y.
M. Saif, A. M. Fadley, J. R. Glisson, L. R. McDougald, L. K. Nolan, and D. E.
Swayne, ed. Blackwell Publishing, Ames, Iowa, p:1068-1085.
McEvoy, J. 2001. Safe limits for veterinary drug residues: what do they mean? Northern
Ireland Veterinary Today, Spring. 37-40.
McGruder, B. M., W. Zhai, M. M. Keralapurath, L. W. Bennett, P. D. Gerard, and E. D.
Peebles. 2011. Effects of in ovo injection of electrolyte solutions on the pre- and
post-hatch physiological characteristics of broilers. Poult. Sci. 90:1058-1066.
McNulty, M. S., and J. S. Guy. 2003. Avian enteroviruslike viruses. Pages 326-332 in
Diseases of Poultry. Y. M. Saif, ed. Iowa State University Press, Ames.
Molenaar, R., I. A. M. Reijrink, R. Meijerhof, and H. van den Brand. 2008. Relationship
between hatchling length and weight on later productive performance in broilers.
World’s Poult. Sci. J. 64:599-604.
Molenaar, R., R. Meijerhof, I. Van den Anker, M. J. W. Heetkamp, and J.Van den Borne.
2010. Effect of eggshell temperature and oxygen concentration on survival rate
and nutrient utilization in chicken embryos. Poult. Sci. 89:2010-2021.
Moran Jr. E. T. 2007. Nutrition of the developing embryo and hatchling. Poult. Sci.
86:1043-1049.
Moura, L., V. Vakharia, M. Liu, and H. Song. 2007. In ovo vaccine against infectious
bursal disease. Int. J. of Poult. Sci. 6:770-775.
Muramatsu, T., K. Hiramoto, N. Koshi, J. Okumura, S. Miyoshi, and T. Mitsumoto.
1990. Importance of albumen content in whole-body protein synthesis of the
chicken embryo during incubation. Br. Poult. Sci. 31:101-106.
Naidoo V., L. J. McGawa, S. P. R. Bisschop, N. Duncan, J. N. Eloff. 2008. The value of
plant extracts with antioxidant activity in attenuating coccidiosis in broiler
chickens. Vet. Parasit.153:214-219.
Olsen, M .W. and T. C. Byerly. 1936. Multiple turning and orienting eggs during
incubation as they affect hatchability. Poult. Sci. 15:88-95.
Ofek, I., D. Mirelman, and N. Sharon. 1977. Adhesion of Escherichia coli to the lumen
mucosal cells by mannose receptors. Nature 265:623-625.

64

Oviedo-Rondón, E.O., S. Clemente-Hernández, F. Salvador, P. Williams, and R. Losa.
2006. Essential Oils on Mixed Coccidia Vaccination and Infection in Broilers1
Int. J. of Poult. Sci. 5:723-730.
Parkhurst, C. R., and G. J. Mountney. 1988. Incubation and hatchery management. In
Poultry Meat and Egg Production. Van Nostrand Reinhold Company, New York.
67-72.
Parsons, A. H., 1982. Structure of the eggshell. Poult. Sci. 61:2013-2021.
Patten, B. M. 1920. The early embryology of the chick. Philadelphia: P. Blakiston's Son
and Co 9-58.
Peebles, E. D., and J. Brake, 1987. Eggshell quality and hatchability in broiler breeder
eggs. Poult. Sci. 66:596-604.
Peek, H. W., and W. J. Landman. 2003. Resistance to anticoccidial drugs of Dutch avian
Eimeria spp. Field isolates originating from 1996, 1999 and 2001. Avian Pathol.
32:391-401.
Peek, H. W., W. J. Landman. 2011 Coccidiosis in poultry: anticoccidial products,
vaccines and other prevention strategies. Vet Q 31:143-161.
Plavnik, I., B. Macovsky, and D. Sklan. 2002. Effect of feeding whole wheat on
performance of broiler chickens. Anim. Feed Sci. Technol. 96:229-236.
Price, K. R., 2012. Use of live vaccines for coccidiosis control in replacement layer
pullets. J. Appl. Poult. Res. 21:679-692.
Pulikanti, R., E. D. Peebles, W. Zhai, L. W. Bennett, and P. D. Gerard, 2012.
Physiological relationships of the early post-hatch performance of broilers to their
embryo and eggshell characteristics. Poult. Sci. 91:1552-1557.
Rahn, H., R. A. Ackerman, and C. V. Paganelli. 1977. Humidity in the avian nest and egg
water loss during incubation. Physiol. Zool. 50:269-283.
Reid, W.M., 1978. Coccidiosis. Diseases of poultry, 7th ed., M. S. Hofstad, B. W.
Calnek, C. F. Helmboldt, W. M. Reid, and H. W. Yoder, Jr., ed. Iowa State
University Press. Ames, Iowa, p:784-805.
Reid, W. M., and P. L. Long. 1979. A diagnostic chart for nine species of fowl coccidia.
Pages 5-24 in Georgia Agric. Exp. Stn. Tech. Bull. N. B. Bowen, ed. College of
Agriculture, University of Georgia, Athens.
Reid, W. M. 1990. History of avian medicine in the United States × Control of
coccidiosis. Avian Dis. 34:509-525.
65

Reynolds, D. L. 2003. Multicausal enteric diseases. Pages 1169-1171 in Diseases of
Poultry. Y. M. Saif, ed. Iowa State University Press, Ames.
Rice, J. T., and W. M. Reid. 1973. Coccidiosis immunity following early and late
exposure to Marek’s disease. Avian Dis. 17:66-71.
Roberts, S. J., A. L. Smith, A. B. Wes, L. Wen, R. C. Findly, M. J. Owen, and A. C.
Hayday. 1996. T-cell alpha + and gamma delta + deficient mice display abnormal
but distinct phenotypes toward a natural, widespread infection of the intestinal
epithelium. Proc. Nat. Acad. Sci. 93:11774-11779.
Romanoff, A. L. 1929. Laboratory incubator for the biological study of chick embryo.
Sci. 69:197-198.
Romanoff, A. L., 1960. The avian embryo. Structural and functional development.
MacMillan Co., New York 1041-1083.
Romanoff A. L., and Romanoff, A. J. 1949. The Avian Egg. John Wiley and Sons, New
York 231-238.
Rose, M. E., P. Hesketh. 1979. Immunity to coccidiosis: T-lymphocyte- or Blymphocyte-deficient animals. Infect Immun. 26:630-637.
Schering-Plough Animal Health Corporation. 2007. Coccivac®-B Normal Reaction:
Oocyst Shedding Pattern. Schering-Plough Animal Health Technical Service
Bulletin, p:366.
Schetters, T. P. M., H. A. J. M. Janssen, and A. N. Vermeulen. 1999. A new vaccination
concept against coccidiosis in poultry. In: van der Sluis, W. ed. World Poult.
Elsevier, Amsterdam, p:23-24.
Shapiro, D. 2001. Coccidiosis control in replacement pullets. Int. Hatchery Practice
15:13-17.
Sharma, J. M., and B. R. Burmester. 1982. Resistance to Marek’s disease at hatching in
chickens vaccinated as embryos with the turkey herpesvirus. Avian Dis. 26:134149.
Sharma, J. M., L. F. Lee, and P. S. Wakenell. 1984. Comparative viral, immunologic, and
pathologic responses of chickens inoculated with herpesvirus of turkeys as
embryos or at hatch. Am. J. Vet. Res. 45:1619-1623.
Sharma, J. M. 1986. Embryo vaccination of specific-pathogenfree chickens with
infectious bursal disease virus: tissue distribution of the vaccine virus and
protection of hatched chickens against disease. Avian Dis. 30:776-780.

66

Shirley, M. W. 1994. Coccidial parasites from the chicken: discrimination of different
populations of Eimeria tenella by DNA hybridisation. Res. Vet. Sci. 57:10-14.
Shirley, M. W., and D. A. Harvey. 1996. Eimeria tenella: genetic recombination of
markers for precoccious development and arprinocid resistance. Appl. Parasitol.
37:293-299.
Shirley, M.W., A. L. Smith, D. P. Blake. 2007. Challenges in the successful control of the
avian coccidia. Vaccine 25:5540-5547.
Sozcu, A., and A. Ipek. 2015. Acute and chronic eggshell temperature manipulations
during hatching term influence hatchability, broiler performance, and ascites
incidence. Poult. Sci. 94:319-327.
Spring, P. C., K. A. Dawson, and K. E. Newman. 2000. The effects of dietary
mannanoligosaccharides on caecal parameters and concentration of enteric
bacteria in the caeca of salmonella-challenged broiler chicks. Poult. Sci. 79:205211.
Swinkels, W. J., J. Post, J. B. Cornelissen, B. Engel, W. J. Boersma, and J. M. Rebel.
2006. Immune responses in Eimeria acervulina infected one-day-old broilers
compared to amount of Eimeria in the duodenum, measured by real-time PCR.
Vet Parasitol. 138:223-233.
Tako, E., P. R. Ferket, and Z. Uni. 2004. Effects of in ovo feeding of carbohydrates and
β-hydroxy-β-methylbutyrate on the development of chicken intestine. Poult. Sci.
83:2023-2028.
Terepka, A., J. Coleman, H. Armbrecht, and T. Gunter. 1976. Transcellular transport of
calcium. Symp. Soc. exp. Biol. 30:117-140.
Tewari, A. K., and B. R. Maharana. 2011. Control of poultry coccidiosis: changing trends
J. Parasit. Dis. 35:10-17.
Tong, Q., C. E. Romanini, V. Exadaktylos, C. Bahr, D. Berckmans, H. Bergoug, N.
Eterradossi, N. Roulston, R. Verhelst, I. M. McGonnell, and T. Demm. 2013.
Embryonic development and the physiological factors that coordinate hatching in
domestic chickens. Poult. Sci. 92:620-628.
Townsley, T. S. 1931. The humidity factor in incubation. Report of Proceedings of the
4th World’s Poultry Congress at the Crystal Palace, London, England: July 22-30,
1930. p:136-145.
Trout, J. M., and H. S. Lillehoj. 1995. Eimeria acervulina infection: evidence for the
involvement of CD8+ T lymphocytes in sporozoite transport and host protection.
Poult. Sci. 74:1117-1125.
67

Tyzzer E. E., H. Theiler, and E. E. Jones. 1932. Coccidiosis in gallinaceous birds II. A
comparative study of species of Eimeria of the chicken. Am. J. Hyg. 15:319-393.
Uni, Z., E. Tako, O. Gal-Garber, and D. Sklan. 2003. Morphological, molecular, and
functional changes in the chicken small intestine of the late-term embryo. Poult.
Sci. 82:1747-1754.
Uni, Z., P. R. Ferket, E. Tako, and O. Kedar. 2005. In ovo feeding improves energy status
of late-term chicken embryos. Poult. Sci. 84:764-770.
Vermeulen, A.N., D. C. Schaap, and P. M. Schetters. 2001. Control of coccidiosis in
chickens by vaccination Vet. Parasito. 100:13-20.
Vissiennon, T., H. Kroger, T. Kohler, and R. Kliche. 2000. Effect of avilamycin, tylosin
and ionophore anticoccidials on Clostridium perfringens enterotoxaemia in
chickens. Berliner Mu¨nchner Tierarztliche Wochenschrift. 113:9-13.
Waldenstedt, L., K. Elwinger, A. Lunden, P. Thebo, M. R. Bedford, and A. Uggla.2000.
Intestinal digesta viscosity decreases during coccidial infection in broilers. Br.
Poult. Sci. 41:459-464.
Wallach, M. 2010. Role of antibody in immunity and control of chicken coccidiosis.
Trends in Parasitology 26:382-387.
Weber, F. H., M. Farrand, M. A. LeMay, D. O. Lewis, K. C. Genteman, and N. A. Evans.
2001. Movement of oocysts within chicken embryos after in ovo vaccination with
Eimeria maxima. Page 184 in VIIIth International Coccidiosis Conference, Palm
Cove, Australia. Australian Society for Parasitology, Queensland, Australia.
Weber, F. H., K. C. Genteman, M. A. LeMay, D. O. Lewis, and N. A. Evans. 2004.
Immunization of broiler chicks by in ovo injection of infective stages of Eimeria.
Poult. Sci. 83:392-399.
Willemsen, H., K. Tona, V. Bruggeman, O. Onagbesan, and E. Decuypere. 2008. Effects
of high CO2 level during early incubation and late incubation in ovo
dexamethasone injection on perinatal embryonic parameters and post-hatch
growth of broilers. British Poult. Sci. 49:222-231.
Williams, R. B. 1994. Safety of the attenuated anticoccidial vaccine Paracox in broiler
chickens isolated from extraneous coccidial infection. Vet. Res. Comm. 18:189198.
Williams, R. B. 1999a. A compartmentalised model for the estimation of the cost of
coccidiosis to the world’s chicken production industry. Int. J. Parasitol. 29:12091229.

68

Williams, R. B., 1999b. Anticoccidial vaccines: the story so far. World Poult. Spec.
Suppl. Coccidiosis 3:23-25.
Williams, R. B. 2002. Anticoccidial vaccines for broiler chickens: Pathways to success.
Avian Pathol.31:317-353.
Williams, R. B. 2003. Optimizing anticoccidial vaccine efficacy in broilers. World
Poultry, Special Supplement Cocci. 4: 29-31.
Williams, R. B. 2005. Intercurrent coccidiosis and necrotic enteritis of chickens: rational,
integrated disease management by maintenance of gut integrity. Avian Pathol.
34:159-180.
Williams C. 2007. In ovo vaccination for disease prevention, Pfizer Animal Health,
International Poultry Production. 15:7-8.
Williams, C. J., and B. A. Hopkins, 2011. Field evaluation of the accuracy of vaccine
deposition by two different commercially available in ovo injection systems.
Poult. Sci. 90:223-226.
Wineland, 2014. Allowing the embryo to grow. ChickMaster 29:1-6.
Woods, W. G., K. G. Whithear, D. G. Richards, G. R. Anderson, W. K. Jorgensen, R. B.
Gasser. 2000. Single-strand restriction fragment length polymorphism analysis of
the second internal transcribed spacer (ribosomal DNA) for six species
of Eimeria from chickens. Aust Int J Parasitol. 30:1019-1023.
Youn, H. J., and J. W. Noh. 2001. Screening of the anticoccidial effects of herb extracts
against Eimeria tenella. Vet. Parasitol. 96:257-263.
Young, R., and A. Craig. 2001. The use and misuse of antibiotics in UK Agriculture –
Part 3. Residues of dangerous drugs in intensively produced chicken meat and
eggs. Bristol, UK: The Soil Association.
Zhai, W., S. Neuman, M. A. Latour, and P. Y. Hester. 2008. The effect of in ovo
injection of L-carnitine on hatchability of White Leghorns. Poult. Sci. 87:569572.
Zhai, W., D. E. Rowe, and E. D. Peebles, 2011a. Effects of commercial in ovo injection
of carbohydrates on broiler embryogenesis. Poult. Sci. 90:1295-1301.
Zhai, W., P. D. Gerard, R. Pulikanti, and E. D. Peebles. 2011b. Effects of in ovo injection
of carbohydrates on embryonic metabolism, hatchability, and subsequent somatic
characteristics of broiler hatchlings. Poult. Sci. 90:2134-2143.

69

Zhai, W., L. W. Bennett, P. D. Gerard, R. Pulikanti, and E. D. Peebles, 2011c. Effects of
in ovo injection of carbohydrates on somatic characteristics and liver nutrient
profiles of broiler embryos and hatchlings. Poult. Sci. 90:2681-2688.
Zulkifli, I., N. Abdullah, N. M. Azrin, and Y. W. Ho. 2000. Growth performance and
immune response of two commercial broiler strains fed diets containing
Lactobacillus cultures and oxytetracy-cline under heat stress conditions. Br. Poult.
Sci. 41:593-597.

70

EFFECTS OF COCCIDIOSIS VACCINE ADMINISTERED BY
IN OVO INJECTION ON THE HATCHABILITY AND
HATCHING CHICK QUALITY OF BROILERS
Abstract
Effects of the in ovo injection of a commercial coccidiosis vaccine on the
hatchability and hatching chick quality parameters of Ross × Ross 708 broilers were
examined. There were 4 treatment groups arranged on each of 7 replicate tray levels of a
single-stage incubator (28 treatment-replicate groups). Each treatment- replicate (TR)
group contained 63 eggs (1,764 eggs total). On d 18.5 of incubation, eggs were subjected
to one of 4 treatments using a commercial multi-egg injector. Three control groups (noninjected, dry-punch, and diluent-injected) and one treatment group (injected with diluent
containing Inovocox EM1 vaccine) were used. On d 18.5 of incubation, the site of
injection (SOI) and stage of embryo development (ES) were determined. On d 21.0 of
incubation, hatchability of injected eggs (HI), chick BW, yolk sac, and liver weights were
determined. On d 21.0 of incubation (d 0 posthatch), 20 chicks from each of the 28 TR
groups (560 birds total) were placed in corresponding isolated wire-floored battery cages.
On a daily basis, from d 0 to 14 posthatch, pooled fecal samples from each individual
replicate cage were collected for oocyst output determination. There was no significant
difference among treatments for HI or chick BW on d 21 of incubation. In the non71

injected control and treated groups, mean HI were 93.1 and 89.4 %, respectively, and
chick BW were 43.8 and 43.1 g, respectively. Mean embryonic stage score was 2.09, and
91.2 % of SOI were in the amnion. Oocyst shedding began 4 d posthatch (d 6 postinjection), and reached a peak at d 7 posthatch (d 10 post-injection). It was concluded
that the in ovo injection of Inovocox EM1 vaccine does not have a detrimental effect on
broiler embryogenesis or hatching chick quality.
Keywords: chick quality, embryo, hatchability, Inovocox EM1 vaccine, in ovo
injection
Introduction
The conventional posthatch methods of vaccination such as subcutaneous
injection, spray, drinking water, or feed applications may result in a lack of consistent
vaccine delivery and subsequent poor vaccine efficacy. Where possible these methods
are being replaced by in ovo injection technology, which is a faster, more effective, and
uniform method of vaccine delivery (Williams, 2007). Hatchery-applied vaccines for
Marek’s disease virus (MD), Infectious Bursal Disease Virus (IBDV), and coccidiosis
vaccines can be administered to late-stage chicken embryos via in ovo injection
(Jochemsen and Jeurissen, 2002; Weber and Evans, 2003). The in ovo vaccination of
broiler hatching eggs occurs widely in commercial hatcheries in North America, South
America, Europe, and Asia (Jochemsen and Jeurissen, 2002). Avian coccidiosis is a
parasitic disease of poultry caused by protozoan parasites of the genus Eimeria (phylum
Apicomplexa). Eimeria infects the intestinal tract and is transmitted between birds by a
fecal-oral route. Annual economic losses to the commercial poultry industry due to
coccidiosis are estimated at $800 million worldwide, and $127 million in the U.S.
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(Chapman, 2009). These losses include costs incurred by in-feed medication, mortality,
poor feed efficiency, and impaired performance (Williams, 1998). Coccidiosis is
therefore considered as one of the top diseases of concern to the broiler industry
worldwide.
In the U.S., the coccidiosis vaccine has become widely used as a means of
controlling coccidiosis in broiler chickens. Coccidiosis vaccines are used as alternatives
to chemotherapeutic agents for the control of coccidiosis (Chapman, 2000). These
vaccines can be used either alone or as part of a rotation program in combination with
other anticoccidial programs, depending on the season of the year (Chapman, 2000). The
Inovocox EM1 (EM1) vaccine (Zoetis Inc., Kalamazoo, MI) contains live oocysts of 3
common species of coccidia: Eimeria acervulina, E. maxima, and E. tenella. The EM1
vaccine is recommended for in ovo vaccination of late stage [18 to19 days of incubation
(doi)] embryonated chicken eggs for the prevention of coccidiosis caused by these 3
species of coccidia. The success of in ovo vaccination and the subsequent efficacy of the
vaccine are influenced by the application technique used, the timing of the injection
relative to the stage of embryonic development, and the exact site of vaccine deposition
(site of injection; SOI) in the developing embryo. An in ovo vaccination technique must
be easy to apply, achieve solid vaccine efficacy, support embryo health, and ensure chick
quality (Williams and Zedek, 2010). The in ovo injection machine developed by Embrex
(Embrex Inovoject system; Zoetis Inc.), has evolved into a commercial applicator that is
capable of simultaneously injecting over 50,000 eggs per hour, making in ovo
vaccination a more reliable method of vaccine application (Williams, 2007). The timing
of in ovo injection must synchronize with the appropriate stage of embryonic
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development in order to achieve the desired vaccine outcome. The stage of development
that is most appropriate is one that allows for the targeted embryonic sites to become
optimum in size and position for precise and accurate injection. Chicken embryonic
development starts as early as 44 h into incubation, beginning with the development of
the heart and vascular system (Tong et al., 2013). By 2 and 3 doi, there is the
development of the central nervous system and the appearance of functional systems such
as the limb buds and auditory pit. The embryo begins to move into hatching position by
14 doi, entering the growth phase prior to hatching (Mellor and Diesch, 2007). The entire
developmental period of the chicken embryo occurs within a 21 d period, and its stages
are generally divided into 3 developmental phases based on external features: the early,
middle, and late stages. The various organs and associated nervous, circulatory, and
reproductive systems are formed during the first 2 stages, while growth and maturation of
these organs occur in the third stage.
Although several methods of staging chicken embryonic development have been
described (Tong et al., 2013), the use of developmental stage scores provides a more
practical, field-based approach that can be used to determine embryonic physiological
development. This developmental stage scoring system utilizes predictable physiological
markers and developmental features to generate an additive score that ranges from 1 to 7,
depending on the stage of embryonic development (unpublished data, Embrex SOP
#EMB-007, ‘Site of Injection and Staging Embryos’). This embryonic stage score (ES)
can then be used as a predictable marker for determining the age of the chicken embryo.
The age and stage of development of the embryo is important in determining the accuracy
of vaccine deposition or SOI. The SOI can occur in 5 different locations in the egg of the
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developing late stage embryo. These areas are the air cell (AC), amnion (AM), allantois
(AL), embryo body (EM), and the yolk sac (Williams, 2007). The injection of vaccines
into any of these compartments within the egg may influence the efficacy of a vaccine,
the survival of the embryo, and the response of the embryo to the vaccine. A precise
deposition of the vaccine into the correct in ovo site is needed in order to obtain an
optimal response by the embryo to the vaccine (Williams and Hopkins, 2011).
Information on the effects of the in ovo injection of the commercial EM1 vaccine on
chicken embryos at 18 through 19 doi, and on subsequent hatching chick quality is
limited in the scientific literature. A more precise and practical approach for evaluating
the success of in ovo injection under commercial hatchery settings is also currently
unavailable. Therefore, the objective of this study was to investigate effects of the
commercial EM1 vaccine on the hatchability and chick quality variables of broilers
embryos injected as embryos at 18.5 doi, and to provide a stepwise and practical
approach for evaluating the outcome of in ovo coccidiosis vaccination under commercial
hatchery practice.
Materials and Methods
General
This study was conducted under a protocol that was approved by the Institutional
Animal Care and Use Committee of Mississippi State University. A total of 2,520 Ross
× Ross 708 broiler hatching eggs collected from a single 48-wk-old commercial broiler
breeder flock were held for 2 d under standard storage conditions and were then
individually weighed before being set. A total of 1,764 embryonated eggs that were of
good quality and within ±10 % of the mean weight of all eggs weighed (60 ± 6.0 g), were
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randomly assigned to 28 treatment-replicate groups (4 treatment groups on each of 7
incubator tray levels) each containing 63 eggs, in a Jamesway model PS 500® setter unit
(Jamesway Incubator Company Inc., Cambridge, Ontario, Canada) (Pulikanti et al.,
2012). Each tray level served as a replicate unit (experimental block). On d 16 of
incubation, eggs were candled as specified by Ernst et al. (2004), and eggs with cracked
shells and those that were unfertilized or contained dead embryos were removed and
discarded. After candling, a total of 1,594 embryonated eggs were retained, and were
randomly assigned to all 4 treatment groups, each containing approximately 56 eggs, on
each of the 7 tray levels in the setter. All eggs were incubated under standard conditions
(Peebles and Brake, 1987).
Injection and experimental layout
On 18.5 doi, eggs were injected using an Embrex Inovoject multi-egg injection
system capable of simultaneously injecting a tray of 42 eggs. In order to achieve the
manufacturer’s vaccination recommendation, 3 vials containing 8,000 doses each of EM1
vaccine were reconstituted in 1,200 mL of sterile commercial MD vaccine diluent (Merial
Co., Duluth, GA) and administered at the rate of 50 µL per egg. Vaccinal oocyst count
was conducted following vaccine reconstitution to determine the number of oocysts
contained per dose administered into each individual embryonated egg. During the
injection process, 50 µL vaccine samples were collected directly from the injection
needle into a quality control plate. The vaccine samples containing viable oocysts were
then placed in vials and transported in cold condition to the laboratory. Aliquots of
samples were placed onto microscope slides and the number of oocysts per field counted.
Each dose of EM1vaccine consisting of 375 oocysts from each of the acervulina,
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maxima, and tenella species of Eimeria, was injected into each individual embryonated
egg, with each embryonated egg receiving equal number of oocysts. During the injection
process each egg was subjected to one of the following treatments: non-injected
(treatment 1), dry-punch (treatment 2), diluent-injected [treatment 3 (50 µL of
commercial diluent)], and EM1 vaccine-injected [treatment 4 (50 µL of commercial
diluent containing EM1vaccine)]. Eggs belonging to the non-injected group were
subjected to the same procedures as the other treatment groups, except that they were not
injected. Following the completion of the entire injection process, all eggs were
subsequently transferred to a Jamesway model PS 500 hatcher unit (Jamesway Incubator
Company Inc., Cambridge, Ontario, Canada), in which eggs in their respective treatment
replicate groups were assigned to a hatcher basket which corresponded to their positions
in the setter.
Site of injection and embryo staging
During the in ovo injection process on 18.5 doi, a total of 120 embryonated eggs
were injected with coomassie brilliant blue G-250 (colloidal) dye. The dye was injected
alongside the EM1vaccine using 2 designated injection lines on the Embrex Inovoject
System. The concurrent in ovo injection of the dye with the EM1vaccine was used to
validate the localization of the vaccine by evaluating the location of the dye within the
injected embryonated eggs. The SOI and ES of each embryonated egg were subsequently
determined following the injection on 18.5 doi.
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Data collection
On 0 doi, individual egg weights were recorded. On 21 doi (d of hatch),
hatchability of injected eggs (HI) and hatchling BW (HBW) were determined. Mean HI
and HBW were obtained for each of the 28 treatment-replicate groups. Furthermore, on d
of hatch, 3 chicks from each treatment replicate group (84 total) were euthanized,
weighed, and necropsied for intestine, yolk sac and liver extraction. Absolute chick BW,
intestine (IW), yolk sac (YSW), liver weights (LW), and yolk-free BW (YFBW) were
determined. Subsequently, intestine (RIBW), yolk sac (RYBW) and liver weights
(RLBW) relative to BW; and intestine (RIYFW) and liver (RLYFW) weights relative to
YFBW were calculated. Similarly, chick yolk free body mass (YFBM) and chick BW
relative to set egg weight (RBSW) were calculated. All relative values were expressed as
percentages. The YFBM was also expressed as a percentage and was calculated by
dividing YFBW by BW, and multiplying the result by 100. Hatch residue analysis was
conducted according to the procedures of Ernst et al. (2004) to determine post-injection
embryonic mortality (PIM). Only embryos that were observed to have died after
injection on 18.5 doi were included in the determination of PIM.
Embryo euthenization and evaluation of vaccine deposition
Embryo euthenization and SOI evaluation were conducted according to methods
described by Williams and Hopkins (2011). Following the injection of coomassie blue
dye, test eggs were retained in their incubation flats and were placed in air-tight bags
according to treatment. Embryos contained in their shells were euthanized using CO2 gas,
and were then stored cold (4oC) for 4 hours. After euthenization, each egg was carefully
dissected to determine its SOI (dye deposition site) and ES. Only normally developed
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embryos were included in the determination of SOI and ES. The SOI of each egg was
designated as either AC, AM, AL, or EM, with EM injections subdivided into
intramuscular (i.m) and subcutaneous (s.c) injections. The correct SOI for optimal EM1
vaccine efficacy were those that delivered vaccine into the AM (Jochemsen and
Jeurissen, 2002; Williams, 2007) or EM intramuscular/subcutaneous (Williams and
Hopkins, 2011). For the evaluation of ES, the following physiological parameters and
scoring system were used: Internal pip: 0 or 1; external pip: 0 or 1; head of the embryo
located on its right side: 0 or 1, with 0 being absent and 1 being present. Furthermore,
yolk absorption was scored from 1 to 4: 1 = yolk stalk and intestine present within the
yolk sac; 2 = no yolk stalk present and the yolk sac bi-lobed in shape; 3 = yolk sac loses
its bi-lobed shape; and 4 = yolk is completely absorbed and there is no discernible shape.
The ES scores were additive, with a maximum score of 7. For example, if an embryo had
a score of 1 for internal pip, 1 for external pip, 1 for head to the right, and a score of 2 for
yolk absorption, this produced an ES of 5 out of 7. The higher the ES, the more
advanced was embryonic development. In general, by evaluating embryonic
developmental features (ES), it is possible to determine the approximate physiological
age of the embryo at the time of in ovo injection, and subsequently to determine the
success of the in ovo injection.
Chicks placement and determination of oocysts output
At hatch, 20 chicks from each of the 28 treatment-replicate groups were weighed
and placed in isolated wire-floored battery cages and given feed and water ad libitum for
14 d. The ration used met or exceeded National Research Council (1994) requirements
for broiler chickens. Chicks used in all experiments were straight-run. From d 0 to 14
79

posthatch, the entire (pooled) fecal output of all the birds in each individual pen was
collected daily. The determination of oocysts per gram of feces (OPGF) was performed
as previously described by Weber and Evans (2003), and Ryley et al. (1976). Briefly,
each entire fecal output was weighed, and an aliquot of approximately 2 g of feces was
mixed with an amount of water equivalent to approximately 6 × the volume of feces and
homogenized using a hand-held spatula in order to create a suspension. The suspensions
were then placed in centrifuge tubes, and centrifuged at 10,000 ×g for 8 min. The
supernatant was then discarded and the process was repeated for a second wash.
Following the second wash and centrifugation at 10,000 ×g for 8 min, the supernatant
was discarded and the precipitant was re-suspended in sugar solution to increase the
specific gravity of the fecal sample solution, so that the oocysts would float to the surface
and be trapped onto a cover slip placed over the test tube. The cover slip was then
removed and placed on a slide and was viewed under the microscope for enumeration of
oocysts. The number of oocysts per pen was determined and the mean oocyst per gram of
feces within each treatment was calculated.
Statistical description
A randomized complete block design was used, with each of the 7 tray levels of
the setter and each of the 7 hatching basket levels in the hatcher representing a block. All
4 treatment groups were randomly arranged and represented within each level (block).
All variables were analyzed using the MIXED procedure of SAS software 9.3 (SAS
institute, 2012). Treatments were viewed as fixed effects and blocks as random effects.
A one-way ANOVA was used to analyze treatment differences for all the parameters
investigated. Least-square means were compared in the event of significant global
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effects. Global and least-square means differences were considered significant at P ≤
0.05.
Results
There were no significant treatment effects on HI (P = 0.08) or HBW (P = 0.43)
at 21.0 doi (Fig. 3.1 and 3.2). However, HI at 21.0 doi in the non-injected control group
was numerically higher compared to that in the diluent-injected control and the vaccineinjected treatment groups. The HI means in the non-injected, dry punch, diluent-injected,
and vaccine-injected treatment groups were 93.1, 91.7, 90.6, and 89.4 %, respectively
(Pooled SEM = 0.98 %). The HBW means in the non-injected, dry punch, diluentinjected, and vaccine-injected treatment groups were 43.4, 43.8, 43.8, and 43.8 g,
respectively (Pooled SEM = 0.23 g). Similarly, there were no significant treatment effects
on any of the other hatching chick quality variables evaluated in this study. Nevertheless,
the treatment means for each of these hatching chick quality parameters are provided in
Table 3.1 for observation. Mean RBSW ranged from 71.9 % in the diluent-injected
group to 72.9 % in the non-injected control group, with the vaccine-injected group being
intermediate at 72.2 %. Mean YFBW of chicks ranged from 38.0 g in the vaccinated
group to 38.6 g in the diluent-injected group. Furthermore, YFBM was 87.3 % in the
non-injected control group, 88.8 % in the diluent-injected group, and 88.2 % in the
vaccine-injected group.
Posthatch oocyst output following the in ovo injection of the EM1 vaccine is
shown in Figure 3.3. The oocysts of all 3 species of Eimeria (acervulina, maxima, and
tenella) were recovered from fecal samples, confirming that the embryos became infected
subsequent to the in ovo injection of the coccidiosis vaccine. Oocyst output was greatest
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on d 7 posthatch, when embryos received E. acervulina, E. maxima, and E. tenella in ovo
on 18.5 doi. This peak was followed by a second, smaller peak at d 10 posthatch.
Beginning at d 4 and 5 posthatch, small (approximately 20×16 µm) and large
(approximately 32×28 µm) sized oocysts that are, respectively, indicative of E.
acervulina and E. maxima infection, were observed in the feces of most birds that
received the EM1vaccine. Peak oocyst output observed on d 7 posthatch suggests that all
Eimeria spps were present. A second, smaller peak of oocyst output detected by d 10
posthatch suggests that there was a delayed output of oocysts in a few chicks. Chicks
hatched from control eggs that received no injection, a dry-punch injection, or a diluent
injection, did not shed a detectable numbers of oocysts during the 2 wk posthatch period.
Mean ES for 118 embryonated eggs at 18.5 doi was 2.09 ± 0.43. Furthermore, the SOI
evaluation of those same eggs at 18.5 doi indicated that 84.7, 15.3, 6.8, and 8.5 % of the
eggs received vaccine in AM, EM, i.m, and s.c sites, respectively (Table 3.2).
Discussion
The HI of eggs that were injected with the EM1vaccine was largely unaffected.
Although there was a numerical decrease in HI in the vaccine-injected group, there were
also similar decreases observed in the dry punch and diluent-injected control groups in
comparison to the non-injected control group. This numerical decrease in HI may have
resulted from the creation of injection holes in the embryonated eggs belonging to these
groups (dry punch, diluent-injected and vaccine-injected groups). Nevertheless, treatment
had no significant effect on mean HI at 21 doi, and most notably, in ovo injection of the
EM1 vaccine did not cause any detrimental effects on hatchability. Similarly, treatment
had no significant effect on mean chick BW at 21 of doi. Furthermore, there were no
82

statistical differences between the vaccine-injected and control groups for all the chick
quality parameters determined in this study. The YFBM, which is YFBW divided by
BW, is an indicator of chick development during incubation and has been positively
correlated with subsequent chick performance (Molenaar et al., 2011). The in ovo
injection of the EM1 vaccine, therefore, did not adversely affect embryonic development
or survivability when assessed at 21 doi, and likewise exerted no subsequent negative
effects on hatchling quality.
The success of any in ovo vaccination depends on at least 2 major factors. These
major factors include the stage of development that the embryo is at when injected, and
the accuracy of vaccine deposition in the appropriate SOI. The stages of chicken embryo
development are generally divided into three major phases (early-, mid- and late- phase)
and are practically classified into embryonic days (ED) based on a 24 h calendar time
period (Tong et al., 2013). The ES system, however, is a more precise method of
evaluating and classifying embryonic development by utilizing physiological markers
and developmental features of the embryos that follow a predictable sequence. The ES
scoring system utilizes an additive scale that increases with developmental maturation to
a maximum of 7. The points are added when specific criteria are met as the embryo
develops towards hatching (unpublished data, Embrex SOP #EMB-007, ‘Site of Injection
and Staging Embryos’). Embryos with a high ES are more developed than are embryos
with a low ES. The ES is a predictor of the actual physiological age of an embryo and is
influenced by factors such as incubation time and conditions, flock breed and genetics,
and maternal nutrition. Accurate information regarding embryonic development is
important for SOI accuracy and eventual vaccine efficacy. Previous extensive work
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conducted on in ovo vaccination under commercial standard practice (Williams and
Zedek, 2010; Williams and Hopkins, 2012) suggests that the deposition of in ovo-injected
vaccine in the appropriate location is critical for the protective efficacy of the vaccine
against Marek’s disease (MD). The 5 regions of embryonated eggs that are primarily
involved with in ovo injection include the AC, AL, AM, EM and yolk sac (YS). The EM
region can be further divided into s.c, i.m, intra-cranial, intra-orbital, or intra-abdominal
regions. It has been suggested that the EM1vaccine must be delivered into the AM or
EM (i.m or s.c) regions to achieve a successful vaccination. Vaccines or other solutions
deposited in the AM are imbibed or aspirated by the embryo prior to hatching
(Jochemsen and Jeurissen, 2002). Delivery into the AC, AL, intra-cranial, intra-orbital, or
intra-abdominal regions are regarded as unsatisfactory vaccine deliveries, and will lead to
an ineffective vaccination and possibly the death of the embryo. In a previous study in
which the relationship between ES and SOI (unpublished data) was evaluated, it was
shown that when ES was between 1 and 3, there was an 80 to 94 % chance of vaccine
deposition occurring in the AM, and 6 to 20 % chance of vaccine deposition occurring in
the EM. An ES of 2 ensures that the percentage likelihood for an injection occurring in
the AM, EM, and AL was 94, 4, and 2 %, respectively. However, with an ES of 4 to 7,
the percentage likelihood for injections occurring in the EM is 70 to 90 %, and the
percentage likelihood for injections occurring in the AM is 5 to 30 %. Another earlier
study (unpublished data) was conducted to show the relationship between ES and
embryonic age at ED 17.5, 18.0, 18.5, and 19.0. Data was obtained using eggs from 6
flocks of 3 breed crosses (5,341 total eggs) that were set in a Jamesway incubator at
different times. The results showed that there was a significant (P = 0.05) distribution of
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ES values across all 4 embryonic ages. In brief, ED 17.5, 18.0, 18.5, and 19.0
corresponded to ES 1, 2, 3, and 4, respectively, in approximately 60 % of the embryo
population. Based on these results, the SOI and ES in a test population of the current
study that occupied approximately 10 % of the total embryo population were evaluated
using protein-staining blue dye to determine the efficacy of the EM1vaccine. Results
showed that mean ES was of 2.09 ± 0.43 (mean ± SD) and that the percentage injections
in the AM and EM were 84.7 and 15.3 % (i.m., 6.8 %; s.c., 8.5 %), respectively. The ES
and SOI results in this study showed that the embryos were at a physiological stage of
development that corresponded to ED 18.0 and 18.5, and that 91.5 % of vaccine
deliveries were in the AM and EM. Vaccine deposition in the AM, i.m or s.c (right
breast area) of the developing embryo is the specified target site for optimal uniform
vaccination. The physiological markers for these embryos at ED 18.0 and 18.5 were:
head at the right wing, internal pip may be present or absent, external pip is absent, and
with yolk absorption scores between 1 and 2. This stage of physiological development
corresponds to a time that is recommended for injection of the EM1vaccine for optimal
vaccine delivery and subsequent vaccine uptake by the embryo. In addition, the ES
showed uniformity of the embryo population (based on the SD). This uniformity ensures
that a great percentage of the embryos received the vaccine in similar manner and can
influence the subsequent outcome of the vaccination during field challenge.
Following the in ovo injection of the EM1vaccine, the success of vaccination was
further determined by the evaluation of fecal oocyst recovery from the posthatch chicks.
The assessment of vaccinal oocyst output was used to ensure that the birds vaccinated
with the EM1vaccine actually received vaccinal oocysts by way of in ovo injection.
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Post-injection oocyst output evaluation indicates that the chicks were in fact infected with
all 3 Eimeria spps when EM1was administered in ovo. Moreover, there were no oocysts
in the feces of chicks from the non-injected and diluent-injected control groups. Peak
oocyst output was observed at d 7 posthatch, indicating that the coccidia life cycle started
at hatch. This is consistent with previous work, in which the in ovo injection of oocysts
resulted in a shedding peak at approximately 7 d posthatch (Weber and Evans, 2003). It
has been suggested that following an in ovo injection of coccidial oocysts, oocysts may
remain inactive in the embryo’s intestine after being ingested from the amniotic fluid
with no significant life cycle changes occurring until the chicks hatch (Weber et al.,
2001). As with previous studies (Weber et al., 2004), the current evidence suggests that
the initiation of immunity in response to the EM1 vaccine oocysts occurs at hatch. This
evidence is based on the time that oocysts of E. acervulina (4 d posthatch) and E. maxima
(6 d posthatch) were observed in their feces in relation to their known prepatent life cycle
period (Conway and McKenzie, 1991). Oocysts or intestinal lesions were histologically
undetected at hatch for all 3 Eimeria spps. This suggests a mild vaccinal reaction to
infection that is capable of inducing the development of an immune response.
In conclusion, the in ovo injection of the EM1vaccine on 18.5 doi in Ross × Ross
708 broilers had no detrimental effect on hatching chick quality. It also did not adversely
affect embryonic survivability, as evidenced by the lack of any adverse treatment effects
on HI. Furthermore, the injection of the EM1vaccine produced a vaccine-induced
infection that was made evident by the OPGF counts occurring between 1 and 14 d
posthatch in the vaccine-injected group. The use of qualitative procedures, namely SOI
and ES, ensured that the injection of the EM1vaccine between 18 and 18.5 doi provided
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accurate delivery of the vaccine into the AM and EM (i.m or s.c), and the recovery of
oocysts during the posthatch period was indicative of a stimulation of immunity
necessary for protection against coccidial challenge.
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Figure 3.1

Hatchability on d 21.0 of incubation as a percentage of embryonated
injected eggs

In non-injected, dry punch, and diluent-injected (50 µL) controls and eggs injected with
the EM1vaccine in 50 µL of diluent.1,2
1
Data from 7 replicate units was used for calculation of means for each treatment group.
2
No significant difference among treatment groups for hatchability (P = 0.08).
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Figure 3.2

Hatching BW on d 21.0 of incubation

In non-injected, dry punch and diluent-injected (50 µL) controls, and eggs injected with
the EM1vaccine in 50 µL of diluent.1,2
1
Data from 7 replicate units was used for calculation of means for each treatment group.
2
No significant difference among treatment groups for hatching BW (P = 0.43).

Figure 3.3

Posthatch oocysts shedding by broiler chicks after in ovo injection with the
EM1 vaccine on d 18.5 of incubation

Seven replicate pens were used to calculate mean number of oocysts per gram of feces.
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EFFECTS OF COCCIDIOSIS IN OVO VACCINATION ON BROILER
PERFORMANCE
Abstract
Effects of the in ovo injection of a commercial coccidiosis vaccine on hatching
chick quality parameters and 14 d posthatch oocyst shedding pattern has been previously
examined. This study was designed to examine broiler performance during the 14 d
posthatch period of oocyst shedding following the in ovo injection of a commercial
coccidiosis vaccine. On each of 7 replicate tray levels of a single-stage incubator, a total
of 4 treatment groups were randomly represented, with each treatment (TR) group
containing 63 eggs. Treatments were administered using a commercial multi-egg injector
on 18.5 d of incubation (doi). The treatments included 3 control groups (non-injected,
dry-punch, and diluent-injected) and one treatment group (injected with diluent
containing Inovocox EM1 vaccine). On 21 doi, 20 chicks from each of the 28 treatment
replicate groups were placed in corresponding wire-floored battery cages. Feed intake
(FI), BW gain (BWG), and feed conversion ratio (FCR) were determined for the 0 to 7, 7
to 14, and cumulative 0 to 14 d of age (doa) intervals. There was no significant treatment
effect on BW at 0 and 7 doa, but there was significant treatment effect on BW at 14 doa.
There was significant treatment effect on BWG, FI, and FCR in the 7 to 14 and 0 to 14
doa intervals, but there was no significant treatment effect on BWG, FI, and FCR in the 0
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to 7 doa interval. The performance parameters measured in birds belonging to the
diluent-injected and vaccine-injected groups were significantly different from those in
birds belonging to the non-injected and dry-punch control groups. However, the
performance parameters were not significantly different between the diluent-injected and
vaccine-injected groups. It was concluded that use of the Inovocox EM1 vaccine in
commercial diluent has no detrimental effect on the overall post-hatch performance of
broilers.
Key words: Inovocox EM1 vaccine, chicks, in ovo injection, performance, posthatch
Introduction
Among the world’s poultry producers, coccidiosis continues to be one of the most
commonly reported diseases (Biggs, 1982; Williams 1999), with subclinical coccidiosis
being the most commonly reported form. Without the demonstration of overt clinical
symptoms, subclinical coccidiosis is characterized by weight loss, reduced weight gain,
and poor feed efficiency (Williams, 1999). Due to historic resistance to in-feed
anticoccidials against strains of Eimeria parasites, and to increasing public awareness of
drug residues in poultry products, the use of live coccidia vaccines has become an option
of greater interest for the control of coccidiosis (William, 2002; McEvoy, 2001). The life
span of the meat-type bird averages only 42 d (William, 2002). Therefore, early
vaccination is a practicable method of controlling coccidiosis because it allows for an
earlier protection against coccidiosis infection. In ovo vaccination of embryos with live
parasites ensures the controlled delivery of a precise dose of vaccinal oocysts to each
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embryo, which results in the early development of more uniform protection (William,
2002).
Although the use of vaccination for control of coccidiosis infection has become
widely accepted (William, 2002), adverse effects on early broiler growth performance
has been reported (Lehman et al, 2009). Studies have shown that under commercial
conditions, early temporary reductions in BW gain (BWG) and feed efficiency between
14 and 28 d of age (doa), can occur as a result of vaccination with live non-attenuated
coccidial oocysts (William, 2002; Chapman et al., 2002). This temporary reduction in
BWG is usually followed by a compensatory increase in BWG by 35 to 42 doa (Mathis,
1999; Mathis and Lang, 2001). While the effect of vaccination programs on broiler growout performance has been examined (Mathis, 1999), only a few studies have examined
the performance of broilers during the early post-vaccination peak of oocyst shedding.
The objective of this current study was to evaluate the growth performance (feed
intake, BWG, and feed efficiency) of broilers during the first 14 d of vaccine-derived
coccidial oocyst shedding, without being concurrently challenged with an Eimeria
infection. The birds that were evaluated for their performance in this study had been
previously vaccinated with the EM1 vaccine via in ovo injection on 18.5 d of incubation
(doi) and had displayed coccidial oocyst shedding from 0 to 14 doa (Sokale et al., 2015a).
To the authors’ knowledge, this is the first study that describes the performance
characteristics of broilers during the first 14 d of oocyst shedding following an in ovo
vaccination with the Inovocox EM1 (EM1) vaccine.
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Materials and Methods
General
This study was conducted according to a protocol that was approved by the
Institutional Animal Care and Use Committee of Mississippi State University. A total of
2,520 broiler hatching eggs (Ross × Ross 708) collected from a commercial breeder flock
at 48 wk of age, were held for 2 d under standard storage conditions after collection. Prior
to setting, eggs were individually weighed and only eggs that had normal appearance and
that weighed within 10 % of the mean weight of all eggs (60 ± 6.0 g) were set (Pulikanti
et al., 2012). A total of 1,764 eggs were incubated under standard conditions (Peebles and
Brake, 1987; Zhai et al., 2011) in a Jamesway model PS 500 setter unit (Jamesway
Incubator Company Inc., Cambridge, Ontario, Canada). There were 28 treatmentreplicate groups (4 treatment groups on each of 7 replicate tray levels), with each
containing 63 eggs, arranged in the setter. On 18 doi, eggs were candled to remove those
that were unfertilized or contained dead embryos as described by Ernst et al. (2004). On
18.5 doi, eggs were injected according to one of the 4 treatments specified below.
Experimental layout
Eggs were injected using an Embrex Inovoject injector system (Zoetis Animal
Health, Research Triangle Park, NC). The methodology for confirmation of site of
injection, egg handling, and the injection procedure were as described in detail by Sokale
et al. (2015a). Briefly, EM1 vaccine was reconstituted in sterile commercial Marek’s
Disease vaccine diluent (Merial Co., Duluth, GA) and administered at a rate of 50 µL per
egg on 18.5 doi. The number of oocysts contained per dose administered into each
individual embryonated egg was determined in a previous study (Sokale et al. 2015a). A
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total of 375 oocysts from each of the acervulina, maxima, and tenella species of Eimeria,
were injected into each individual embryonated egg. Treatments included non-injected,
dry-punch, and diluent-injected (50 µL of commercial diluent delivered to each egg)
controls. All eggs were subsequently transferred to a Jamesway model PS 500 hatcher
unit (Jamesway Incubator Company Inc., Cambridge, Ontario, Canada), in which eggs in
their respective treatment replicate groups were assigned hatcher basket positions which
corresponded to their arrangement in the setter.
Data collection
On 21 doi, 20 straight-run chicks from each of the 28 treatment replicate groups
were randomly selected, wing-banded, weighed, and placed in each of 28 isolated wirefloored battery cages of a light-controlled research facility. Chicks were placed in the
battery cages using the same experimental design that was used for the arrangement of
eggs in the hatcher unit. Pen conditions, including brooding environment, were
monitored twice daily throughout the grow-out period to ensure their conformity to
commercial standards. Chicks were given feed and water ad libitum for 14 d. All birds
were fed a standard Mississippi State University broiler basal starter diet which was
formulated to meet or exceed NRC (1994) recommendations throughout the 14 d period
(Sokale et al., 2015a). Although housed in the same facility and under the same
conditions, the groups which did not receive vaccine were kept separate from the
vaccinated groups to reduce the risk of cross-contamination (Sokale et al., 2015a). Bird
numbers, BW, and feed weights were determined for each pen on a weekly basis from 0
to 14 doa. Furthermore, BWG, feed intake (FI), feed conversion ratio (FCR), and
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percentage mortality (PM) were determined for the 0 to 7, 7 to 14, and cumulative 0 to
14 doa intervals.
At 0, 3, 5 and 7 doa, one bird from each of the 7 replicate groups in the noninjected, diluent-injected, and vaccine-injected treatment groups (7 birds per treatment)
were euthanized, and their intestinal tracts were collected and fixed in 10 % buffered
neutral formalin solution for subsequent coccidia scoring by histopathological
examination. The formalin-fixed intestine tissues (duodenum, mid-intestine, and cecum)
were routinely processed for histopathology and evaluated for the presence of coccidia.
The tissues were collected and trimmed such that complete sagittal circumferential
sections of the duodenum, mid-intestine, and cecum were made available for
examination. Based on coccidia numbers, samples were assigned one of the following
quantitative observational scores: Score 1: no coccidia; Score 2: 1 to 30 coccidia; Score
3: 31 to 100 coccidia; Score 4: more than 100 coccidia. Mean coccidia scores for each
treatment are presented in Table 4.2.
Statistical description
A randomized complete block design was used during the incubation and growout periods. Treatment was viewed as a fixed effect and block as a random effect in the
one-way ANOVA of absolute BW, weekly BW gain, FI, FCR, PM, and coccidia count.
All variables were analyzed using the MIXED procedure of SAS software 9.3 (SAS
institute, 2012). Least-square means were compared in the event of significant global
effects. Global and least-square means differences were considered significant at P ≤
0.05.
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Results and discussion
The performance characteristics of broiler chickens that were administered the
EM1 vaccine on 18.5 doi was measured during the first 14 d of oocyst shedding. This
performance evaluation was conducted in order to determine any effect on broiler
performance during the first few days of oocyst shedding when initial infection is being
established for the development of immunity against coccidiosis (Weber et al., 2004).
There were no significant effects due to treatment for mean BW at 0 and 7 doa, or BWG,
FI, and FCR in the 0 to 7 doa interval. However, there were significant effects due to
treatment for mean BW at 14 doa (P < 0.001), for BWG (P < 0.001), FI (P = 0.004), and
FCR (P = 0.002) in the 7 to 14 doa interval, and for BWG (P < 0.001), FI (P = 0.005),
and FCR (P = 0.001) in the 0 to 14 doa interval. For reference, treatment means for BW
at 0, 7, and 14 doa, and for BWG, FI, and FCR in each of these age intervals are provided
in Table 4.1. The BW of birds at 14 doa was higher in birds belonging to the dry-punch
and non-injected control groups in comparison to those belonging to the vaccine-injected
and diluent-injected groups. In the 7 to 14 and 0 to 14 doa intervals, the BWG and FI of
birds belonging to the dry-punch and non-injected control groups were significantly
higher in comparison to those in the vaccine-injected and the diluent-injected groups. In
the 7 to 14 and 0 to 14 doa intervals, the FCR of birds belonging to the diluent-injected
and vaccine-injected groups was significantly higher in comparison to those in the drypunch and non-injected control groups. There were no significant treatment effects on the
PM of birds in the 0 to 7 and 7 to 14 doa intervals. Furthermore, the cumulative (0 to 14
doa) PM (CPM) of birds was not significantly affected by treatment. The CPM of birds
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in the non-injected, dry-punch, and diluent-injected control groups, and in the vaccineinjected treatment group is presented in Fig. 4.1.
Histopathological examination of the intestinal tissue samples obtained from birds
vaccinated via in ovo injection of the EM1 vaccine confirmed the presence of coccidia
parasites from all 3 species of Eimeria, at 3, 5 and 7 doa, with peak counts observed
between 5 and 7 doa (Table 1). This outcome is a similar to the oocyst per gram of feces
(OPGF) count previously examined in these same birds, which showed peak oocyst
output occurring at 7 and 10 doa (Sokale et al., 2015a). In general, coccidia counts were
low in most of the intestinal sections examined. The predominant species in the
duodenum and mid-intestine were Eimeria acervulina and Eimeria maxima, respectively.
In some sections of the duodenum and mid-intestine, it was not possible to definitively
identify the species of coccidia based on morphology; however, the coccidia did not
exhibit clustering that is typical of Eimeria acervulina, and were likely Eimeria maxima.
In the cecum, the morphology of the coccidia and their location within the mucosa were
consistent with that of Eimeria tenella. The colonization of the gut by coccidial parasites,
and the pattern of oocyst shedding in the feces, is consistent with the normal life cycle of
Eimeria. The sporozoites from the sporulated vaccinal oocysts are released by the
grinding activity of the gizzard, and subsequently penetrate the intestinal mucosa to begin
asexual development (schizogony). Sexual development (gametogony) eventually occur
which ultimately resulted in the release of fecal oocysts. The duration of this first phase
of the organism’s life cycle lasts approximately 7 d (Chapman, 2002), which corresponds
with the peak of initial coccidial cycling as observed in this study, and that of fecal
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oocyst output as demonstrated by Sokale et al., 2015a. By 14 doa, initial oocyst
production is commonly reduced.
No difference in BW among treatment groups was observed at 7 doa. More
specifically, birds that were administered the EM1 vaccine did not show any decrease in
BW during the period of peak oocyst cycling (7 doa) when compared to those in the nonvaccinated group. However BW was significantly decreased in the vaccine-injected and
diluent-injected groups at 14 doa (Table 4.1). Although the BW of the birds in the drypunch and non-injected control groups were higher in comparison to those in the vaccineinjected and diluent-injected groups, there was no difference in BW between the vaccineinjected group and the diluent-injected control group at 14 doa. A similar trend was
observed in the other performance parameters that were measured in this study. In the 7
to 14 and 0 to 14 doa intervals, BWG and FI were higher in birds belonging to the drypunch and non-injected control groups in comparison to those belonging to the vaccineinjected and diluent-injected groups. In addition, in the 7 to 14 and 0 to 14 doa intervals,
FCR was higher in birds belonging to the diluent-injected and vaccine-injected groups in
comparison to those belonging to the non-injected and dry-punch control groups.
Nevertheless, in the 7 to 14 and 0 to 14 doa intervals, the FI, BWG, and FCR of the birds
in the vaccine-injected and diluent-injected groups were not significantly different. As in
this study, Bello et al. (2014) showed that in the 7 to14 doa interval, BWG was
numerically higher in a non-injected control group in comparison to that in a diluentinjected control group. The results of this study indicate that the injection of diluent
affected the performance parameters of broiler embryos. They further suggest that
increased hatchling BW in response to diluent injection may result in a lower feed
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consumption and BWG during early posthatch life. The diluent used in this study is
widely used commercially as a carrier for Marek’s disease vaccine. Although the precise
constitution of the commercial diluent is proprietary, it is suggested that the diluent may
increase the relative water content of the bodily tissue of the birds, thereby increasing
chick BW at hatch, and may provide nutrients that stimulate growth. Although this effect
may be of a limited duration during the chicks’ posthatch life, it affects the FI, BWG, and
FCR of the chicks during that time. On the other hand, although this study did not
specifically show a reduction in the early growth performance of broilers vaccinated with
the EM1 vaccine, a transient reduction in early growth during the peak of vaccinal oocyst
infection has been shown in several other studies. Parker et al. (2007) and Walk et al.
(2011) showed a significant reduction in the FI and BWG of vaccinated birds up to 17
and 18 doa, respectively, when compared to non-vaccinated birds. However, Weber et al.
(2004) showed that the BWG of chicks immunized with 1 × 105 sporulated Eimeria
praecox was not significantly different from that of non-immunized birds through 14 doa.
The CPM of birds in the 0 to 14 doa interval was not significantly different among
treatments, indicating that addition of the EM1 vaccine in the commercial diluent exerted
no adverse effects on the growth performance of the broilers.
In conclusion, in ovo injection of the EM1 vaccine in 50 µL of commercial
diluent on 18.5 doi had no detrimental effect on the hatchability of broiler hatching eggs,
or the subsequent quality of hatchlings, as earlier demonstrated by Sokale et al. (2015a).
Likewise, it had no detrimental effect on posthatch survivability or on 14 d grow-out
performance, as demonstrated in the current study.
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0.005
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0.139b
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0.005
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0.298a

0.296a
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<0.01

0.006

0.218b

0.214b

0.254a

0.252a

BWG3
(kg)

0.05

0.007
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0.3101b

0.337a

0.336a

FI3(kg)

0.01

0.023

1.41a

1.46a

1.33b

1.33b

FCR3

1

Means within a column with no common superscript differ (P ≤ 0.05).
20 birds in each of 7 replicate units used to calculate each treatment mean.
BW1 = d 0 BW; BWG1 = d 0 to 7 BW gain; FI1 = d 0 to 7 feed intake; FCR1 = d 0 to 7 feed conversion ratio; BW2 = d 7 BW;
BWG2 = d 7 to 14 BW gain; FI2 = d 7 to 14 feed intake; FCR2 = d 7 to 14 feed conversion ratio; BW3 = d 14 BW; BWG3 = d 0 to
14 BW gain; FI3 = d 0 to 14 feed intake; FCR3 = d 0 to 14 feed conversion ratio.

a,b
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0.044

Diluent-injected
control

0.044

0.044

Dry-punch
control

Vaccine-injected

0.043

BW1
(kg)

Growth performance parameter means in the non-injected, dry-punch, and diluent-injected control groups, and in the
vaccine-injected treatment group.1

Non-injected
control

Table 4.1
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1

1.0

1.0

1.0

d3

0.38

0.17

1.3

1.0

1.0

d5

Midgut

0.38

0.06

1.1

1.0

1.0

d7

1

1

1.0
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1.0
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1

1

1.0

1.0

1.0
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0.16
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Cecum

0.18
0.20

1.4

1.0

1.0
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1

Means within a parameter with no common superscript differ (P ≤ 0.05).
1 bird in each of 7 replicate units (7 birds per treatment) was used to calculate each treatment mean. Each intestinal section was
scored using the following matrix 1: no coccidia observed; 2: 1 to 30 coccidia observed; 3: 31 to 100 coccidia observed; 4: more
than 100 coccidia observed.

a,b

1.0

VaccineInjected

1.0

1.0

Non-injected
control

Diluentinjected control

d0

Duodenum

Mean coccidia counts by histological examination in the non-injected and diluent-injected control groups, and in the
vaccine-injected treatment group at 0, 3, 5, and 7 d of age.1

Age of bird in
days

Table 4.2
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Figure 4.1

Cumulative (d 0 to 14 posthatch) percentage mortality (PM) in birds

In the non-injected, dry-punch and diluent-injected (50 µL) control groups, and in the
vaccine-injected treatment group.1
1
No significant difference among treatment groups for percentage mortality (P = 0.25).
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EFFECTS OF IN OVO INJECTION OF DIFFERENT DOSAGES OF INOVOCOX
EM1 VACCINE AND TURN-OUT TIMES ON BROILER PERFORMANCE
Abstract
The in ovo injection of Inovocox EM1 vaccine (EM1) at the recommended dose
of 50 µL per egg on 18.5 d of incubation (doi) has been shown to have no detrimental
effect on hatchability and the performance characteristics of broilers through 14 d
posthatch (poh). The effects of in ovo injection of EM1 at 1× or 10× dosage levels and 2
turn-out times on the chick quality and poh performance of Ross × Ross 708 broilers
were determined in this current study. All 48 treatment-replicate groups (6 treatments on
each of 8 replicate tray levels) each containing 60 eggs, were randomly arranged in a
single-stage Jamesway incubator. On 19 doi, eggs were subjected to 1 of 3 treatments
using a commercial Inovoject system. Treatments included a noninjected control, and 1×
and 10× dosages of EM1. These 3 treatments groups were then partitioned into 2 turn-out
time groups on 21 doi (day of hatch). The subsequent treatment combination designation
were as follows: treatment 1- noninjected control with d 7 poh turn-out, treatment 2noninjected control with d 10 poh turn-out, treatment 3 - 1× dose of EM1 with d 7 poh
turn-out, treatment 4 - 1× dose of EM1 with d 10 poh turn-out, treatment 5 - 10× dose of
EM1 with d 7 poh turn-out, and treatment 6 - 10× dose of EM1 with d 10 poh turn-out.
On 21 doi, hatchability of injected eggs (HI), embryonic mortality, hatchling BW
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(HBW), organ weights, yolk sac weight (YSW) and yolk-free BW (YFBW) were
determined. Similarly, chicks from each treatment replicate group were placed in
corresponding floor pens which were previously sub-divided in order to obtain the
desired turn-out times. Feed intake, BW gain, and feed conversion ratio were determined
for the weekly and cumulative 0 to 35 poh d of age (doa) intervals. There was no
treatment effect on HI, HBW, and YFBW on 21 doi. However there was significant
treatment effect on BW, YSW, and RBSW. Body weight on d 28 poh, BW gain and FCR
in the 21 to 28 doa interval, and BWG in the 0 to 35 doa interval, were all affected by
treatment. There was no significant difference among all the vaccine-injected treatment
groups irrespective of dose and turn-out time. In conclusion, the in ovo injection of EM1
vaccine up to 10× the recommended dosage and turn-out times at 7 or 10 d poh, had no
detrimental effect on the chick quality and overall posthatch performance of broilers.
Key words: chicks, Inovocox EM1 vaccine, in ovo injection, performance,
posthatch
Introduction
Avian coccidiosis caused by a protozoan parasite of the genus Eimeria, continues
to be one of the most common diseases of poultry. Avian coccidiosis in poultry increases
their susceptibility to secondary diseases such as necrotic enteritis (Williams, 2005), and
the subclinical form can negatively impact their performance. This parasite develops in
the intestinal tract of birds, causing morbidity, mortality, and poor feed efficiency and
weight gain. Coccidia oocysts are ubiquitous to commercial chicken houses and,
therefore, complete eradication of coccidiosis is impossible (Chapman, 2000; Tewari and
Maharana, 2011). The control of coccidiosis is achieved by use of in-feed anticoccidials
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and coccidiosis vaccines in different types of grow-out programs, such as a rotation
control program (Chapman et al., 2002; Chapman, 2009). In addition, coccidiosis
vaccines are used throughout the year for the control of coccidiosis in antibiotics-free or
organic commercial operations. Coccidiosis vaccines do not leave any residue in meat
and are therefore, safe for poultry meat consumption (Van Immerseel et al., 2009).
Efficacy of the coccidiosis vaccine, when used either exclusively year round or in a
rotation program with in-feed anticoccidials, requires the establishment of immunological
competence by the cycling of oocysts. Exposing birds to multiple coccidial life cycles
(oocyst cycling) initiates an immune response necessary for the control of coccidiosis
(Chapman et al., 2002; Tewari and Maharana, 2011). Furthermore, the use of partial
house brooding management following administration of the coccidiosis vaccine,
Coccivac-B by spray at day of hatch, has been recommended by the vaccine
manufacturer (Schering-Plough Animal Health, 2007). Partial house brooding over a
period of 7 to 14 days allows birds to be repeatedly exposed to high numbers of oocysts
produced by the build-up of vaccinal oocysts. This fecal-oral repeated exposure initiates
the development of immune competence against coccidiosis (Mathis, 2001). However,
unlike use of the spray form of the coccidiosis vaccine, the duration of exposure of birds
to built-up coccidial oocysts under partial house brooding conditions and its subsequent
effects on performance following the in ovo administration of Inovocox EM1 vaccine has
not been documented in the scientific literature. Therefore, the objective of this study was
to determine an optimal turn-out time in the presence of high and low doses of Inovocox
EM1 vaccine (EM1) for the optimization of oocyst re-cycling without negatively
impacting grow-out performance.
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Materials and Methods
General
All experimental procedures were approved by the Mississippi State University
Institutional Animal Care and Use Committee. Ross × Ross 708 broiler hatching eggs
(2,160) were obtained from a 45 wk old commercial breeder flock, and held for 2 d under
standard storage conditions prior to setting. On 0 d of incubation (doi), eggs were
weighed, and eggs that had normal appearance (Zhai et al.,2011b; Bello et al., 2014) were
labeled and randomly assigned to each of 8 incubator tray levels in a Jamesway model PS
500 single stage incubator (Jamesway Incubator Co. Inc., Cambridge, Ontario, Canada).
Each tray level served as a replicate unit. A total of 1,440 eggs were incubated under
standard conditions (Peebles and Brake, 1987; Zhai et al., 2011a). There were 6
treatment groups, each containing 30 eggs that were represented on each of 8 replicate
tray levels (blocks) in the setter (a total of 48 treatment-replicate groups). Eggs were
candled on 18 doi, and all unfertilized eggs or eggs that contained dead embryos were
removed (Ernst et al., 2004). After candling, a total of 1,310 embryonated eggs were
retained in all 48 treatment-replicate groups, each containing approximately 27
embryonated eggs. Incubator dry and wet bulb temperatures were set at 37.5 ± 0.1 and
28.9 ± 0.1°C, respectively, and monitored twice daily for the entire incubation period. On
19 doi, eggs were either not injected or were subjected to one of the 2 treatments
described below.
Injection and experimental layout
Injection of eggs was performed on 19.0 doi using an Embrex Inovoject injector
system (Zoetis Animal Health, Research Triangle Park, NC), as described by Sokale et al.
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(2015a). In order to achieve the manufacturer’s recommendation of a 1× dose of EM1, 3
vials (8,000 doses each) of EM1 were reconstituted in 1,200 mL of sterile commercial
MD vaccine diluent (Merial Co., Duluth, GA). Similarly, to achieve a 10× dose of EM1,
30 vials (8,000 doses each) of EM1 vaccine were reconstituted in 1,200 mL of sterile
commercial MD vaccine diluent (Merial Co., Duluth, GA ). The vaccines were injected
through the air cell with 50 µL of solution per egg for both the 1× dose and 10× dose. On
19 doi, the site of injection (SOI) was confirmed using coomassie brilliant blue G-250
(colloidal) dye that was concurrently injected in a separate delivery than EM1 (Sokale et
al., 2015a). During the injection process, eggs belonging to a particular treatment group
were injected together before changing to another treatment group to avoid crosscontamination between treatment groups. Eggs in the non-injected control group were
subjected to the same process as the injected treatment groups, except that they were not
injected with EM1. Once the entire injection process was completed, eggs were
transferred to the hatcher unit (Jamesway Incubator Company Inc., Cambridge, Ontario,
Canada) on their corresponding replicate tray levels. Eggs in the hatcher baskets were
arranged in a way to prevent cross-contamination between the injected and non-injected
hatched chicks. All eggs were held outside the incubator for an approximate 5 min time
interval between injection and transfer. Approximately 60 embryonated eggs per
treatment group were randomly arranged on each of 8 replicate tray levels and were
subjected to one of the following treatments: treatment 1 - noninjected control; treatment
2 - 1× dose of EM in 50 µL of diluent; or treatment 3 - 10× dose of EM1 in 50 µL of
diluent. However, each of the 3 treatment groups were subsequently divided into each of
2 turn-out times during the grow-out phase, so that 6 treatment groups (3 injections × 2
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turn-out times treatments) were ultimately formed. Therefore, at the beginning of the
grow-out phase, chicks were allotted to one of the following 6 treatment groups:
treatment 1- noninjected control with d 7 turn-out (NIC7); treatment 2 - noninjected
control with d 10 turn-out (NIC10); treatment 3 - 1× dose of EM1 with d 7 turn-out (1×
VI7); treatment 4 - 1× dose of EM1 with d 10 turn-out (1× VI10); treatment 5 - 10× dose
of EM1 with d 7 turn-out (10× VI7); and treatment 6 - 10× dose of EM1 with d 10 turnout (10× VI10).
On 21 doi, a total of 20 straight-run chicks from each of the 48 treatment-replicate
groups were randomly selected, wing-banded, weighed, and placed in each of 48
miniature floor pens measuring 1.1 m2/pen, within a temperature controlled research
facility. In order to achieve the specified turn-out times, chicks were initially placed in a
3/4 (0.84 m2) portion of each pen, with a stocking density of 0.04 m2 /bird. The pens
were divided using plastic wire mesh that prevented birds from crossing over to the
unused side of the pen without interfering with air flow. Birds were turned-out on d 7
and 10 posthatch (poh). A total of 24 treatment-replicate pens were randomly selected
and turned-out at each time period. Turning-out involved the removal of the plastic wire
mesh used to divide each pen, so that birds are allowed the entire 1.1 m2 space in each
pen, with a stocking density of 0.06 m2 /bird up to 35 d poh. A total of 960 chicks (20
chicks × 48 pens) were placed on previously used litter (had been used for 2 previous
grow-out cycles). Ad-libitum feed and water were provided to birds in each pen during
grow-out. Birds were fed standard Mississippi State University broiler diets, which were
formulated to meet or exceed NRC (1994) recommendations, through d 35 poh. Birds
were provided crumbled starter diet from d 0 to 14, pelletized grower diet from d 15 to
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28, and pelletized finisher diet from d 29 to 35. House temperature conditions were
monitored and recorded twice daily for the entire duration of the grow-out period.
Data collection
Set egg weight (SEW) was recorded on 0 doi. Incubation temperature was
monitored and recorded twice daily during the incubation period. On day of injection
(19.0 doi), SOI and embryo staging (ES) were determined. On 21.0 doi, 16 chicks from
each treatment group were wing-banded, euthanized, weighed, and necropsied for
determination of chick BW, YSW, liver (LW), whole intestine (IW), and heart weight
(HW). The hatchability of injected fertilized eggs (HI) and hatching chick BW (HBW)
were also determined on 21.0 doi. The cumulative percentage mortality of un-hatched
embryos at late incubation stage (PLD; 15.0 to 18.5 doi) was determined at 21.0 doi.
Furthermore, the following hatching chick quality parameters were determined: BW,
yolk-free BW (YFBW), yolk-sac weight (YSW), yolk-sac relative to BW (RYBW), IW
relative to BW (RIBW), IW relative to YFBW (RIYFW), LW relative to BW (RLBW),
LW relative to YFBW (RLYFW), HW relative to BW (RHBW), HW relative to YFBW
(RHYFW), BW relative to SEW (RBSW), YFBW relative to SEW (RYFWSW), and
yolk free body mass (YFBM). The YFBM which measures the development of chicks
during incubation is calculated by dividing YFBW by BW (Sokale et al., 2015a). On d 28
poh, 2 chicks from each treatment-replicate group (16 total birds per treatment) were
euthanized, weighed, and necropsied for determination of BW, fresh IW, and RIBW.
Bird numbers, BW, and feed weights on a pen basis were determined weekly for each
treatment-replicate group from d 0 to 35 poh. Furthermore, BWG, feed intake (FI), and
feed conversion ratio (FCR) were determined for the 0 to 7, 7 to 14, 14 to 21, 21 to 28,
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28 to 35, and 0 to 35 d of age (doa) intervals. Percentage cumulative mortality (CPM)
for the cumulative 0 to 35 doa interval was also determined.
Statistical description
A randomized complete block design was used in this study in both the incubation
and grow-out phase of the study. Each tray level represented a block, and all treatments
were equally and randomly represented in each block. The chick quality data on 21.0 doi
were analyzed using the 3 injection dose groups, while the performance data were
analyzed using the 3 injection dose and the 2 turn-out times. All variables were analyzed
using the MIXED procedure of SAS software 9.3 (SAS institute, 2012). Treatment was
viewed as a fixed effect and block as a random effect to analyze for the effects of
treatments on the chick quality variables, d 28 poh variables, CPM in the 0 to 35 doa
interval, and weekly BW gain, FI, and FCR using a one-way ANOVA. A split-plot
analysis of absolute weekly BW was performed with treatment, age, and their interaction
designated as a fixed effect and block as a random effect. Least-square means were
compared in the event of significant global effects (Steel and Torrie, 1980). Global and
least-square means differences were considered significant at P ≤ 0.05.
Results
There was no significant difference in SEW between the noninjected control
(NIC), 1× dose of EM1 (1×EM1), and 10× dose of EM1 (10×EM1) treatments at 0 doi.
The SEW means for NIC, 1×EM1, and 10×EM1 groups were 64.8, 64.6, and 64.5 g
(Pooled SEM = 0.18 g), respectively. The chick quality results in response to the NIC,
1×EM1, and 10×EM1 treatments were also compared. There was no significant treatment
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effect on HI or HBW at 21.0 doi (Figs. 5.1 and 5.2). The HI means for the NIC, 1×EM1,
and 10×EM1 treatment groups were 96.1, 93.1, and 95.1 % (Pooled SEM = 1.17 %),
respectively. The HBW means for the NIC, 1×EM1, and 10×EM1 treatment groups were
45.2, 44.8, and 44.7 g (Pooled SEM = 0.22 g), respectively. The treatment means for each
of the hatching chick quality variables evaluated are provided in Table 5.1. There was a
significant treatment effect on BW (P = 0.01) and YSW (P = 0.04) on 21.0 doi. The BW
and YSW were highest in the NIC group and lowest in the 10×EM1 group, with the
1×EM1 group being intermediate. However, there was no significant treatment effect on
YFBW. There was a significant treatment effect on RBSW (P = 0.01). The RBSW was
significantly highest in the NIC group and lowest in the 10×EM1 treatment group, with
the 1×EM1 group being intermediate. The RBSW means in the NIC, 1×EM1, and
10×EM1 treatment groups were 70.7, 68.5, and 66.7 % (Pooled SEM = 0.92 %),
respectively. There was no significant treatment effect on mean BW at d 0, 7, 14, 21, and
35 poh. However, there was significant treatment effect on BW at d 28 poh (P = 0.003).
The BW on d 28 poh was significantly higher in the NIC7 group in comparison to all the
other 4 vaccine-injected and turn-out time combination treatment groups (1×VI7,
1×VI10, 10×VI7, and 10×VI10). Nevertheless, there was no significant difference
between the NIC10 group and the NIC7 or 1×VI7 groups. Treatment did not
significantly affect mean BWG in the 0 to 7, 7 to 14, 14 to 21, and 28 to 35 doa intervals.
However, there was a significant treatment effect on BWG in the 21 to 28 (P = 0.003),
and the 0 to 35 (P = 0.05) doa intervals. The BWG of the birds in the 21 to 28 doa
interval was significantly higher in the NIC7 and NIC10 groups in comparison to all of
the other 4 vaccine-injected treatment groups. However, there was no significant
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difference between all of the 4 vaccine-injected and turn-out time combination treatment
groups, irrespective of the dose and turn-out time. The BWG of the birds in the 0 to 35
doa interval was significantly higher in the NIC7 group in comparison to all of the 4
vaccine-injected and turn-out time combination treatment groups. There was no
significant treatment effect on FI in the 0 to 7, 7 to 14, 14 to 21, 21 to 28, 28 to 35 or 0 to
35 doa intervals. There was also no significant treatment effect on FCR in the 0 to 7, 7 to
14, 14 to 21, 28 to 35, and 0 to 35 doa intervals. However, there was a significant
treatment effect on FCR in the 21 to 28 doa interval (P = 0.03). The FCR of the birds was
highest in the 1×VI7 and 10×VI10 groups, and lowest in the NIC10 group. There was a
significant treatment effect on d 28 poh RIBW (P = 0.04). The RIBW of the birds was
highest in the 1×VI7 group, and lowest in the NIC10 group. For BW on d 28 poh, BWG
in the 0 to 35 doa interval, FCR in the 21 to 28 doa interval (Table 5.3), and for d 28 poh
RIBW (Fig. 5.6), there was no significant difference among the 4 vaccine-injected and
turn-out time combination treatment groups irrespective of dose and turn-out time. For
reference, treatment means for BW at each age period, and for BWG, FI, and FCR in
each age interval are provided in Tables 5.2 and 5.3. There was no significant difference
among treatment groups for cumulative late dead embryos (PLD) and the CPM (0 to 35
doa) of the birds. The PLD of embryos and the CPM of the poh broilers in the control and
treatment groups are presented in Figs. 5.3 and 5.4, respectively. The SOI and ES were
evaluated in this study, using approximately 7 % of the in ovo injected embryonated
eggs. The mean ES at 19.0 doi was 4.60 ± 0.99. The SOI evaluation of those same eggs at
19.0 doi indicated that 6.8 and 93.2 % of the eggs received vaccine in the AM and EM
respectively, with the EM injection being 81.5 % i.m and 11.7 % s.c.
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Discussion
In a previous study in which EM1 vaccine was injected in ovo at 50 µL per egg
on 18.5 doi, it was shown that EM1 did not have a negative effect on embryogenesis
through 21.0 doi (Sokale et al., 2015a) or performance through 14 d poh (Sokale et al.,
2015b). In this current study, the effects of 2 types of EM1 doses on embryogenesis, and
2 types of EM1 doses with 2 turn-out times on d 0 to 35 poh performance were evaluated.
The evaluation of the results of hatching chick quality variables on 21.0 doi shows that
the in ovo injection of Ross × Ross 708 broiler hatching eggs with either the 1× dose or
10× dose of EM1 vaccine in 50 µL of commercial diluent does not affect embryogenesis.
In comparison to the NIC, injection of the 10× dose resulted in an increase in BW and
RBSW on 21.0 doi. However, there was no difference in YFBW among treatment
groups. The difference in BW may have resulted from the difference in YSW which was
higher in the 10× dose treatment group in comparison to the NIC group. This result is
consistent with a previous study conducted by Zhai et al., (2011a). In that study, it was
found that in comparison to noninjected controls, the injection of carbohydrates resulted
in an increase in chick BW and YSW on day of hatch without causing any subsequent
difference in YFBW. However, in comparison to noninjected controls, Bello et al.,
(2013) did not show any difference in BW, YSW, RBSW, or YFBW on day of hatch,
when embryos were injected with 25 (OH) D3. It can be said that the in ovo injection
process in itself, or the in ovo injection of any substance, may affect some hatching chick
quality variables. Therefore, when considering the effects of in ovo injected substances
on embryonic development, variables such as BW and YFBW should be evaluated
together (Zhai et al., 2011a). In addition, there were no differences among treatment
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means for HI, HBW, and PLD on 21.0 doi in the current study. This showed that Ross ×
Ross 708 hatching chicks can withstand up to 10× the recommended dose of EM1
vaccine without any obvious detrimental effect on embryogenesis. A further evaluation
the SOI showed that at 19.0 doi, 81.5 % of the sampled embryos were injected i.m (in the
right breast muscle), and, therefore, may have been able to withstand the in ovo injection
of EM1 up to 10× the recommended dose. The effective control of coccidiosis by use of
vaccines either alone or as part of rotation programs requires 2 major factors; firstly, the
uniformity of vaccine application is important, and secondly, a recycling of oocysts for
development of immunity is crucial. The former, which typically occurs in the hatchery,
has demonstrated tremendous success, primarily due to improvements in vaccine
application techniques (Chapman et al., 2002; Chapman, 2009; Tewari and Maharana,
2011), and the ability to determine the stage of embryo development at the time of in ovo
injection (Williams and Zadek, 2010). For example, in the current study, the ES and SOI
results suggest that the developmental stage of the embryos when eggs were in ovoinjected, corresponded to that between 19.0 and 19.5 doi, with vaccine deposition
primarily in the right breast muscle. The EM1 vaccine is recommended for vaccinating
18 to 19 doi embryos, and although the preferred SOI is within the AM, studies have
shown as embryos approach hatch, the volume of amniotic fluid available for injection
becomes reduced, making it less possible to deposit the vaccine within the amniotic
cavity (Jochemsen and Jeurissen, 2002). Therefore, as the broiler embryo
developmentally approaches hatch, the probability of injecting in the intra-cranial, intraorbital, or intra-abdominal regions of the embryo can increase (Williams and Zedek,
2010). For successful vaccination to occur in ED 19.0 embryo using the Inovoject®
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system, the EM1vaccine must be delivered into the AM or EM (i.m or s.c) regions of the
embryo. Therefore, the success of in ovo vaccination in this current study was 100 % (6.8
% AM; 81.5 % i.m; 11.7 % s.c); which is consistent with the expected outcome for
embryos that are injected in ovo between 19.0 and 19.5 doi (unpublished data).
The recycling of oocysts for the development of immunocompetence, which
typically occurs in the chicken house, continues to pose a challenge to producers. This is
due in part to the interplay of numerous factors present within the chicken house (e.g.
light, temperature, ventilation, feed, flock density, litter moisture, etc.). In practice, the
recycling of oocysts is achieved through partial house brooding, in which birds are
confined to a section of the house, usually a 1/3 or 1/2 portion of the house for a limited
period of time. The limited period of time is usually between 7 and 14 d. Thereafter, birds
are turned-out to the entire house for the remainder of the grow-out period (Hix, 2013).
During partial house brooding, birds are exposed to multiple coccidial life cycles to
initiate and establish development of immunity against coccidiosis. The selection of a
turn-out time during partial house brooding ensures that optimal oocyst recycling is
achieved without the risk of reversion to clinical coccidiosis and a subsequent negative
impact on grow-out performance. Unlike the spray type of coccidiosis vaccine (CoccivacB), an ideal turn-out time following the in ovo administration of EM1 vaccine has not yet
been documented in scientific literature. Therefore, an objective in this study was to
determine an ideal turn-out time in conjunction with the administration of the EM1
vaccine for achievement of optimal oocyst recycling without having a negative impact on
performance. Bird performance was evaluated against 2 turn-out times (d 7 and 10) and
2 doses (1× and 10 × doses) of the EM1 vaccine. The performance of birds administered
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the 1× dose that were subsequently turned out at d 7 or 10, was the same in comparison to
the performance of birds injected with the 10 × dose and that were also turned out on
either day. Although BW at d 28 poh, and BWG and feed efficiency in the 21 to 28 d poh
intervals were lower in all the vaccine injected treatment groups in comparison to the
control group, these time points corresponded to the peak period of oocyst cycling
(Broomhead, 2012). In addition, the RIBW at d 28 poh in all the vaccine injected
treatment groups, was similar in comparison to the control group, which further indicated
that the peak in coccidial life cycle development and oocyst cycling occurred in the
gastrointestinal tract at this period. This is consistent with a study by Küçükyilmaz et al,
(2012), that showed a significantly high cecal weight and overall intestine length in
coccidial infected birds compared with uninfected birds. Further, the increase in RIBW at
d 28 poh may have resulted in decrease BW of the birds belonging to the vaccine group
when compared to birds in the control group, at the same time period. However, there
was no difference among treatment groups for BW and feed efficiency at d 35 poh. This
was due to a compensatory gain in BW that following its reduction at the peak of oocyst
cycling (Broomhead, 2012; Mathis, 2001; Williams and Gobbi, 2002).
In conclusion, this study confirms that the in ovo injection of the EM1 vaccine on
19.0 doi, at a either 1× or 10× dose in 50 µL of commercial diluent has no detrimental
effect on the hatchability of injected eggs, or on hatchling BW, RBSW, YFBW, embryo
survivability, and other hatchling quality variables that were examined in this study. In
addition, birds administered either the 1× or 10× dose of EM1 vaccine and that were
turned out on either d 7 or 10 poh showed similar grow-out performance outcomes.
Therefore, it is recommended that under ideal house conditions, that a 1× dose of EM1
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vaccine in 50 µL of commercial diluent in conjunction with partial house brooding up to
10 d poh will ensure adequate oocyst cycling without negatively affecting grow-out
performance.
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0.01
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0.06

0.18
0.39

0.92
0.01

64.50 66.69b

64.55 68.50ab

64.82 70.75a

0.83
0.09

60.57

61.22

63.11

0.06
0.96

2.21

2.20

2.19
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5.14

4.98

4.76

0.14
0.24

5.66

5.57

5.33

0.03
0.42

1.21

1.16

1.22

0.06
0.12

2.81

2.63

2.66

0.07
0.26

3.09

2.94

2.98

0.01
0.49

0.33

0.34

0.35

0.02
0.91

0.78

0.77

0.76

0.02
0.97

0.86

0.86

0.85

0.28
0.04

3.95b

4.70ab

4.94a

0.60
0.13

9.15

10.60

10.76

Means within a variable with no common superscript differ (P ≤ 0.05).
1Body weight (BW), yolk-free BW (YFBW), set egg weight (SEW), BW as a percentage of set egg weight (RBSW), yolk-free BW as a

a-b

43.01b

10× dose
vaccine

39.07

44.21ab 39.52

1× dose
vaccine

40.92

45.86a

Noninjected
control

percentage of set egg weight (RYFWSW), intestine weight (IW), intestine weight as a percentage of BW (RIBW), intestine weight as a
percentage of yolk-free BW (RIYFW), liver weight (LW), liver weight as a percentage of BW (RLBW), liver weight as a percentage of yolkfree BW (RLYFW), heart weight (HW), heart weight as a percentage of BW (RHBW), heart weight as a percentage of yolk-free BW
(RHYFW), yolk sac weight (YSW), yolk sac weight as a percentage of BW (RYBW), and yolk-free body mass (YFBM).
2
Two birds in each of 8 replicate units per treatment (16 birds per treatment group) were used to calculate each treatment mean.
3
Thirty eggs in each of 8 replicate units per treatment (240 eggs per treatment group) were used to calculate each treatment mean.

0.60
0.13

90.85

89.40

89.24

YFBW SEW3 RBSW RYFWSW IW RIBW RIYFW LW RLBW RLYFW HW RHBW RHYFW YSW RYBW YFBM
(g)
(g)
(%)
(%)
(g)
(g)
(%)
(g)
(%)
(%)
(g)
(%)
(%)
(g)
(%)
(%)

Somatic and yolk parameter means in the noninjected control group and in the 1× dose and 10× dose EM1 vaccine
treatment groups.1,2

Treat-ments BW (g)

Table 5.1
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0.210

0.392

0.907

0.885

0.0327

1.336

1.326

1.311

1.335

1.348

1.295

FCR1

0.318

0.0029

0.160

0.161

0.166

0.162

0.161

0.168

BW2 (kg)

0.151

0.0066

0.273

0.276

0.269

0.279

0.277

0.294

BWG2
(kg)

0.099

0.0070

0.355

0.356

0.347

0.351

0.359

0.376

FI2 (kg)

0.352

0.0140

1.299

1.290

1.296

1.260

1.296

1.279

FCR2

0.249

0.0085

0.436

0.438

0.437

0.442

0.444

0.463

BW3 (kg)

0.404

0.0081

0.407

0.399

0.407

0.410

0.414

0.424

BWG3
(kg)

0.668

0.0099

0.590

0.582

0.584

0.597

0.596

0.603

FI3 (kg)

0.676

0.0178

1.450

1.460

1.438

1.456

1.444

1.421

FCR3

2

20 birds in each of 8 replicate units used to calculate each treatment mean.
BW1 = d 0 body weight (BW); BWG1 = d 0 to 7 BW gain; FI1 = d 0 to 7 feed intake; FCR1 = d 0 to 7 feed conversion ratio;
BW2 = d 7 BW; BWG2 = d 7 to 14 BW gain; FI2 = d 7 to 14 feed intake; FCR2 = d 7 to 14 feed conversion ratio; BW3 = d 14
BW; BWG3 = d 14 to 21 BW gain; FI3 = d 14 to 21 feed intake; FCR3 = d 14 to 21 feed conversion ratio.

P-values

0.0040

0.0029

1

0.154

0.115

0.154

0.158

10× dose vaccine + d 0.045
10 turn-out
SEM
0.0003

0.121

0.156

0.156

0.159

FI1 (kg)

0.116

0.045

1× dose vaccine + d
10 turn-out

0.117

0.116

0.123

BWG1
(kg)

0.045

0.045

1× dose vaccine + d
7 turn-out

10× dose vaccine + d
7 turn-out

0.045

Non-injected control
+ d 10 turn-out

0.046

BW1 (kg)

Performance parameter means in the noninjected control group and in the 1× dose and 10× dose of EM1 vaccine
treatment groups.1

Non-injected control
+ d 7 turn-out

Table 5.2
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0.0144
0.176

SEM

P-values

0.003

0.0127

0.640b

0.639b

0.643b

0.641b

0.688a

0.694a

BWG4
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0.116

0.0142

1.073

1.047

1.038

1.056
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1.089

FI4(kg)

0.026

0.0267

1.676a

1.643ab

1.619abc

1.651a

1.566c

1.569bc

FCR4

0.003

0.0207

1.492c

1.490c

1.495c

1.512bc

1.561ab

1.592a

BW5 (kg)

0.848

0.0170

0.554

0.532

0.545

0.543

0.564

0.547

BWG5
(kg)

0.672

0.0263

1.225

1.165

1.178

1.177

1.192

1.194

FI5(kg)

0.909

0.0569

2.216

2.191

2.184

2.168

2.124

2.191

FCR5

0.071

0.0316

2.066

2.046

2.056

2.076

2.139

2.159

BW6 (kg)

0.047

0.0302

1.990bc

1.962c

1.985bc

1.990bc

2.059ab

2.082a

BWG6
(kg)

0.411

0.0482

3.396

3.304

3.306

3.337

3.379

3.421

FI6(kg)

0.235

0.0140

1.596

1.583

1.569

1.574

1.556

1.551

FCR6

Means within a column with no common superscript differ (P ≤ 0.05).
1
20 birds in each of 8 replicate units used to calculate each treatment mean.
2
BW4 = d 21 body weight (BW); BWG4 = d 21 to 28 BW gain; FI4 = d 21 to 28 feed intake; FCR4 = d 21 to 28 feed conversion
ratio; BW5 = d 28 BW; BWG5 = d 28 to 35 BW gain; FI5 = d 28 to 35 feed intake; FCR5 = d 28 to 35 feed conversion ratio; BW6
= d 35 BW; BWG6 = d 0 to 35 BW gain; FI6 = d 0 to 35 feed intake; FCR6 = d 0 to 35 feed conversion ratio.

a-c

0.843

10× dose vaccine + d
10 turn-out

0.844

1× dose vaccine + d
10 turn-out
0.839

0.852

1× dose vaccine + d
7 turn-out

10× dose vaccine + d
7 turn-out

0.863

Non-injected control
+ d 10 turn-out

0.888

BW4 (kg)

Performance parameter means in the noninjected control group and in the 1× dose and 10× dose of EM1 vaccine
treatment groups.1

Non-injected control
+ d 7 turn-out

Table 5.3
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Figure 5.1

Hatchability on d 21.0 of incubation as a percentage of fertilized injected
eggs (HI)

In noninjected control group (NIC) and in eggs injected with 1× dose of EM1vaccine (1×
VI), or 10× dose of EM1vaccine (10× VI) in 50 µL of diluent.1,2
1
Data from 8 replicate units was used for calculation of means for each treatment group.
2
No significant difference among treatment groups for hatchability (P = 0.22).
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Figure 5.2

Hatching BW on d 21.0 of incubation

In noninjected control group (NIC) and in eggs injected with 1× dose of EM1vaccine (1×
VI), or 10× dose of EM1vaccine (10× VI) in 50 µL of diluent.1,2
1
Data from 8 replicate units was used for calculation of means for each treatment group.
2
No significant difference among treatment groups for hatching BW (P = 0.32).
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Figure 5.3

Late dead chicks on d 21.0 of incubation as a percentage of fertilized
injected eggs

In noninjected control group (NIC) and in eggs injected with 1× dose of EM1 vaccine (1×
VI), or 10× dose (10× VI) of EM1vaccine (10× VI).1,2
1
Data from 8 replicate units was used for calculation of means for each treatment group.
2
No significant difference among treatment groups for late dead chicks (P = 0.36).
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Figure 5.4

Grow-out cumulative percentage mortality

In the noninjected control + d 7 turn-out (NIC7) and noninjected control + d 10 turn-out
(NIC10) groups, and the 1× dose + d 7 turn-out (1×VI7) , 1× dose + d 10 turn-out
(1×VI10), 10× dose + d 7 turn-out (10×VI7), and 10× dose + d 10 turn-out (10×VI10) of
EM1vaccine treatment groups.1
1
No significant difference among treatment groups for percentage mortality (P = 0.09).
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Figure 5.5

Absolute intestine weight on d 28 post-hatch

In the noninjected control + d 7 turn-out (NIC7) and noninjected control + d 10 turn-out
(NIC10) groups, and the 1× dose + d 7 turn-out (1×VI7) , 1× dose + d 10 turn-out
(1×VI10), 10× dose + d 7 turn-out (10×VI7), and 10× dose + d 10 turn-out (10×VI10) of
EM1vaccine treatment groups.1,2
1
Data from 8 replicate units was used for calculation of means for each treatment group.
2
No significant difference among treatment groups for intestine weight (P = 0.20).
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Figure 5.6

Relative intestine weight on d 28 post-hatch as a percentage of BW

In the noninjected control + d 7 turn-out (NIC7) and noninjected control + d 10 turn-out
(NIC10) groups, and the 1× dose + d 7 turn-out (1×VI7) , 1× dose + d 10 turn-out
(1×VI10), 10× dose + d 7 turn-out (10×VI7), and10× dose + d 10 turn-out (10×VI10) of
EM1vaccine treatment groups.1,2
a-c
Means among treatment groups with no common superscript differ (P ≤ 0.05).
1
Data from 8 replicate units was used for calculation of means for each treatment group.
2
Significant difference among treatment groups for relative intestine weight (P = 0.04).
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DIFFERENTIAL EFFECTS OF BROILER EMBRYO AGE ON THE QUANTITATIVE
PATHOGENICITY OF THE INOVOCOX EM1 VACCINE
Abstract
Control of coccidiosis continues to pose a challenge to commercial poultry
producers and as a result, coccidia vaccines are being used in a rotation program to
achieve effective coccidiosis control. Inovocox EM1 vaccine (EM1) allows early vaccine
oocyst cycling and the development of immunity to reduce the effects of wild-type
coccidia present within broiler houses. This immunocompetence results in a reduction of
intestinal lesions and a subsequent improvement in performance. The EM1 is
administered to healthy broiler embryos at 18- to 19- d of incubation (doi) as an aid in the
prevention of coccidiosis caused by 3 spp. of Eimeria. Based on this recommendation,
several commercial hatcheries vaccinate broiler embryos during transfer at either 18.5 or
19 doi. However, it is unclear whether a difference in the age of the embryos at the time
of in ovo injection can impact the cycling of the vaccine oocysts and subsequent
posthatch broiler performance. Therefore, the objective of our study was to evaluate
effects of administering the EM1 at 18.5 and 19.0 d of embryo age (EDOA) on hatching
chick quality, oocyst output per gram of litter, the presence of intestinal lesions, and
grow-out performance. Chicks were hatched on 21.0 doi and placed on floor pens that
had been covered with fresh new shavings from 0 to 35 posthatch (poh). In general,
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treatments were comprised of 3 injection-types (IT) and 2 EDOA that were arranged in a
factorial design. Main effects of EDOA and IT, and their interactive effects were
observed on various hatching chick quality variables. Furthermore, main effects of
EDOA on grow-out performance were observed up to d 35 poh. Peak oocyst shedding
and intestinal lesion scores were also observed at d 21 and 28 poh, respectively. In
conclusion, IT had no detrimental effects on hatching chick quality. However, difference
in embryonic age affected performances.
Key words: chicks, embryo, Inovocox EM1 vaccine, in ovo injection,
performance
Introduction
Coccidia are obligate intracellular parasites that develop and multiply in the
intestinal epithelium, causing damage to the structure of the intestine, impaired nutrient
absorption, poor feed utilization, poor growth, high morbidity and mortality (McDougald
et al., 2008), and susceptibility to other diseases (William et al. 2003; Li et al., 2010).
Inovocox EM1 vaccine (EM1) is used for the in ovo vaccination of embryonated chicken
eggs at 18 to 19 d of incubation (doi) for the prevention of coccidiosis caused by Eimeria
acervulina, Eimeria maxima, and Eimeria tenella. The control of coccidiosis by a live
non-attenuated EM1 vaccine involves the in ovo injection of a controlled dose of Eimeria
oocysts that stimulates a localized immune response in the bird. This stimulation results
more specifically through a replication of the vaccine oocysts within the mucosal lining
of the intestine, thereby inducing some degree of pathogenicity within the gut
(McDougald et al., 2008; Tewari, 2011). The degree of pathogenicity of coccidiosis can
be measured by parameters such as performance, levels of mortality and morbidity,
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extent of intestinal gross and microscopic lesions, and amount of oocyst shedding
(Johnson and Reid, 1970; Idris et al., 1997). Although successful immuno-protection by
EM1 against a coccidiosis challenge has been reported in several studies, no study has
reported effects of the in ovo administration of EM1 at 18.5 or 19.0 doi on the
development of pathogenicity in broilers and the subsequent effects on their grow-out
performance. It is unclear whether the difference in embryonic age at the time of
injection has any effect on the efficacy of EM1 against a coccidiosis infection.
Therefore, the objective in this study was to determine effects of the EM1 vaccine
administered to Ross × Ross 708 broiler chicken embryos at 18.5 or 19.0 d of age on
subsequent chick quality, posthatch performance, coccidiosis pathogenicity, and pattern
of oocyst cycling. An additional objective was to determine whether or not effects of
EM1 vaccination are influenced by physiological differences in embryos at 18.5 and 19.0
d of embryo age (EDOA).
Materials and Methods
General
All experimental procedures involving animals were approved by the Mississippi
State University Institutional Animal Care and Use Committee. A total of 2,880 Ross ×
Ross 708 broiler hatching eggs obtained from a single commercial breeder flock at 45 wk
of age, were held for approximately 2 d under standard storage conditions before setting.
Prior to set on 0 doi, eggs were individually weighed, and only eggs that had normal
appearance (Zhai et al., 2011b; Bello et al., 2014) and that were within ± 10 % of the
mean weight of all set eggs, were randomly assigned to each of 10 incubator tray levels,
with each tray level representing a replicate unit in a Jamesway model PS 500 single
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stage incubator (Jamesway Incubator Co. Inc., Cambridge, Ontario, Canada). At 0 doi, a
total of 2,400 eggs were incubated under standard conditions (Peebles and Brake, 1987;
Zhai et al., 2011a). In order to achieve 18.5 and 19.0 EDOA, eggs were set approximately
12 h apart. A 3 × 2 factorial arrangement of treatments was utilized in this study. This
arrangement was comprised of 3 injection-types (IT) and 2 EDOA (18.5 and 19.0). There
were a total of 3 treatment groups as follows: treatment 1 - noninjected control (NIC) on
18.5 and 19.0 EDOA; treatment 2 - diluent injected control (DIC; 50 µL of diluent
injected) on 18.5 and 19.0 EDOA; and treatment 3 - EM1 in 50 µL of diluent (VI) on
18.5 and 19.0 EDOA. A total of 1,200 eggs were randomly assigned to each of the 3
treatment groups on each of 10 replicate tray levels at each of the 18.5 and 19.0 EDOA
(2,400 eggs total). Each of the 3 treatment groups contained 80 eggs that were
represented on each of the 10 replicate setter tray levels. Eggs were candled on 18 doi,
and any egg containing dead embryo or unfertilized eggs were removed (Ernst et al.,
2004). Overall, approximately 2,100 embryonated eggs were retained after candling, and
were randomly arranged in all of the 30 treatment-replicate groups for each of 18.5 and
19.0 EDOA (60 total IT × EDOA treatment-replicate groups), with each containing
approximately 35 embryonated eggs. Incubator dry and wet bulb temperatures were set at
37.5 ± 0.1 and 28.9 ± 0.1°C, respectively, and monitored twice daily for the entire
incubation period.
Vaccination and experimental layout
In ovo injections were given when the embryos attained 18.5 or 19.0 d of age. An
Embrex Inovoject injector system (Zoetis Animal Health, Research Triangle Park, NC)
was used to deliver the injections, as described by Sokale et al. (2015a). Eggs were
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injected through the air cell with a blunt tip injector needle [18.4 cm length and 1.27 mm
bore width] to target the amnion. The needle provide approximately 2.49 cm injection
depth from the top of the large end of the egg. The EM1 vaccine was reconstituted with
sterile commercial Marek’s Disease vaccine diluent (Merial Co., Duluth, GA) and
administered at a volume of 50 µL per egg. On d of injection, 2 embryonated eggs from
each flat were concurrently injected with coomassie brilliant blue G-250 (colloidal) dye
for subsequent evaluation of site of injection (SOI) and embryo stage score (ES), as
described by Sokale et al., (2015a). During the injection process, eggs were injected
based on IT treatment group, starting with the NIC group, then the DIC and VI groups, in
that order. The IT treatment were administered in this particular order to ensure that there
was no cross-contamination between treatment groups. Although eggs in the NIC group
were not injected with EM1, these eggs were subjected to the same injection process as
were the injected treatment groups. Eggs were transferred to the hatcher unit (Jamesway
Incubator Company Inc., Cambridge, Ontario, Canada) following the injection process.
All eggs remained outside the incubator at room temperature for a maximum of 5 min,
during the injection and transfer processes. The hatcher baskets (containing the injected
embryonated eggs) were arranged in a manner that prevented cross-contamination
between the injected and non-injected hatched chicks.
Data collection
Chick quality data
Individual set egg weights (SEW) were recorded on 0 doi. On d of injection (18.5
and 19.0 EDOA), SOI and ES were determined. On d of hatch (21.0 doi), the hatchability
of injected embryonated eggs (HI) and hatching chick BW (HBW) were determined.
140

Approximately 30 chicks from each of the 60 treatment-replicate groups were used to
determine mean HBW. In addition, 2 chicks from each of those treatment-replicate
groups were wing-banded, euthanized, weighed, and necropsied for determination of
chick BW (BW), yolk sac weight (YSW), yolk-free BW (YFBW), and intestine weight
(IW). The following hatching chick quality parameters were also subsequently
determined: yolk-sac weight relative to BW (RYBW), IW relative to BW (RIBW), IW
relative to YFBW (RIYFW), and yolk free body mass (YFBM; which is a proportion of
YFBW to BW).
Performance data
On d of hatch, 17 straight-run chicks were randomly selected from each of the 60
treatment-replicate groups and were wing-banded, weighed, and placed in each of 60
corresponding miniature floor pens, measuring 0.91 m × 1.22 m, within a temperatureand light-controlled research facility. Chicks were placed in the pens using the same
experimental design that was utilized for the arrangement of embryonated eggs in the
hatcher unit. Birds were placed on fresh wood-shavings litter, and house temperature
conditions were monitored and recorded twice daily throughout the entire grow-out
period. The entire grow-out phase was conducted in a manner that ensured close
conformity to commercial broiler production standards. All birds were provided adlibitum feed and water. Feed was formulated according to that for standard Mississippi
State University broiler basal diets (diets contained no in-feed anti-coccidial), and met or
exceeded NRC (1994) recommendations through d 35 posthatch (poh). Birds were
provided starter (crumbled), grower (pelletized), and finisher (pelletized) diets on d 0 to
14, 14 to 28, and 29 to 35 poh, respectively. Bird numbers, BW, and feed weights on a
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pen basis were determined weekly from d 0 to 35 poh. Body weight gain, feed intake
(FI), and feed conversion ratio (FCR) were determined for the 0 to 7, 7 to 14, 14 to 21,
21 to 28, 28 to 35, and 0 to 35 d of age (doa) intervals. On d 14, 21, 28 and 35 poh, litter
samples were collected from each individual pen for the determination of oocyst output
per gram of litter (OPGL) by a method previously described by Sokale et al., (2015a).
Microscopic pathology data
On each of d 14, 21, 28, and 35 poh, 5 birds were randomly selected from the
DIC-18.5 EDOA; and the VI-18.5 and 19.0 EDOA treatment groups, for
histopathological examination. The selected birds were individually weighed and
euthanized, and their intestinal tracts (duodenum, mid-intestine, and cecum) were
collected and fixed in 10 % buffered neutral formalin solution. The formalin-fixed
intestine tissues were routinely processed and examined by a histopathology support
method used in poultry production, as described by Wilson et al. (2015) and Menconi et
al. (2015). The pathological evaluation conducted on the intestinal samples include
coccidia counts, coccidial lesions, villus height and crypts measurements, presence of
inflammatory cells, the presence of bacteria and other protozoa, and signs of
inflammatory reactions in the intestinal mucosa. In general, the evaluations obtained
were categorized into coccidia lesion mean scores, and mean total gut lesion scores
(inflammation, repair, and coccidia lesions). Based on the extent of the lesions, the
intestinal samples were assigned one of the following observational scores: 1: within
normal limits; 2: mild lesion; 3: moderate lesion; and 4: marked to severe lesion.
Similarly, based on the number of E. acervulina present in the entire gut, the samples
were assigned one of the following quantitative scores: score 1: no coccidia; score 2: 1 to
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2 clusters; score 3: 3 to 5 clusters; score 4: more than 5 clusters. Further, based on the
number of E. maxima and E. tenella present in the entire gut, samples were assigned one
of the following scores: score 1: 0 to 2 coccidia; score 2: 3 to 30 coccidia; score 3: 31 to
100 coccidia; score 4: more than 100 coccidia.
Statistical description
A randomized complete block design was utilized in both the incubation and
grow-out phases of the study. IT, EDOA, and their interaction were viewed as fixed
effects and block as a random effect. A one-way ANOVA was used to analyze the
following parameters: HI, HBW, YFBW, YSW, RYBW, YFBM, IW, RIBW, and
RIYBW on d of hatch; and BWG, FI, and FCR at separate weeks. A one-way ANOVA
was also used to test for EDOA related differences for the SOI and ES. A split-plot
analysis was used to test for the main effects of IT and EDOA, and the interactive effects
of IT and EDOA on weekly BW from d 0 to 35 poh. All parameters were analyzed using
the MIXED procedure of SAS software 9.3 (SAS institute, 2012). The microscopic lesion
scores (MLS) were analyzed by the Kruskal-Wallis test for non-parametric data. The
main effects of treatment (DIC- and VI-18.5 EDOA, and VI-19.0 EDOA) and poh (d 14,
21, 28 and 35) on coccidial and total gut lesion mean scores, were evaluated. Leastsquare means were compared in the event of significant global effects (Steel and Torrie,
1980). Global and least-square means differences were considered significant at P ≤ 0.05.
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Results
Hatchability and chick quality
Mean SEW was 64.5 g (Pooled SEM = 0. 34 g). There were no main or
interactive effects involving IT or EDOA on HI at d of hatch (Table 6.1). There were
significant main effects due to EDOA on HBW (P = 0.002), YSW (P = 0.001), RYBW (P
= 0.001), and IW (P < 0.001) at d of hatch (Table 6.1). The HBW, YSW, and RYBW of
birds in the 18.5 EDOA group were higher compared with those of birds in the 19.0
EDOA group. However, the IW of birds in the 19.0 EDOA group was higher compared
with that of birds in the 18.5 EDOA group. There were significant main effects of IT (P =
0.045), and EDOA (P < 0.001) on RIBW (Table 6.1). The RIBW of birds in the DIC
group was higher compared with the NIC group, with the VI group being intermediate. In
addition, the RIBW of birds in the 19.0 EDOA group was higher compared to birds in the
18.5 EDOA group. There was a significant IT × EDOA interaction effect on RIYFW (P =
0.05; Table 6.1). In the 18.5 EDOA group, the RIYFW of birds in the VI group was
higher compared with that in the NIC group, with the DIC group being intermediate.
Whereas, in the 19.0 EDOA group, the RIYFW of birds in the DIC group was higher
compared with that in the NIC and VI groups. There was no main effect due to IT or an
IT × EDOA interactive effect on YFBW or YFBM. However, there was a significant (P =
0.001) main effect due to EDOA on YFBM (Table 6.1). The YFBM of birds in the 19.0
EDOA group was higher compared with that of birds in the 18.5 EDOA group. For
reference, the means for all of the hatching chick quality variables evaluated are
presented in Table 6.1.

144

Embryo Stage Score (ES) and Site of Injection (SOI)
A proportion of embryonated eggs in this study were injected in real time with
coomassie brilliant blue dye along with all the eggs in the various IT groups. The dyeinjected eggs were evaluated for ES and SOI in other to estimate the ES and SOI of all
the treatment eggs in this study. Mean ES in the 18.5 EDOA group was significantly (P =
0.01) different compared with the mean ES of the 19.0 EDOA group. Mean ES on 18.5
and 19.0 EDOA were 2.44 and 3.24, respectively. Furthermore, the SOI result showed
that there was a significant difference in the dye deposited in the amnion (AM; P = 0.03),
subcutaneous (s.c; P = 0.01), and intramuscular (i.m; P = 0.02) regions in embryos. Dye
deposition in the AM was significantly higher in the 18.5 EDOA group compared with
the 19.0 EDOA group; whereas, dye deposition in the s.c and i.m were significantly
higher in the 19.0 EDOA group compared to the18.5 EDOA group. Dye deposition in the
AM in the 18.5 and 19.0 EDOA groups were 88.2 and 73.2 %, respectively. Dye
deposition in the s.c in the 18.5 and 19.0 EDOA groups were 2.9 and 4.9 %, respectively,
and dye deposition in the i.m in the 18.5 and 19.0 EDOA groups were 8.8 and 21.9 %,
respectively.
Live Performance
There was an IT × EDOA interactive effect for mean BW of the birds at d 0 poh
(P = 0.005), of FI (P = 0.036) and BWG (P = 0.014) in the d 14 to 21 interval; of FI (P =
0.051) in the d 28 to 35 interval; and of FI (P = 0.018) and FCR (P = 0.009) in the d 0 to
35 poh interval. In the 18.5 EDOA group, the BW of the birds at d 0 poh in the DIC and
NIC groups were higher compared with those in the VI group. Whereas, in the 19.0
EDOA group, the BW of the birds at d 0 poh was not significantly different among the
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treatment groups. In addition, BW at d 0 poh was higher in birds belonging to the 18.5
EDOA group in comparison to those in the 19.0 EDOA group. However, there was no
main effect due to IT on BW at d 0 poh. The BWG and FI of birds in the 19.0 EDOA
group in the d 14 to 21 poh interval was higher in the NIC and DIC groups in comparison
to those in the VI group. Whereas, there was no significant treatment effect on d 14 to 21
poh BWG and FI in the 18.5 EDOA group. There was a significant main effect due to
EDOA on the BW of birds at d 7 (P < 0.001), 14 (P < 0.001), 21 (P < 0.001), and 35 (P =
0.004) poh; and 0 to 7 (P = 0.003), 7 to 14 (P = 0.009), 14 to 21 (P < 0.001), 28 to 35 (P
= 0.015), and 0 to 35 (P = 0.001) d poh FI. There was also a significant main effect due to
EDOA on BWG (P < 0.001) and FCR (P < 0.001) in the d 0 to 7 interval; BWG in the d 7
to 14 (P = 0.023) and d 14 to 21 (P = 0.002) interval; and BWG (P = 0.003) and FCR (P
= 0.048) in the 0 to 35 d poh interval. The BW and BWG at these time periods were
higher in birds belonging to the 19.0 EDOA group compared to birds belonging to the
18.5 EDOA group. There was a significant main effect due to IT on BW at d 28 poh (P =
0.032); on BWG in the 14 to 21 d interval (P = 0.040); on FI in the d 21 to 28 interval (P
= 0.002); on BWG (P = 0.052) and FI (P = 0.045) in the d 28 to 35 interval; and on FI (P
= 0.03) in the d 0 to 35 poh interval. For all poh d intervals, the BW, BWG and FI of
birds in the VI group were lower in comparison to those in the control group. For
reference, the means for all the performance parameters in each of the treatment groups
are presented in Tables 6.2 and 6.3.
Oocysts counts and microscopic lesion score
Coccidial oocyst shedding from litter samples collected on week 2, 3, 4, and 5 of
this study was maximal at d 21 poh. There was a significant (P < 0.05) treatment effect
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on total coccidia counts and on mean total gut lesion scores on d 14, 21, 28 and 35 poh.
The total coccidia counts and mean total gut lesion scores of birds in the 19.0 EDOA-VI
treatment group was higher compared to birds in the 18.5 EDOA-DIC treatment group.
However, those for the 19.0 EDOA-VI were not significantly different from those of
birds in the 18.5 EDOA-VI treatment group. Furthermore, there were no significant
differences among the treatment groups for coccidia counts and mean total gut lesion
scores at d 14, 21, 28 and 35 poh. Total coccidia count and mean total gut lesion scores of
the birds were highest at d 28 poh. For reference, coccidia lesion mean scores and mean
total gut lesion scores in each of the treatment groups are presented in Figs. 6.1 and 6.3,
respectively. The mean coccidia lesion scores and total mean gut lesion scores in each of
the treatment group on each day are presented in Figs. 6.2 and 6.4, respectively. The
OPGL for birds belonging to the VI treatment group on d 0, 14, 21, 28, and 35 poh are
presented in Fig. 6.5.
Discussion
In ovo injection of broiler chickens with live oocysts vaccine is an accepted
method of coccidiosis disease control. Several methods of administering live oocyst
vaccines to bird have been developed, since the first anticoccidial vaccine (Coccivac®)
was made available in 1952 (Williams, 2002). The in ovo injection of broiler hatching
eggs has now become widely accepted worldwide in the commercial poultry industry
(Williams, 2007). Earlier developed methods of vaccine administration have included
feed or drinking water application (Williams, 1994), eye-spray application to 1-day-old
chicks (Chapman, et al., 2002), and gel application (Danforth et al., 1998). Weber and
Evans (2003) have demonstrated the possibility of immunizing broiler chickens via in
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ovo injection for the different life cycle stages of Eimeria tenella. The live non-attenuated
EM1 vaccine is widely used among commercial broiler chicken producers for the
vaccination of healthy broilers between 18 and 19 doi, for the prevention of coccidiosis
caused by Eimeria acervulina, Eimeria maxima, and Eimeria tenella. The effects of
EM1 administered on d 18 (Weber and Evans, 2003; Weber et al., 2004) and d 19
(Mathis et al., 2014) of incubation on subsequent poh live performance have been
studied. However, effects of 18.5 and 19.0 EDOA EM1 injections on embryogenesis, and
on vaccination efficacy and poh live performance have not been previously studied. As in
previous studies, the in ovo injection of EM1 vaccine administered to Ross × Ross 708
broiler hatching eggs did not adversely affect embryogenesis. Upon examination of the
hatching chick quality parameters evaluated in this study, it is apparent that there were
developmental differences in the embryos from the Ross × Ross 708 broiler hatching
eggs at 18.5 and 19.0 EDOA. This observation is based on differences in the HBW,
YSW, RYBW, IW, RIBW, RIYFW, and YFBM of the 18.5 and 19.0 EDOA embryos.
The HBW, YSW, and RYBW parameters were greater in birds belonging to the 18.5
EDOA group in comparison to the 19.0 EDOA group. However, the IW, RIBW, RIYFW
and YFBM of birds belonging to 19.0 EDOA group were greater in comparison to those
belonging to the 18.5 EDOA group. The lack of IT and IT × EDOA effects on HBW,
YSW, RYBW, IW, and YFBM, suggests that the observed effects were due entirely to
EDOA. Although HBW, YSW, and RYBW were significantly higher in birds belonging
to the 18.5 EDOA group in comparison to the 19.0 EDOA group, there were no
treatment-related differences in YFBW. The YFBW of birds belonging to 18.5 EDOA
group was not different from those belonging to the 19.0 EDOA group. This suggests that
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the increase in HBW was associated with an increase in YSW. The greater amount of
residual yolk sac was in turn due to a higher retention of moisture in the yolk sac and
body tissues of birds in the 18.5 EDOA group. This effect is similar to previous studies,
in which it was reported that there was an increase in total hatching chick BW following
the in ovo injection of saline or carbohydrates (Zhai et al., 2011a,b), digestible
carbohydrates (Uni et al., 2005), or 25 (OH) D3 (Bello et al., 2013). Yolk sac-free BW is
a more accurate indicator of actual embryo growth, because it eliminates the additional
effects of changes in yolk sac weight in response to yolk sac absorption by the hatching
chick (Zhai et al., 2011a, b). Further, differences in the hatching chick quality parameters
of 18.5 and 19.0 EDOA may have resulted from differences in the various incubational
factors that optimize the incubation process. Previous studies have described various
incubational factors that influence broiler embryonic physiology and subsequent poh
growth characteristics. Such factors include temperature and relative humidity (Molenaar
et al., 2011a; Pulikanti et al., 2012), egg composition and subsequent yolk sac nutrient
utilization (Murakami et al., 1992; Moran, 2007), egg weight loss (Peebles et al., 2005;
Pulikanti et al., 2012), and incubation length (van de Ven et al., 2011). The embryonic
developmental process of chicken requires a balance between these multiple factors in
order to achieve optimum hatchability and chick quality. The 12 h incubational difference
between 18.5 and 19.0 EDOA may have resulted in the chick quality differences
observed at d of hatch as well as the subsequent treatment-related differences observed in
poh live performances. ES and SOI results in this study further indicate that there are
developmental differences between the 18.5 and 19.0 EDOA embryos. An ES of 3.24 in
the 19.0 EDOA group compared with that of a 2.44 in the 18.5 EDOA group, indicate
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that at the time of in ovo injection, the embryos belonging to the 19.0 EDOA group were
more advanced in development than those in the 18.5 EDOA group. In addition, the SOI
results indicate that degree of embryonic development affected the percentage of AM
injections. Dye deposition occurred more often in the AM of embryos belonging to the
18.5 EDOA group in comparison to those belonging to the 19.0 EDOA group. Further,
YFBM was greater in birds belonging to 19.0 EDOA group compared to those belonging
to the 18.5 EDOA group. This may be due to a higher internal temperature, an increased
water loss, lower moisture concentration, and more rapid embryonic metabolism (Zhai et
al., 2011b; Pulikanti et al., 2012) in the eggs belonging to the 19.0 EDOA group. Yolk
free body mass (YFBW divided by total BW), which is a measure of percentage of yolkfree BW, has been positively correlated with the birds’ subsequent poh performance. A
higher YFBM is indicative of a more advanced stage of embryonic development
(Molenaar, 2011).
Poultry producers utilize performance (BWG and FCR) data as criteria for
evaluating the effects of coccidiosis on a broiler flock. In a previous study, in which the
EM1 vaccine was administered at 18.5 doi, it was shown that EM1 did not affect mean
BW at 0 d poh (Sokale et al., 2015b). This finding was different from results obtained in
this current study. In the current study, the 0 d poh BW of the birds were decreased when
they were injected at18.5 doi, with EM1 vaccine (Table 6.2). The contrasting results of
the two studies may be attributed to differences in the incubation processes used in each.
In the current study, embryos of two different EDOA were incubated together, whereas,
embryos of like EDOA were incubated together in the contrasting study. Therefore, the
total heat production of the eggs at a particular doi (that was based on the 18.5 EDOA
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eggs) was greater in the study examining the two different EDOA. This difference in the
two studies may have caused the EM1 vaccine to have different effects. An EDOA effect
was also observed on BW at d 7, 14, 21, and 35 poh, and on BWG and FI at all the poh
age intervals (except for the d 28 to 35 poh d interval), and for FCR in the d 0 to 7 and d
0 to 35 poh age intervals. These effects of EDOA on poh performance suggest that chick
quality differences between the 18.5 and 19.0 EDOA groups are extended up to d 35 poh.
This finding is consistent with a previous study conducted by Pulikanti et al. (2013), in
which embryo temperature during incubation influenced the BW and relative organ
weights of broilers, up to d 48 poh. The effect of IT on BW and BWG were observed at d
28 poh and in the d 28 to 35 poh age interval, respectively. It is possible that equilibrium
for poh performance in the 18.5 and 19.0 EDOA groups was reached in the d 28 and 35
poh age interval, and may be due to the fact that only IT-related effects on BW, BWG,
and FI were observed by d 28 poh.
The BW at d 28 poh, and the BWG and FI that were observed in the 28 to 35 d
poh age interval were higher in birds belonging to the control groups compared with
those in the EM1 group. Furthermore, litter oocysts counts, coccidia lesion scores, and
total gut lesion scores in the EM1 injected birds were highest at d 21 and 28 poh. These
findings are consistent with findings in the report by Mathis et al. (2014), in which the
recovery of coccidial oocysts from litter was highest from birds in the EM1-vaccinated
group at 21 d poh, with oocyst shedding continuing up to d 35 poh. In addition, similar to
an earlier finding, the peak of oocyst shedding at d 21 poh and coccidial cycling at d 28
poh may have resulted in a lower BW, BWG, and FI that was observed in the d 28 to 35
poh interval. Previous studies have shown that a depression in performance may occur
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during peak oocyst shedding, with a compensatory improvement in performance
occurring later during grow-out (Mathis, 1999; Williams and Gobbi, 2002; Broomhead,
2012; Mathis, 2014). Mathis (1999) stated that birds exhibiting peak intestinal coccidial
lesions at d 21 poh, still have adequate time for compensatory weight gain. However,
birds exhibiting intestinal lesions at d 35 poh are not afforded the adequate time for
compensatory weight gain. In this current study, peak intestinal lesion occurred at d 28
poh. However, by d 35 poh, there was no difference in the BW of birds among the
treatment groups, indicating that compensatory weight gain had occurred within the
flock. The delay in peak coccidial cycling can be attributed to a lack of early moisture
build up in the new litter that was utilized in this study. It has been shown that a
minimum litter moisture content of approximately 25 % is needed for maximum coccidial
cycling (Gingerich, 2012).
In conclusion, chick quality was optimized in chicks that had an additional 12 h
incubational time advantage (19.0 EDOA group). Noted improvements in the quality
characteristics of the chicks were likewise observed in their poh grow-out performance
parameters up to d 35 poh. In addition, the performance (BW, BWG, and FI) of the EM1vaccinated group was reduced during peak coccidia oocyst cycling and shedding. Peak
oocyst shedding occurred at d 21 poh, with coccidia cycling occurring up to d 35 poh.
This resulted in a reduction in performance in the d 28 to 35 poh age interval. The results
obtained in this study also indicated that improvements in embryonic development during
incubation are able to likewise influence grow-out live performance. However,
differences in chick quality parameters that are associated with differences in embryo age
at the time of in ovo injection do not influence EM1 vaccine efficacy.
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Hatching chick quality parameter means in the embryonic day of age (EDOA) 18.5 and 19.0, with injection-type (IT)
of noninjected and diluent-control groups, and vaccine-injected group.1, 2

EDOA
0.203
0.002
0.247
0.001
0.250
0.001
<0.001
<0.001
<0.001
0.001
IT× EDOA
0.482
0.744
0.422
0.553
0.622
0.704
0.099
0.110
0.050
0.704
a-b
Means within a variable with no common superscript differ (P ≤ 0.05).
1
Hatchability of injected eggs (HI), Hatchling BW (HBW), Chick BW (BW), yolk sac weight (YSW), yolk-free BW (YFBW), yolk sac weight as a
percentage of BW (RYBW), intestine weight (IW), intestine weight as a percentage of BW (RIBW), intestine weight as a percentage of yolk-free BW
(RIYFW), yolk-free body mass (YFBM).
2
4 birds in each of 10 replicate units per treatment (40 birds per treatment group) were used to calculate each treatment mean.
3Approximately 60 eggs in each of 10 replicate units per treatment group were used to calculate each treatment mean.

P-values
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<0.0001
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FCR3

a-b

IT × EDOA
0.0051 0.6640 0.2831 0.8468 0.9808
0.5078 0.5803 0.8614 0.6122 0.0135 0.0364
0.0947
Means within a column with no common superscript differ (P ≤ 0.05).
1
34 birds in each of 10 replicate units used to calculate each treatment mean.
2
BW1 = d 0 BW; BWG1 = d 0 to 7 BW gain; FI1 = d 0 to 7 feed intake; FCR1 = d 0 to 7 feed conversion ratio; BW2 = d 7 BW; BWG2 = d 7 to 14 BW gain;
FI2 = d 7 to 14 feed intake; FCR2 = d 7 to 14 feed conversion ratio; BW3 = d 14 BW; BWG3 = d 14 to 21 BW gain; FI3 = d 14 to 21 feed intake; FCR3 = d
14 to 21 feed conversion ratio.
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Performance parameter means in the embryonic day of age (EDOA) 18.5 and 19.0, with injection-type (IT) of
noninjected and diluent-control groups, and vaccine-injected group.1, 2
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0.3446 0.3969 0.3249 0.5229 0.8798
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0.051 0.272
0.925
0.927
0.018
0.009
Means within a column with no common superscript differ (P ≤ 0.05).
1
34 birds in each of 10 replicate units used to calculate each treatment mean.
2
BW4 = d 21 BW; BWG4 = d 21 to 28 BW gain; FI4 = d 21 to 28 feed intake; FCR4 = d 21 to 28 feed conversion ratio; BW5 = d 28 BW; BWG5 = d 28 to
35 BW gain; FI5 = d 28 to 35 feed intake; FCR5 = d 28 to 35 feed conversion ratio; BW6 = d 35 BW; BWG6 = d 0 to 35 BW gain; FI6 = d 0 to 35 feed
intake; FCR6 = d 0 to 35 feed conversion ratio.
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Performance parameter means in the embryonic day of age (EDOA) 18.5 and 19.0, with injection-types (IT) of
noninjected and diluent-control groups, and the vaccine-injected group.1, 2
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Figure 6.1

Mean coccidia score by treatment for Eimeria acervulina, E. maxima, and
E. tenella.

Trt. 2 = Diluent-injected control group; Trt. 3 = EDOA 18.5 EM1 vaccine-injected group,
and Trt.6 = EDOA 19.0 EM1 vaccine-injected group on d 14, 21, 28 and 35 posthatch1.
1
Data from 20 birds was used for calculation of means for each treatment group.
a-b
Means within a column with no common superscript differ (P = 0.007).
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Figure 6.2

Mean coccidia score by treatment and day posthatch for Eimeria
acervulina, E. maxima, and E. tenella

14-2 = day 14 diluent-injected control group; 14-3 = day 14 EDOA 18.5 EM1 vaccineinjected group; 14-6 = day 14 EDOA 19.0 EM1 vaccine-injected group; 21-2 = day 21
diluent-injected control group; 21-3 = day 21 EDOA 18.5 EM1 vaccine-injected group;
21-6 = day 21 EDOA 19.0 EM1 vaccine-injected group; 28-2 = day 28 diluent-injected
control group; 28-3 = day 28 EDOA 18.5 EM1 vaccine-injected group; 28-6 = day 28
EDOA 19.0 EM1 vaccine-injected group; 35-2 = day 35 diluent-injected control group;
35-3 = day 35 EDOA 18.5 EM1 vaccine-injected group; 35-6 = day 35 EDOA 19.0 EM1
vaccine-injected group.1,2
1
Data from 5 birds was used for calculation of means for each treatment group.
2
No significant difference was observed among treatment groups within each day of age.
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Figure 6.3

Mean total gut lesion score (inflammation, repair, and coccidia) by
treatment for Eimeria acervulina, E. maxima, and E. tenella

Trt. 2 = Diluent-injected control group; Trt. 3 = EDOA 18.5 EM1 vaccine-injected group;
Trt.6 = EDOA 19.0 EM1 vaccine-injected group on d 14, 21, 28 and 35 posthatch.1
1
Data from 20 birds was used for calculation of means for each treatment group.
a-b
Means within a column with no common superscript differ (P = 0.015).
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Figure 6.4

Mean total gut lesion score (inflammation, repair, and coccidia) by
treatment and day posthatch for Eimeria acervulina, E. maxima, and E.
tenella

14-2 = day 14 diluent-injected control group; 14-3 = day 14 EDOA 18.5 EM1 vaccineinjected group; 14-6 = day 14 EDOA 19.0 EM1 vaccine-injected group; 21-2 = day 21
diluent-injected control group; 21-3 = day 21 EDOA 18.5 EM1 vaccine-injected group;
21-6 = day 21 EDOA 19.0 EM1 vaccine-injected group; 28-2 = day 28 diluent-injected
control group; 28-3 = day 28 EDOA 18.5 EM1 vaccine-injected group; 28-6 = day 28
EDOA 19.0 EM1 vaccine-injected group; 35-2 = day 35 diluent-injected control group;
35-3 = day 35 EDOA 18.5 EM1 vaccine-injected group; 35-6 = day 35 EDOA 19.0 EM1
vaccine-injected group.1,2
1
Data from 5 birds was used for calculation of means for each treatment group.
2
No significant difference was observed among treatment groups within each day of age.
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Figure 6.5

Oocysts per gram of litter on Days 0, 14, 21, 28, and 35 posthatch, for birds
that were vaccinated with the EM1 vaccine

Peak oocyst shedding in the litter was on d 21 posthatch.1
1
Data from 10 replicate pens was used for calculation of means for each day.
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CONCLUSIONS AND APPLICATIONS
Today, in ovo application of the Inovocox EM1 vaccine for the control of
coccidiosis occurs routinely in many commercial broiler hatcheries in the USA. The
overall purpose of in ovo vaccination is to vaccinate every viable broiler embryo safely
and uniformly in order to allow them to achieve immunocompetence prior to potential
coccidiosis field challenges. However, several factors can affect the development of an
adequate immune response before a field challenge occurs. This current research reveals
some of the physiological components of this process that when discerned, can help
maximize the outcome and efficacy of the EM1 vaccine. The following are components
of this process that are demonstrated in this study:
1.

Accurate vaccine deposition into the amnion (AM) is influenced by the
physiological stage of the embryo at the time of injection. In ovo
vaccination of late-stage embryos (D18.5) with an embryo stage score of 2
to 3 resulted in accurate vaccine deposition in over 90 % of embryos. Site
of injection (SOI) accuracy was higher in embryos injected on 18.5 doi,
than in those injected on 19.0 doi. On the other hand, embryonic stage
score (ES) was higher in embryos injected on 19.0 doi when compared to
those injected on 18.5 doi. A higher ES indicates a more developed
embryo. As the embryos develop towards the hatching stage, the accuracy
of vaccine deposition decreases because of a reduction in the amount of
AM within the embryonated egg. The preferred SOI for the EM1vaccine is
the AM. Other SOI such as intramuscular (preferably at the right breast
muscle area) and subcutaneous sites, are also accepted as viable injection
sites.
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2.

The in ovo administration of EM1 vaccine at 18.5 or 19.0 doi is safe, with
no detrimental effects on hatchability, chick quality parameters, and
embryo survivability. In addition, EM1 administered up to 10 × the
recommended dose showed no detrimental effects on embryonic and chick
quality parameters.

3.

The kinetics of oocyst shedding showed that fecal oocyst shedding began
at day 4 posthatch (6 d post injection), and peaked at 7 d posthatch (10 d
post injection), with a smaller peak at day 10 posthatch.

4.

Coccidia oocyst output and cycling were highest between day 21 and 28
posthatch, which resulted in a decrease in BWG during this period in the
EM1 vaccinated birds. However, a compensatory BWG occurred by day
35 posthatch.

5.

Chicks that were produced from the embryos injected on 19.0 doi had
better chick quality characteristics in comparison with those produced
from embryos injected on 18.5 doi. This differential effect was discovered
on day of hatch and subsequently affected grow-out performance up to 35
days posthatch. However, grow-out performance and the pattern of
coccidia cycling were similar in embryos injected with the EM1 vaccine
on either day 18.5 or 19.0 of incubation.

6.

This study showed that turn-out times on day 7 or 10, in the presence of a
low dose (1×) or high dose (10×) EM1 vaccine, did not negatively affect
performance. Therefore, under ideal conditions, partial house brooding up
to day10 posthatch at the recommended EM1 dose, will ensure adequate
oocyst cycling without negatively affecting grow-out performance.
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